,tid,pref_name,lig_chemblid,aid,outcome,title
1645,CHEMBL3706,ADAM17,CHEMBL211770,268588,Active,inhibition of tace by fret assay
1461,CHEMBL3706,ADAM17,CHEMBL1683463,578212,Active,inhibition of tace assessed as substrate cleavage by measuring increase in fluorescence after 16 hrs
25,CHEMBL3706,ADAM17,CHEMBL1939844,641682,Active,inhibition of tace using mca lys pro leu gly leu dap dnp  ala arg nh2 as substrate preincubated for 4 hrs measured every 15 secs for 20 mins by fluorescence analysis
1406,CHEMBL3706,ADAM17,CHEMBL3355723,1172328,Active,inhibition of human recombinant adam17 using mca plaqav dpa rsssr nh2
2217,CHEMBL3706,ADAM17,CHEMBL391676,292733,Active,inhibition of tace
84,CHEMBL3706,ADAM17,CHEMBL137383,215266,Active,in vitro binding affinity against porcine tace
1851,CHEMBL4247,ALK tyrosine kinase receptor,CHEMBL514409,390035,Active,binding affinity to human alk at 10 um relative to control
443,CHEMBL220,Acetylcholinesterase,CHEMBL4063321,1470901,Active,inhibition of electric eel ache
685,CHEMBL220,Acetylcholinesterase,CHEMBL3754631,1273004,Active,inhibition of electric eel ache using atc as substrate preincubated for 5 mins followed by substrate addition measured after 2 mins by ellman's assay
2323,CHEMBL220,Acetylcholinesterase,CHEMBL3934708,1318844,Active,inhibition of wistar rat brain ache using acetylthiochloline iodide as substrate after 30 mins by ellman's method
1797,CHEMBL220,Acetylcholinesterase,CHEMBL239834,300873,Inactive,inhibition of recombinant human ache activity
1788,CHEMBL220,Acetylcholinesterase,CHEMBL3958499,1330795,Active,inhibition of electric eel ache using acetylthiocholine iodide as substrate incubated for 5 mins followed by substrate addition measured for 1 min by ellman's method
992,CHEMBL220,Acetylcholinesterase,CHEMBL3338962,1166296,Active,inhibition of electric eel ache by ellman's method
1006,CHEMBL220,Acetylcholinesterase,CHEMBL322343,30682,Active,compound was evaluated for the inhibition of acetylcholinesterase of bovine erythrocytes
1766,CHEMBL220,Acetylcholinesterase,CHEMBL262565,238665,Active,dissociation constant for inhibition of fetal bovine serum acetylcholinesterase
1007,CHEMBL220,Acetylcholinesterase,CHEMBL322343,30692,Active,inhibition of acetylcholinesterase  ache activity in bovine erythrocytes
442,CHEMBL220,Acetylcholinesterase,CHEMBL4063321,1459902,Active,inhibition of electric eel ache using acetylthiocholine iodide as substrate preincubated for 15 mins followed by substrate addition measured after 20 mins by ellman's method
1008,CHEMBL220,Acetylcholinesterase,CHEMBL322343,30692,Active,inhibition of acetylcholinesterase  ache activity in bovine erythrocytes
1010,CHEMBL220,Acetylcholinesterase,CHEMBL322343,272365,Active,inhibition of bovine erythrocyte ache
1062,CHEMBL220,Acetylcholinesterase,CHEMBL240899,300873,Inactive,inhibition of recombinant human ache activity
593,CHEMBL220,Acetylcholinesterase,CHEMBL3338954,1166296,Active,inhibition of electric eel ache by ellman's method
119,CHEMBL220,Acetylcholinesterase,CHEMBL2336431,733748,Active,inhibition of ache in wistar rat brain cortex using acetylthiocholine iodide as substrate by ellman's colorimetric method
1641,CHEMBL220,Acetylcholinesterase,CHEMBL3897721,1318844,Active,inhibition of wistar rat brain ache using acetylthiochloline iodide as substrate after 30 mins by ellman's method
1260,CHEMBL220,Acetylcholinesterase,CHEMBL2331606,733748,Inactive,inhibition of ache in wistar rat brain cortex using acetylthiocholine iodide as substrate by ellman's colorimetric method
1229,CHEMBL220,Acetylcholinesterase,CHEMBL4095975,1439217,Active,inhibition of electric eel ache using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured for 1 min by ellman's method
1230,CHEMBL220,Acetylcholinesterase,CHEMBL237667,302143,Active,inhibition of electrophorus electricus ache by ellman's method
1009,CHEMBL220,Acetylcholinesterase,CHEMBL322343,243153,Active,in vitro inhibitory activity against bovine acetylcholinesterase
1145,CHEMBL220,Acetylcholinesterase,CHEMBL3955170,1330795,Active,inhibition of electric eel ache using acetylthiocholine iodide as substrate incubated for 5 mins followed by substrate addition measured for 1 min by ellman's method
1826,CHEMBL220,Acetylcholinesterase,CHEMBL3628053,1252806,Active,inhibition of human recombinant ache using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition by ellman's method
370,CHEMBL220,Acetylcholinesterase,CHEMBL3895802,1330795,Active,inhibition of electric eel ache using acetylthiocholine iodide as substrate incubated for 5 mins followed by substrate addition measured for 1 min by ellman's method
686,CHEMBL220,Acetylcholinesterase,CHEMBL3754631,1273006,Active,inhibition of human ache using atc as substrate preincubated for 5 mins followed by substrate addition measured after 2 mins by ellman's assay
2154,CHEMBL220,Acetylcholinesterase,CHEMBL397100,300873,Inactive,inhibition of recombinant human ache activity
695,CHEMBL220,Acetylcholinesterase,CHEMBL484306,404842,Active,inhibition of bovine erythrocyte ache by ellman's assay
2180,CHEMBL220,Acetylcholinesterase,CHEMBL592432,462900,Inactive,inhibition of human recombinant ache by modified ellman's spectrophotometric method
22,CHEMBL220,Acetylcholinesterase,CHEMBL2163791,697831,Inactive,inhibition of electric eel ache by ellman's method
778,CHEMBL220,Acetylcholinesterase,CHEMBL3335021,1162589,Active,inhibition of human recombinant ache using acetylthiocholine iodide substrate incubated for 15 mins by spectrophotometry based ellman's method
2090,CHEMBL223,Alpha-1d adrenergic receptor,CHEMBL154508,1275241,Active,displacement of [3h] prazosin from human adra1a receptor
1989,CHEMBL223,Alpha-1d adrenergic receptor,CHEMBL3760063,1275241,Active,displacement of [3h] prazosin from human adra1a receptor
2450,CHEMBL1871,Androgen Receptor,CHEMBL44,1259243,Inactive,qhts assay to identify small molecule antagonists of the androgen receptor  ar signaling pathway using the mda cell line in the presence of 0 5 nm r1881
2451,CHEMBL1871,Androgen Receptor,CHEMBL44,1259243,Inactive,qhts assay to identify small molecule antagonists of the androgen receptor  ar signaling pathway using the mda cell line in the presence of 0 5 nm r1881
2452,CHEMBL1871,Androgen Receptor,CHEMBL44,1259243,Inactive,qhts assay to identify small molecule antagonists of the androgen receptor  ar signaling pathway using the mda cell line in the presence of 0 5 nm r1881
2453,CHEMBL1871,Androgen Receptor,CHEMBL44,1259379,Inactive,qhts assay to identify small molecule agonists of the androgen receptor  ar signaling pathway in the presence of an antagonist   cell viability counter screen
2456,CHEMBL1871,Androgen Receptor,CHEMBL44,1259381,Inactive,qhts assay to identify small molecule agonists of the androgen receptor  ar signaling pathway in the presence of an antagonist
2455,CHEMBL1871,Androgen Receptor,CHEMBL44,1259379,Inactive,qhts assay to identify small molecule agonists of the androgen receptor  ar signaling pathway in the presence of an antagonist   cell viability counter screen
2449,CHEMBL1871,Androgen Receptor,CHEMBL44,1259242,Inactive,qhts assay to identify small molecule antagonists of the androgen receptor  ar signaling pathway using the mda cell line in the presence of 0 5 nm r1881   cell viability counter screen
2457,CHEMBL1871,Androgen Receptor,CHEMBL44,1259381,Inactive,qhts assay to identify small molecule agonists of the androgen receptor  ar signaling pathway in the presence of an antagonist
2458,CHEMBL1871,Androgen Receptor,CHEMBL44,1259387,Active,qhts assay to identify small molecule agonists of the androgen receptor  ar signaling pathway in the presence of an antagonist: summary
2459,CHEMBL1871,Androgen Receptor,CHEMBL44,1389452,Active,inhibition of hdac6/hsp90 in human lncap cells assessed as downregulation of ar protein level at 2 5 um after 24 hrs by western blot method
2454,CHEMBL1871,Androgen Receptor,CHEMBL44,1259379,Inactive,qhts assay to identify small molecule agonists of the androgen receptor  ar signaling pathway in the presence of an antagonist   cell viability counter screen
2432,CHEMBL1871,Androgen Receptor,CHEMBL44,743033,Inactive,qhts assay to identify small molecule antagonists of the androgen  receptor  ar signaling pathway   cell viability counter screen
2448,CHEMBL1871,Androgen Receptor,CHEMBL44,1259242,Inactive,qhts assay to identify small molecule antagonists of the androgen receptor  ar signaling pathway using the mda cell line in the presence of 0 5 nm r1881   cell viability counter screen
2441,CHEMBL1871,Androgen Receptor,CHEMBL44,743042,Inactive,qhts assay to identify small molecule antagonists of the androgen  receptor  ar signaling pathway using the mda cell line
2445,CHEMBL1871,Androgen Receptor,CHEMBL44,743063,Active,qhts assay to identify small molecule antagonists of the androgen receptor  ar signaling pathway: summary
2442,CHEMBL1871,Androgen Receptor,CHEMBL44,743042,Inactive,qhts assay to identify small molecule antagonists of the androgen  receptor  ar signaling pathway using the mda cell line
2433,CHEMBL1871,Androgen Receptor,CHEMBL44,743033,Inactive,qhts assay to identify small molecule antagonists of the androgen  receptor  ar signaling pathway   cell viability counter screen
2440,CHEMBL1871,Androgen Receptor,CHEMBL44,743042,Inactive,qhts assay to identify small molecule antagonists of the androgen  receptor  ar signaling pathway using the mda cell line
2443,CHEMBL1871,Androgen Receptor,CHEMBL44,743053,Inactive,qhts assay to identify small molecule agonists of the androgen receptor  ar signaling pathway: summary
2439,CHEMBL1871,Androgen Receptor,CHEMBL44,743041,Inactive,qhts assay to identify small molecule antagonists of the androgen  receptor  ar signaling pathway using the mda cell line   cell viability counter screen
2438,CHEMBL1871,Androgen Receptor,CHEMBL44,743041,Inactive,qhts assay to identify small molecule antagonists of the androgen  receptor  ar signaling pathway using the mda cell line   cell viability counter screen
2446,CHEMBL1871,Androgen Receptor,CHEMBL44,743063,Active,qhts assay to identify small molecule antagonists of the androgen receptor  ar signaling pathway: summary
2437,CHEMBL1871,Androgen Receptor,CHEMBL44,743041,Inactive,qhts assay to identify small molecule antagonists of the androgen  receptor  ar signaling pathway using the mda cell line   cell viability counter screen
2444,CHEMBL1871,Androgen Receptor,CHEMBL44,743053,Inactive,qhts assay to identify small molecule agonists of the androgen receptor  ar signaling pathway: summary
2436,CHEMBL1871,Androgen Receptor,CHEMBL44,743040,Inactive,qhts assay to identify small molecule agonists of the androgen  receptor  ar signaling pathway using the mda cell line
2447,CHEMBL1871,Androgen Receptor,CHEMBL44,1259242,Inactive,qhts assay to identify small molecule antagonists of the androgen receptor  ar signaling pathway using the mda cell line in the presence of 0 5 nm r1881   cell viability counter screen
2435,CHEMBL1871,Androgen Receptor,CHEMBL44,743040,Inactive,qhts assay to identify small molecule agonists of the androgen  receptor  ar signaling pathway using the mda cell line
2434,CHEMBL1871,Androgen Receptor,CHEMBL44,743033,Inactive,qhts assay to identify small molecule antagonists of the androgen  receptor  ar signaling pathway   cell viability counter screen
44,CHEMBL4822,Beta-secretase 1,CHEMBL3670929,1257990,Active,immunofluorescence resonance energy transfer  fret assay: the fret assay was performed essentially as described in gruninger leitch et al journal of biological chemistry  2002 277 7 4687 93  substrate and inhibitor profile of bace  beta secretase and comparison with other mammalian aspartic proteases in summary a peptide is designed that is cleaved by the protease the peptide is labelled with dabcyl at the n terminus and lucifer yellow at the c terminus such that for an intact peptide the lucifer yellow fluorescence is quenched by the dabcyl when the peptide is cut by bace2 the quenching is removed and a fluorescent signal is generated the assay was performed as described in grueninger et al 2002 at ph 4 5 using a substrate concentration of 5  x3bc m a fret peptide based on the tmem27 sequence was devised dabcyl qtleflkips lucy  seq id no: 1 bace2 had a high activity against this sequence which is unrelated to the known app based substrates conversely bace1 had i
1053,CHEMBL4822,Beta-secretase 1,CHEMBL3938461,1344819,Active,time resolved endpoint proteolysis assay: inhibitor compounds prepared at 3 xd7 the desired final concentration in 1 xd7 bace assay buffer  20 mm sodium acetate ph 5 0 10% glycerol 0 1% brij 35 supplemented with 7 5% dmso are pre incubated with an equal volume of autobace 2 enzyme diluted in 1 xd7 bace assay buffer  final enzyme concentration 1 nm in black 384 well nunc plates for 30 minutes at 30 xb0 c the assay is initiated by addition of an equal volume of the qsy7 eisevnldaefc eu amide substrate  200 nm final concentration km8  x3bc m for 4  x3bc m for autobace 2 prepared in 1 xd7 bace assay buffer supplemented with 7 5% dmso and incubated for 90 minutes at 30 xb0 c dmso is present at 5% final concentration in the assay following laser excitation of sample wells at 320 nm the fluorescence signal at 620 nm is collected for 400 ms following a 50  x3bc s delay on a rubystar htrf plate reader  bmg labtechnologies 
43,CHEMBL4822,Beta-secretase 1,CHEMBL3670929,1257989,Active,immunofluorescence resonance energy transfer  fret assay: the fret assay was performed essentially as described in gruninger leitch et al journal of biological chemistry  2002 277 7 4687 93  substrate and inhibitor profile of bace  beta secretase and comparison with other mammalian aspartic proteases in summary a peptide is designed that is cleaved by the protease the peptide is labelled with dabcyl at the n terminus and lucifer yellow at the c terminus such that for an intact peptide the lucifer yellow fluorescence is quenched by the dabcyl when the peptide is cut by bace2 the quenching is removed and a fluorescent signal is generated the assay was performed as described in grueninger et al 2002 at ph 4 5 using a substrate concentration of 5  x3bc m a fret peptide based on the tmem27 sequence was devised dabcyl qtleflkips lucy  seq id no: 1 bace2 had a high activity against this sequence which is unrelated to the known app based substrates conversely bace1 had i
1821,CHEMBL1914,Butyrylcholinesterase,CHEMBL4091683,1465275,Active,inhibition of equine serum bche using butyrylthiocholine chloride as substrate incubated for 15 mins by ellman's method
283,CHEMBL1914,Butyrylcholinesterase,CHEMBL2312573,722585,Inactive,inhibition of equine serum bche using butyrylthiocholine iodide as substrate up to 100 nm after 60 mins by ellman's method
2425,CHEMBL1914,Butyrylcholinesterase,CHEMBL206093,262755,Active,anticholinesterase activity against human plasma bche
1823,CHEMBL1914,Butyrylcholinesterase,CHEMBL4091683,1465285,Active,inhibition of human serum bche using butyrylthiocholine chloride as substrate incubated for 15 mins by ellman's method
2159,CHEMBL1914,Butyrylcholinesterase,CHEMBL3115034,1070089,Active,inhibition of equine serum bche using s butyrylthiocholine chloride as substrate preincubated for 15 mins followed by substrate addition by ellman's method
1642,CHEMBL1914,Butyrylcholinesterase,CHEMBL2413741,765127,Active,inhibition of horse serum bche using acetylthiocholine iodide as substrate preincubated for 5 mins before substrate addition by ellman's method
1808,CHEMBL1914,Butyrylcholinesterase,CHEMBL470715,349872,Active,inhibition of human serum bche by ellman's method
1822,CHEMBL1914,Butyrylcholinesterase,CHEMBL4091683,1465278,Active,inhibition of rat serum bche using butyrylthiocholine chloride as substrate incubated for 15 mins by ellman's method
157,CHEMBL1914,Butyrylcholinesterase,CHEMBL3764376,1279036,Active,inhibition of bche  unknown origin using acetylthiocholine as substrate assessed as reduction of dtnb to tnb preincubated for 20 mins followed by addition of substrate by ellman's kinetic method
1733,CHEMBL1914,Butyrylcholinesterase,CHEMBL465028,395658,Active,inhibition of bche in rat serum after 15 mins by modified ellman method
1309,CHEMBL1914,Butyrylcholinesterase,CHEMBL3604192,1240923,Active,inhibition of equine serum bche using atc iodide substrate by ellman's assay
2265,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3930707,1344404,Active,competition binding assay: the kd of cp 55 940 in the isolated cb1 and cb2 receptor expressing membranes was previously determined to be 2 3 nm and 1 5 nm respectively  see pertwee r g current medicinal chemistry 6 635 664  1999 competition binding assays at 2 5 nm [3h] cp 55 940  perkinelmer were carried out to determine the k1 values for tested compounds membranes  5 10  x3bc g were incubated with radioligand and a range of concentrations of test compounds in binding buffer  50 mm tris ph 7 4 5 mm mgcl2 1 mm edta with 0 5%  w/v bovine serum albumin  bsa  icp bio new zealand at 30 xb0 c for 60 min stock solutions of putative cannabinoid ligands were prepared in dimethyl sulfoxide to a concentration of 10 mm six different final concentrations of compounds were used ranging from 50  x3bc m to 0 1 nm non specific binding was determined in the presence of 1  x3bc m non radioactive cp 55 940  tocris cookson assays were terminated by addition of 2 ml ice cold bi
1512,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3892993,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
2114,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3978981,1318554,Active,intrinsic activity at cb1 receptor in mouse n1e 115 cells assessed as phosphorylation of erk1/2 at 1 nm to 10 um after 10 mins by western blot method
1500,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3970254,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
2113,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3978981,1318548,Active,displacement of [3h] cp55 940 from cb1 receptor in mouse whole brain membranes after 60 mins by liquid scintillation spectrometry
2112,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3956804,1344076,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37  xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30  xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30  xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
1518,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL486548,345340,Active,displacement of [3h]cp 55940 from cb1 receptor in sprague dawley rat cerebellum by liquid scintillation spectrometry
2264,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3959976,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
1448,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3924010,1344624,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
306,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3957074,1344618,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
2061,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL4102348,1433068,Active,displacement of [3h]cp 55 940 from cb1 receptor in rat brain membranes by scintillation counting method
1600,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL4110162,1344624,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
2209,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3949123,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
1652,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3971088,1344698,Active,binding assay: the binding assays were performed by testing the ability of the new compounds to displace the radiolabeled synthetic non selective cannabinoid agonist [3h]cp55940  168 ci/mmol perkinelmer from the human cb1  hcb1 or human cb2  hcb2 receptors on membranes derived from stably transfected hek 293 cells  perkinelmer membranes were diluted in assay buffer  50 mm tris hcl 1 mm edta 1 mm mgcl2 1 mg/ml bsa ph7 4 the amount of membrane was determined for each batch of membranes according to protein binding assay the minimum amount of membrane that gave 50% specific binding was used for the binding assay in most assays binding was tested using 8  x3bc g and 4  x3bc g protein of hcb1 and hcb2 membranes respectively the tested compounds were dissolved in dmso and diluted in assay buffer to a final concentration of 0 1% solvent total binding of [3h]cp55940 was evaluated with 1 5 nm to hcb1 and with 0 5 nm to hcb2 according to kd affinity of [3h]cp55940 for the r
1653,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3971088,1344698,Active,binding assay: the binding assays were performed by testing the ability of the new compounds to displace the radiolabeled synthetic non selective cannabinoid agonist [3h]cp55940  168 ci/mmol perkinelmer from the human cb1  hcb1 or human cb2  hcb2 receptors on membranes derived from stably transfected hek 293 cells  perkinelmer membranes were diluted in assay buffer  50 mm tris hcl 1 mm edta 1 mm mgcl2 1 mg/ml bsa ph7 4 the amount of membrane was determined for each batch of membranes according to protein binding assay the minimum amount of membrane that gave 50% specific binding was used for the binding assay in most assays binding was tested using 8  x3bc g and 4  x3bc g protein of hcb1 and hcb2 membranes respectively the tested compounds were dissolved in dmso and diluted in assay buffer to a final concentration of 0 1% solvent total binding of [3h]cp55940 was evaluated with 1 5 nm to hcb1 and with 0 5 nm to hcb2 according to kd affinity of [3h]cp55940 for the r
1664,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3647325,1258386,Active,radioligand binding assays: the cb1 and cb2 radioligand binding assays described herein are utilized to ascertain the selectivity of compounds of the present application for binding to cb2 relative to cb1 receptors hek293 cells stably expressing human cb2 receptors were grown until a confluent monolayer was formed briefly the cells were harvested and homogenized in te buffer  50 mm tris hcl 1 mm mgcl2 and 1 mm edta using a polytron for 210 second bursts in the presence of protease inhibitors followed by centrifugation at 45 000xg for 20 minutes the final membrane pellet was re homogenized in storage buffer  50 mm tris hcl 1 mm mgcl2 and 1 mm edta and 10% sucrose and frozen at  78 c until used saturation binding reactions were initiated by the addition of membrane preparation  protein concentration of 5 ug/well for human cb2 into wells of a deep well plate containing [3h]cp 55 940  120 ci/mmol a nonselective cb agonist commercially available from tocris in assay buffer 
1665,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3647325,1258387,Active,radioligand binding assays: the cb1 and cb2 radioligand binding assays described herein are utilized to ascertain the selectivity of compounds of the present application for binding to cb2 relative to cb1 receptors hek293 cells stably expressing human cb2 receptors were grown until a confluent monolayer was formed briefly the cells were harvested and homogenized in te buffer  50 mm tris hcl 1 mm mgcl2 and 1 mm edta using a polytron for 210 second bursts in the presence of protease inhibitors followed by centrifugation at 45 000xg for 20 minutes the final membrane pellet was re homogenized in storage buffer  50 mm tris hcl 1 mm mgcl2 and 1 mm edta and 10% sucrose and frozen at  78 c until used saturation binding reactions were initiated by the addition of membrane preparation  protein concentration of 5 ug/well for human cb2 into wells of a deep well plate containing [3h]cp 55 940  120 ci/mmol a nonselective cb agonist commercially available from tocris in assay buffer 
1686,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3932592,1344618,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
1852,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3958904,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
147,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3963316,1344618,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
1843,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3966926,1344618,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
2216,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3397445,1297967,Active,displacement of [3h]cp55940 from human cb1 receptor expressed in cho cell membranes after 2 hrs
307,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3957074,1344618,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
1754,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3960754,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
2165,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3969085,1344076,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37  xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30  xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30  xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
1417,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3907056,1344698,Active,binding assay: the binding assays were performed by testing the ability of the new compounds to displace the radiolabeled synthetic non selective cannabinoid agonist [3h]cp55940  168 ci/mmol perkinelmer from the human cb1  hcb1 or human cb2  hcb2 receptors on membranes derived from stably transfected hek 293 cells  perkinelmer membranes were diluted in assay buffer  50 mm tris hcl 1 mm edta 1 mm mgcl2 1 mg/ml bsa ph7 4 the amount of membrane was determined for each batch of membranes according to protein binding assay the minimum amount of membrane that gave 50% specific binding was used for the binding assay in most assays binding was tested using 8  x3bc g and 4  x3bc g protein of hcb1 and hcb2 membranes respectively the tested compounds were dissolved in dmso and diluted in assay buffer to a final concentration of 0 1% solvent total binding of [3h]cp55940 was evaluated with 1 5 nm to hcb1 and with 0 5 nm to hcb2 according to kd affinity of [3h]cp55940 for the r
1058,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3897862,1344618,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
1420,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3897891,1344076,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37  xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30  xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30  xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
562,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3957783,1344698,Active,binding assay: the binding assays were performed by testing the ability of the new compounds to displace the radiolabeled synthetic non selective cannabinoid agonist [3h]cp55940  168 ci/mmol perkinelmer from the human cb1  hcb1 or human cb2  hcb2 receptors on membranes derived from stably transfected hek 293 cells  perkinelmer membranes were diluted in assay buffer  50 mm tris hcl 1 mm edta 1 mm mgcl2 1 mg/ml bsa ph7 4 the amount of membrane was determined for each batch of membranes according to protein binding assay the minimum amount of membrane that gave 50% specific binding was used for the binding assay in most assays binding was tested using 8  x3bc g and 4  x3bc g protein of hcb1 and hcb2 membranes respectively the tested compounds were dissolved in dmso and diluted in assay buffer to a final concentration of 0 1% solvent total binding of [3h]cp55940 was evaluated with 1 5 nm to hcb1 and with 0 5 nm to hcb2 according to kd affinity of [3h]cp55940 for the r
563,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3957783,1344698,Active,binding assay: the binding assays were performed by testing the ability of the new compounds to displace the radiolabeled synthetic non selective cannabinoid agonist [3h]cp55940  168 ci/mmol perkinelmer from the human cb1  hcb1 or human cb2  hcb2 receptors on membranes derived from stably transfected hek 293 cells  perkinelmer membranes were diluted in assay buffer  50 mm tris hcl 1 mm edta 1 mm mgcl2 1 mg/ml bsa ph7 4 the amount of membrane was determined for each batch of membranes according to protein binding assay the minimum amount of membrane that gave 50% specific binding was used for the binding assay in most assays binding was tested using 8  x3bc g and 4  x3bc g protein of hcb1 and hcb2 membranes respectively the tested compounds were dissolved in dmso and diluted in assay buffer to a final concentration of 0 1% solvent total binding of [3h]cp55940 was evaluated with 1 5 nm to hcb1 and with 0 5 nm to hcb2 according to kd affinity of [3h]cp55940 for the r
581,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3914196,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
583,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL240697,738105,Active,displacement of [3h]cp 55940 from cb1 receptor in mouse whole brain membrane homogenates after 90 mins by liquid scintillation counting
53,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3966311,1344624,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
930,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3889901,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
1071,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3934807,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
41,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3965133,1344698,Active,binding assay: the binding assays were performed by testing the ability of the new compounds to displace the radiolabeled synthetic non selective cannabinoid agonist [3h]cp55940  168 ci/mmol perkinelmer from the human cb1  hcb1 or human cb2  hcb2 receptors on membranes derived from stably transfected hek 293 cells  perkinelmer membranes were diluted in assay buffer  50 mm tris hcl 1 mm edta 1 mm mgcl2 1 mg/ml bsa ph7 4 the amount of membrane was determined for each batch of membranes according to protein binding assay the minimum amount of membrane that gave 50% specific binding was used for the binding assay in most assays binding was tested using 8  x3bc g and 4  x3bc g protein of hcb1 and hcb2 membranes respectively the tested compounds were dissolved in dmso and diluted in assay buffer to a final concentration of 0 1% solvent total binding of [3h]cp55940 was evaluated with 1 5 nm to hcb1 and with 0 5 nm to hcb2 according to kd affinity of [3h]cp55940 for the r
842,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3982907,1344624,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
776,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3696822,1258961,Active,radioligand binding assay: plasma membranes prepared from hek 293 ebna cells transfected with human cb1 or cb2 cannabinoid receptors  3 7 or 3 3  mu mol/mg protein receptor concentration perkinelmer were used for the radioligand binding studies the composition of incubation buffer for cb1 assay was 50 mm tris base 2 5 mm edta 5 mm mgcl sub 2 and 0 5 mg/ml fatty acid free bsa and for cb2 assay was 50 mm tris base 2 5 mm egta 5 mm mgcl sub 2 and 1 mg/ml fatty acid free bsa ph was adjusted to 7 4 by adding 1n hcl plasma membranes were diluted with incubation buffer to provide a final protein concentration of 2 4  mu g  cb1 or 8  mu g  cb2 per well in non binding surface polystyrene 96 well assay plates  corning compound solutions were prepared in silanized glass tubes and dispensed using pipette tips with superslik tm surface competition studies were performed using a final concentration of 0 72 nm [ sup 3h] cp 55 940  100 180 ci/mmol specific activity perkinelmer again
753,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3901343,1344076,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37  xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30  xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30  xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
655,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3959113,1344698,Active,binding assay: the binding assays were performed by testing the ability of the new compounds to displace the radiolabeled synthetic non selective cannabinoid agonist [3h]cp55940  168 ci/mmol perkinelmer from the human cb1  hcb1 or human cb2  hcb2 receptors on membranes derived from stably transfected hek 293 cells  perkinelmer membranes were diluted in assay buffer  50 mm tris hcl 1 mm edta 1 mm mgcl2 1 mg/ml bsa ph7 4 the amount of membrane was determined for each batch of membranes according to protein binding assay the minimum amount of membrane that gave 50% specific binding was used for the binding assay in most assays binding was tested using 8  x3bc g and 4  x3bc g protein of hcb1 and hcb2 membranes respectively the tested compounds were dissolved in dmso and diluted in assay buffer to a final concentration of 0 1% solvent total binding of [3h]cp55940 was evaluated with 1 5 nm to hcb1 and with 0 5 nm to hcb2 according to kd affinity of [3h]cp55940 for the r
656,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3959113,1344698,Active,binding assay: the binding assays were performed by testing the ability of the new compounds to displace the radiolabeled synthetic non selective cannabinoid agonist [3h]cp55940  168 ci/mmol perkinelmer from the human cb1  hcb1 or human cb2  hcb2 receptors on membranes derived from stably transfected hek 293 cells  perkinelmer membranes were diluted in assay buffer  50 mm tris hcl 1 mm edta 1 mm mgcl2 1 mg/ml bsa ph7 4 the amount of membrane was determined for each batch of membranes according to protein binding assay the minimum amount of membrane that gave 50% specific binding was used for the binding assay in most assays binding was tested using 8  x3bc g and 4  x3bc g protein of hcb1 and hcb2 membranes respectively the tested compounds were dissolved in dmso and diluted in assay buffer to a final concentration of 0 1% solvent total binding of [3h]cp55940 was evaluated with 1 5 nm to hcb1 and with 0 5 nm to hcb2 according to kd affinity of [3h]cp55940 for the r
722,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3927971,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
721,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3927971,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
720,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3927971,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
40,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3965133,1344698,Active,binding assay: the binding assays were performed by testing the ability of the new compounds to displace the radiolabeled synthetic non selective cannabinoid agonist [3h]cp55940  168 ci/mmol perkinelmer from the human cb1  hcb1 or human cb2  hcb2 receptors on membranes derived from stably transfected hek 293 cells  perkinelmer membranes were diluted in assay buffer  50 mm tris hcl 1 mm edta 1 mm mgcl2 1 mg/ml bsa ph7 4 the amount of membrane was determined for each batch of membranes according to protein binding assay the minimum amount of membrane that gave 50% specific binding was used for the binding assay in most assays binding was tested using 8  x3bc g and 4  x3bc g protein of hcb1 and hcb2 membranes respectively the tested compounds were dissolved in dmso and diluted in assay buffer to a final concentration of 0 1% solvent total binding of [3h]cp55940 was evaluated with 1 5 nm to hcb1 and with 0 5 nm to hcb2 according to kd affinity of [3h]cp55940 for the r
504,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3909495,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
2417,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL4109101,1344624,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
1187,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL2348278,739850,Active,displacement of [h3] cp 55940 from human recombinant cb1 receptor expressed in cho cells
1282,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3892903,1344076,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37  xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30  xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30  xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
420,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3696847,1258961,Active,radioligand binding assay: plasma membranes prepared from hek 293 ebna cells transfected with human cb1 or cb2 cannabinoid receptors  3 7 or 3 3  mu mol/mg protein receptor concentration perkinelmer were used for the radioligand binding studies the composition of incubation buffer for cb1 assay was 50 mm tris base 2 5 mm edta 5 mm mgcl sub 2 and 0 5 mg/ml fatty acid free bsa and for cb2 assay was 50 mm tris base 2 5 mm egta 5 mm mgcl sub 2 and 1 mg/ml fatty acid free bsa ph was adjusted to 7 4 by adding 1n hcl plasma membranes were diluted with incubation buffer to provide a final protein concentration of 2 4  mu g  cb1 or 8  mu g  cb2 per well in non binding surface polystyrene 96 well assay plates  corning compound solutions were prepared in silanized glass tubes and dispensed using pipette tips with superslik tm surface competition studies were performed using a final concentration of 0 72 nm [ sup 3h] cp 55 940  100 180 ci/mmol specific activity perkinelmer again
1175,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL550419,419194,Active,displacement of [3h]cp 55940 from cb1 receptor in rat brain by filtration assay
1312,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3964993,1344076,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 xd7 ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37  xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30  xb0 c for 30 min compounds were added to a final assay volume of 100  x3bc l and incubated for 30 min at 30  xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50  x3bc l lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan3 and 50  x3bc l detection solutions  20  x3bc m mab alexa700 camp 1:1 and 48  x3bc m ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped w
1153,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL1259076,517909,Active,displacement of [3h]cp55940 from rat brain cb1 receptor
449,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3899134,1344698,Active,binding assay: the binding assays were performed by testing the ability of the new compounds to displace the radiolabeled synthetic non selective cannabinoid agonist [3h]cp55940  168 ci/mmol perkinelmer from the human cb1  hcb1 or human cb2  hcb2 receptors on membranes derived from stably transfected hek 293 cells  perkinelmer membranes were diluted in assay buffer  50 mm tris hcl 1 mm edta 1 mm mgcl2 1 mg/ml bsa ph7 4 the amount of membrane was determined for each batch of membranes according to protein binding assay the minimum amount of membrane that gave 50% specific binding was used for the binding assay in most assays binding was tested using 8  x3bc g and 4  x3bc g protein of hcb1 and hcb2 membranes respectively the tested compounds were dissolved in dmso and diluted in assay buffer to a final concentration of 0 1% solvent total binding of [3h]cp55940 was evaluated with 1 5 nm to hcb1 and with 0 5 nm to hcb2 according to kd affinity of [3h]cp55940 for the r
450,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3899134,1344698,Active,binding assay: the binding assays were performed by testing the ability of the new compounds to displace the radiolabeled synthetic non selective cannabinoid agonist [3h]cp55940  168 ci/mmol perkinelmer from the human cb1  hcb1 or human cb2  hcb2 receptors on membranes derived from stably transfected hek 293 cells  perkinelmer membranes were diluted in assay buffer  50 mm tris hcl 1 mm edta 1 mm mgcl2 1 mg/ml bsa ph7 4 the amount of membrane was determined for each batch of membranes according to protein binding assay the minimum amount of membrane that gave 50% specific binding was used for the binding assay in most assays binding was tested using 8  x3bc g and 4  x3bc g protein of hcb1 and hcb2 membranes respectively the tested compounds were dissolved in dmso and diluted in assay buffer to a final concentration of 0 1% solvent total binding of [3h]cp55940 was evaluated with 1 5 nm to hcb1 and with 0 5 nm to hcb2 according to kd affinity of [3h]cp55940 for the r
1416,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3907056,1344698,Active,binding assay: the binding assays were performed by testing the ability of the new compounds to displace the radiolabeled synthetic non selective cannabinoid agonist [3h]cp55940  168 ci/mmol perkinelmer from the human cb1  hcb1 or human cb2  hcb2 receptors on membranes derived from stably transfected hek 293 cells  perkinelmer membranes were diluted in assay buffer  50 mm tris hcl 1 mm edta 1 mm mgcl2 1 mg/ml bsa ph7 4 the amount of membrane was determined for each batch of membranes according to protein binding assay the minimum amount of membrane that gave 50% specific binding was used for the binding assay in most assays binding was tested using 8  x3bc g and 4  x3bc g protein of hcb1 and hcb2 membranes respectively the tested compounds were dissolved in dmso and diluted in assay buffer to a final concentration of 0 1% solvent total binding of [3h]cp55940 was evaluated with 1 5 nm to hcb1 and with 0 5 nm to hcb2 according to kd affinity of [3h]cp55940 for the r
1124,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL2346978,738105,Active,displacement of [3h]cp 55940 from cb1 receptor in mouse whole brain membrane homogenates after 90 mins by liquid scintillation counting
1381,CHEMBL218,Cannabinoid CB1 receptor,CHEMBL3950538,1343914,Active,camp assay: cho cells expressing human cb1 or cb2 receptors are seeded 17 24 hours prior to the experiment 50 000 cells per well in a black 96 well plate with flat clear bottom  corning costar  3904 in dmem  invitrogen no 31331 1 times ht supplement with 10% fetal calf serum and incubated at 5% co2 and 37 xb0 c in a humidified incubator the growth medium was exchanged with krebs ringer bicarbonate buffer with 1 mm ibmx and incubated at 30 degree c for 30 min compounds were added to a final assay volume of 100 ul and incubated for 30 min at 30 xb0 c using the camp nano trf detection kit the assay  roche diagnostics was stopped by the addition of 50 ul lysis reagent  tris nacl 1 5% triton x100 2 5% np40 10% nan sub 3 and 50 ul detection solutions  20 um mab alexa700 camp 1:1 and 48 um ruthenium 2 aha camp and shaken for 2 h at room temperature the time resolved energy transfer is measured by a trf reader  evotec technologies gmbh equipped with a nd:yag laser as e
1135,CHEMBL253,Cannabinoid CB2 receptor,CHEMBL3968595,1343440,Active,radioligand displacement assay  cp55940 : further characterization of select compounds was performed using radioligand displacement of [3h]1 and equilibrium dissociation constant  ki values were determined selectivity of these compounds at cb1 versus cb2 was also determined by obtaining ki values at either receptor using displacement of [3h]cp55940 in membranes of cho k1 cells over expressing either receptor data reported are average values from 3 6 measurements 
2346,CHEMBL253,Cannabinoid CB2 receptor,CHEMBL2022406,660304,Inactive,displacement of [3h] cp55940 from cb2 receptor after 90 mins by liquid scintillation counting
1134,CHEMBL253,Cannabinoid CB2 receptor,CHEMBL3968595,1343439,Active,radioligand displacement assay  sr141716 : further characterization of select compounds was performed using radioligand displacement of [3h]1 and equilibrium dissociation constant  ki values were determined selectivity of these compounds at cb1 versus cb2 was also determined by obtaining ki values at either receptor using displacement of sr141716  [3h]1 in membranes of cho k1 cells over expressing either receptor data reported are average values from 3 6 measurements 
688,CHEMBL253,Cannabinoid CB2 receptor,CHEMBL2030769,660989,Active,displacement of [3h]cp55940 from cb2 receptor expressed in cho k1 cells
1609,CHEMBL253,Cannabinoid CB2 receptor,CHEMBL67464,297304,Active,displacement of [3h]cp 55940 from cb2 receptor in mouse spleen membrane
1136,CHEMBL253,Cannabinoid CB2 receptor,CHEMBL3968595,1343441,Active,radioligand displacement assay  cp55940 : further characterization of select compounds was performed using radioligand displacement of [3h]1 and equilibrium dissociation constant  ki values were determined selectivity of these compounds at cb1 versus cb2 was also determined by obtaining ki values at either receptor using displacement of [3h]cp55940 in membranes of cho k1 cells over expressing either receptor data reported are average values from 3 6 measurements 
673,CHEMBL261,Carbonic anhydrase I,CHEMBL2326509,727274,Inactive,inhibition of full length human recombinant full length ca1 cytosolic isoform after 15 mins by stopped flow co2 hydration method
676,CHEMBL261,Carbonic anhydrase I,CHEMBL215355,271037,Active,inhibition of human cloned ca1 by co2 hydration assay
1088,CHEMBL261,Carbonic anhydrase I,CHEMBL342390,47710,Active,inhibition of human recombinant carbonic anhydrase i  ca1 
876,CHEMBL261,Carbonic anhydrase I,CHEMBL196871,47710,Active,inhibition of human recombinant carbonic anhydrase i  ca1 
1215,CHEMBL261,Carbonic anhydrase I,CHEMBL121922,50374,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 
245,CHEMBL261,Carbonic anhydrase I,CHEMBL332549,50374,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 
1832,CHEMBL261,Carbonic anhydrase I,CHEMBL215276,271037,Active,inhibition of human cloned ca1 by co2 hydration assay
1172,CHEMBL261,Carbonic anhydrase I,CHEMBL103302,50367,Active,inhibitory activity against human carbonic anhydrase i  ca1 
564,CHEMBL261,Carbonic anhydrase I,CHEMBL2070210,678515,Active,inhibition of human ca1 using co2 as substrate incubated for 6 hrs prior to substrate addition measured for 10 to 100 secs by stopped flow technique
972,CHEMBL261,Carbonic anhydrase I,CHEMBL387402,670598,Inactive,neuroprotective activity in wistar rat acute hippocampal ca1 region assessed as protection from oxygen glucose deprivation induced anoxia depolarization at 1 um administered 15 mins before and during 7 mins oxygen deprivation challenge
973,CHEMBL261,Carbonic anhydrase I,CHEMBL387402,670600,Active,neuroprotective activity in wistar rat hippocampal ca1 region assessed as change in field excitatory postsynaptic potential at basal conditions at 1 to 5 um by electrophysiological analysis
530,CHEMBL261,Carbonic anhydrase I,CHEMBL2326507,727274,Inactive,inhibition of full length human recombinant full length ca1 cytosolic isoform after 15 mins by stopped flow co2 hydration method
1735,CHEMBL261,Carbonic anhydrase I,CHEMBL477748,667533,Active,noncompetitive inhibition of human ca1 using 4npa as substrate for 3 mins by lineweaver burk plot analysis
1704,CHEMBL261,Carbonic anhydrase I,CHEMBL3137754,50354,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 
1969,CHEMBL261,Carbonic anhydrase I,CHEMBL3137750,50354,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 
340,CHEMBL261,Carbonic anhydrase I,CHEMBL215917,271037,Active,inhibition of human cloned ca1 by co2 hydration assay
680,CHEMBL261,Carbonic anhydrase I,CHEMBL3138364,50354,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 
2250,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,436563,Active,inhibition of human recombinant ca1 by stopped flow co2 assay
85,CHEMBL261,Carbonic anhydrase I,CHEMBL6852,47713,Active,inhibition of human carbonic anhydrase i  cai 
86,CHEMBL261,Carbonic anhydrase I,CHEMBL6852,50367,Active,inhibitory activity against human carbonic anhydrase i  ca1 
87,CHEMBL261,Carbonic anhydrase I,CHEMBL6852,50374,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 
2252,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,552127,Active,inhibition of human recombinant ca1 by stopped flow co2 hydration assay
2251,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,459696,Active,inhibition of brucella suis ca1 expressed in escherichia coli bl21 de3 by stopped flow co2 hydration assay
2249,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,367820,Active,inhibition of human recombinant ca1 by stopped flow co2 hydrase assay
2248,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,263636,Active,inhibition of human recombinant ca1
2324,CHEMBL261,Carbonic anhydrase I,CHEMBL1242794,512001,Active,inhibition of human cloned ca1 after 15 mins by stopped flow co2 hydration assay
88,CHEMBL261,Carbonic anhydrase I,CHEMBL6852,239250,Active,inhibitory activity against beta carbonic anhydrase  cab from methanobacterium thermoautotrophicum
2246,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,50367,Active,inhibitory activity against human carbonic anhydrase i  ca1 
2245,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,47713,Active,inhibition of human carbonic anhydrase i  cai 
2238,CHEMBL261,Carbonic anhydrase I,CHEMBL2326508,727274,Inactive,inhibition of full length human recombinant full length ca1 cytosolic isoform after 15 mins by stopped flow co2 hydration method
146,CHEMBL261,Carbonic anhydrase I,CHEMBL2148105,687196,Active,inhibition of human recombinant cytosolic ca1 preincubated for 15 mins by stopped flow co2 hydration method
2380,CHEMBL261,Carbonic anhydrase I,CHEMBL24147,1238074,Active,competitive inhibition of human erythrocytes ca1 using 4 nitrophenylacetate as substrate by lineweaver burk plot analysis
2247,CHEMBL261,Carbonic anhydrase I,CHEMBL6705,50374,Active,inhibitory activity against human recombinant carbonic anhydrase i  ca1 
970,CHEMBL205,Carbonic anhydrase II,CHEMBL234507,296124,Active,binding affinity to bovine ca2 by typical isothermal titration calorimetry
615,CHEMBL205,Carbonic anhydrase II,CHEMBL394355,296124,Active,binding affinity to bovine ca2 by typical isothermal titration calorimetry
441,CHEMBL205,Carbonic anhydrase II,CHEMBL183419,1262264,Active,inhibition of human ca2 incubated for 15 mins prior to testing by stopped flow co2 hydrase assay
2253,CHEMBL205,Carbonic anhydrase II,CHEMBL442798,296124,Active,binding affinity to bovine ca2 by typical isothermal titration calorimetry
317,CHEMBL205,Carbonic anhydrase II,CHEMBL2326506,727273,Inactive,inhibition of full length human recombinant ca2 cytosolic isoform after 15 mins by stopped flow co2 hydration method
2218,CHEMBL205,Carbonic anhydrase II,CHEMBL395543,296124,Active,binding affinity to bovine ca2 by typical isothermal titration calorimetry
440,CHEMBL205,Carbonic anhydrase II,CHEMBL183419,552128,Active,inhibition of human recombinant ca2 by stopped flow co2 hydration assay
318,CHEMBL205,Carbonic anhydrase II,CHEMBL2326506,727275,Active,inhibition of human ca2 ala65ser and asn67gln double mutant expressed in escherichia coli strain bl21  de3 after 6 hrs by stopped flow co2 hydration method
1011,CHEMBL205,Carbonic anhydrase II,CHEMBL2326509,727273,Inactive,inhibition of full length human recombinant ca2 cytosolic isoform after 15 mins by stopped flow co2 hydration method
444,CHEMBL205,Carbonic anhydrase II,CHEMBL1644699,724721,Active,inhibition of human recombinant wild type ca2 by stopped flow co2 hydration method
445,CHEMBL205,Carbonic anhydrase II,CHEMBL1644699,758952,Active,inhibition of human recombinant ca2 by co2 hydration assay
446,CHEMBL205,Carbonic anhydrase II,CHEMBL1644699,1235241,Active,inhibition of human ca2 after 15 mins by stopped flow/co2 hydration assay
447,CHEMBL205,Carbonic anhydrase II,CHEMBL1644699,1461934,Active,inhibition of human ca2 incubated for 15 mins by stopped flow co2 hydration assay
974,CHEMBL205,Carbonic anhydrase II,CHEMBL2321923,727273,Inactive,inhibition of full length human recombinant ca2 cytosolic isoform after 15 mins by stopped flow co2 hydration method
1743,CHEMBL3594,Carbonic anhydrase IX,CHEMBL521690,352789,Active,inhibition of human ca9 catalytic domain by co2 hydration stopped flow assay
1732,CHEMBL3594,Carbonic anhydrase IX,CHEMBL3798303,1295838,Active,slow rate dissociation at human recombinant ca9 catalytic domain after 30 sec by surface plasmon resonance assay
1731,CHEMBL3594,Carbonic anhydrase IX,CHEMBL3798303,1295826,Active,binding affinity to human recombinant ca9 catalytic domain by fluorescence based thermal shift assay
1699,CHEMBL3594,Carbonic anhydrase IX,CHEMBL2070204,678517,Active,inhibition of human ca9 using co2 as substrate incubated for 6 hrs prior to substrate addition measured for 10 to 100 secs by stopped flow technique
2042,CHEMBL3594,Carbonic anhydrase IX,CHEMBL466234,352789,Active,inhibition of human ca9 catalytic domain by co2 hydration stopped flow assay
2091,CHEMBL3594,Carbonic anhydrase IX,CHEMBL468945,352789,Active,inhibition of human ca9 catalytic domain by co2 hydration stopped flow assay
598,CHEMBL3594,Carbonic anhydrase IX,CHEMBL467897,352789,Active,inhibition of human ca9 catalytic domain by co2 hydration stopped flow assay
1258,CHEMBL3242,Carbonic anhydrase XII,CHEMBL2323124,725593,Active,inhibition of human ca12 by stopped flow assay
2206,CHEMBL3242,Carbonic anhydrase XII,CHEMBL466832,352790,Active,inhibition of human ca12 catalytic domain by co2 hydration stopped flow assay
1195,CHEMBL3242,Carbonic anhydrase XII,CHEMBL1290111,539682,Active,inhibition of human recombinant ca12 catalytic domain by stopped flow co2 hydration method
1158,CHEMBL3242,Carbonic anhydrase XII,CHEMBL2070209,678518,Active,inhibition of human ca12 using co2 as substrate incubated for 6 hrs prior to substrate addition measured for 10 to 100 secs by stopped flow technique
418,CHEMBL3242,Carbonic anhydrase XII,CHEMBL4078936,1433067,Active,inhibition of human ca12 by stopped flow co2 hydration method
235,CHEMBL3837,Cathepsin L,CHEMBL1419509,1906,Active,qfret based counterscreen for pfm18aap inhibitors: biochemical high throughput screening assay to identify inhibitors of the cathepsin l proteinase  ctsl1 
2000,CHEMBL308,Cyclin-dependent kinase 1,CHEMBL189136,241038,Active,inhibitory activity against cyclin dependent kinase 1  cdk1 
1255,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL553,256632,Inactive,average binding constant for cdk2 nanot active at 10 um
2359,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL409450,1448892,Active,inhibition of recombinant human n terminal gst tagged cdk2  m1 to l298 residues /cyclin e1  m1 to a395 residues expressed in sf9 cells at 1 um using rb ctf as substrate by filter binding assay
2357,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL409450,1448891,Active,inhibition of recombinant human n terminal gst tagged cdk2  m1 to l298 residues /cyclin a2  m1 to l432 residues expressed in baculovirus infected sf9 cells at 1 um using histone h1 as substrate by filter binding assay
2356,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL409450,1448891,Active,inhibition of recombinant human n terminal gst tagged cdk2  m1 to l298 residues /cyclin a2  m1 to l432 residues expressed in baculovirus infected sf9 cells at 1 um using histone h1 as substrate by filter binding assay
395,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL31965,256632,Inactive,average binding constant for cdk2 nanot active at 10 um
342,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL1973540,53362,Active,inhibitory activity against human cyclin dependent kinase 2  cdk2 
341,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL1973540,53361,Active,evaluated for inhibition of human cyclin dependent kinase 2  cdk2 
2358,CHEMBL301,Cyclin-dependent kinase 2,CHEMBL409450,1448892,Active,inhibition of recombinant human n terminal gst tagged cdk2  m1 to l298 residues /cyclin e1  m1 to a395 residues expressed in sf9 cells at 1 um using rb ctf as substrate by filter binding assay
554,CHEMBL2094128,Cyclin-dependent kinase 2/cyclin A,CHEMBL564829,422323,Active,inhibition of cdk2 in human a2780 cells assessed as reduction of hyperphosphorylated form of retinoblastoma protein at 3 um relative to control
1426,CHEMBL2094128,Cyclin-dependent kinase 2/cyclin A,CHEMBL509032,624844,Active,binding constant for cdk2 kinase domain
553,CHEMBL2094128,Cyclin-dependent kinase 2/cyclin A,CHEMBL564829,422322,Active,inhibition of cdk2 in human a2780 cells assessed as reduction of hyperphosphorylated form of retinoblastoma protein at 1 um relative to control
555,CHEMBL2094128,Cyclin-dependent kinase 2/cyclin A,CHEMBL564829,422324,Active,inhibition of cdk2 in human a2780 cells assessed as accumulation of hypophosphorylated form of retinoblastoma protein at 1 um relative to control
556,CHEMBL2094128,Cyclin-dependent kinase 2/cyclin A,CHEMBL564829,422325,Active,inhibition of cdk2 in human a2780 cells assessed as accumulation of hypophosphorylated form of retinoblastoma protein at 3 um relative to control
557,CHEMBL2094128,Cyclin-dependent kinase 2/cyclin A,CHEMBL564829,1424510,Active,inhibition of cdk2  unknown origin 
2117,CHEMBL1908,Cytochrome P450 11B1,CHEMBL4111388,1344326,Active,cellular enzyme assay: the expression plasmids contains the orf for either human/cyno cyp11b1 or cyp11b2 under the control of a suitable promoter  cmv promoter and a suitable resistance marker  neomycin using standard techniques the expression plasmid is transfected into g 402 cells and these cells are then selected for expressing the given resistance markers individual cell clones are then selected and assessed for displaying the desired enzymatic activity using 11 deoxycorticosterone  cyp11b2 or 11 deoxycortisol  cyp11b1 as a substrate g 402 cells expressing cyp11 constructs were established as described above and maintained in mccoy's 5a medium modified atcc catalog no 30 2007 containing 10% fcs and 400  x3bc g/ml g418  geneticin at 37 xb0 c under an atmosphere of 5% co2/95% air cellular enzyme assays were performed in dmem/f12 medium containing 2 5% charcoal treated fcs and appropriate concentration of substrate  0 3 10  x3bc m 11 deoxycorticosterone 11 deoxycortis
2118,CHEMBL1908,Cytochrome P450 11B1,CHEMBL4111388,1344327,Active,cellular enzyme assay: the expression plasmids contains the orf for either human/cyno cyp11b1 or cyp11b2 under the control of a suitable promoter  cmv promoter and a suitable resistance marker  neomycin using standard techniques the expression plasmid is transfected into g 402 cells and these cells are then selected for expressing the given resistance markers individual cell clones are then selected and assessed for displaying the desired enzymatic activity using 11 deoxycorticosterone  cyp11b2 or 11 deoxycortisol  cyp11b1 as a substrate g 402 cells expressing cyp11 constructs were established as described above and maintained in mccoy's 5a medium modified atcc catalog no 30 2007 containing 10% fcs and 400  x3bc g/ml g418  geneticin at 37 xb0 c under an atmosphere of 5% co2/95% air cellular enzyme assays were performed in dmem/f12 medium containing 2 5% charcoal treated fcs and appropriate concentration of substrate  0 3 10  x3bc m 11 deoxycorticosterone 11 deoxycortis
1408,CHEMBL2722,Cytochrome P450 11B2,CHEMBL2011250,1344534,Active,cellular inhibition assay: v79mz cells expressing human cyp11b1 and human cyp11b2 genes respectively were grown on 24 well cell culture plates  8 xd7 10^5 cells per well with 1 9 cm^2 culture area per well in 1 ml dmem culture medium until confluence before testing the dmem culture medium was removed and 450  x3bc l of fresh dmem containing the inhibitor in at least three different concentrations for determining the ic50 value was added to each well every value was determined at least three times after a pre incubation step of 60 min at 37 xb0 c the reaction was started by the addition of 50  x3bc l of dmem containing the substrate 11 deoxycorticosterone  containing 0 15  x3bc ci of [1 2 3h] 11 deoxycorticosterone dissolved in ethanol final concentration 100 nm the v79mzh11b1 cells were incubated for 25 min the v79mzh11b2 cells were incubated for 50 min controls were treated in the same way without inhibitors the maximum dmso concentration in each well was 1% e
1410,CHEMBL2722,Cytochrome P450 11B2,CHEMBL1440486,1344534,Active,cellular inhibition assay: v79mz cells expressing human cyp11b1 and human cyp11b2 genes respectively were grown on 24 well cell culture plates  8 xd7 10^5 cells per well with 1 9 cm^2 culture area per well in 1 ml dmem culture medium until confluence before testing the dmem culture medium was removed and 450  x3bc l of fresh dmem containing the inhibitor in at least three different concentrations for determining the ic50 value was added to each well every value was determined at least three times after a pre incubation step of 60 min at 37 xb0 c the reaction was started by the addition of 50  x3bc l of dmem containing the substrate 11 deoxycorticosterone  containing 0 15  x3bc ci of [1 2 3h] 11 deoxycorticosterone dissolved in ethanol final concentration 100 nm the v79mzh11b1 cells were incubated for 25 min the v79mzh11b2 cells were incubated for 50 min controls were treated in the same way without inhibitors the maximum dmso concentration in each well was 1% e
337,CHEMBL2722,Cytochrome P450 11B2,CHEMBL1172842,491986,Active,inhibition of human cyp11b2 expressed in hamster v79mzh cells
2128,CHEMBL1978,Cytochrome P450 19A1,CHEMBL3359965,1174179,Active,inhibition of human placental microsomal cyp19 using [1beta 3h]androstenedione substrate pre incubated for 5 mins by scintillation counting method
1368,CHEMBL236,Delta opioid receptor,CHEMBL1387605,504357,Active,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1087,CHEMBL236,Delta opioid receptor,CHEMBL1477197,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
1367,CHEMBL236,Delta opioid receptor,CHEMBL1387605,504357,Active,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1365,CHEMBL236,Delta opioid receptor,CHEMBL1387605,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1369,CHEMBL236,Delta opioid receptor,CHEMBL1387605,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
58,CHEMBL236,Delta opioid receptor,CHEMBL1358924,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
57,CHEMBL236,Delta opioid receptor,CHEMBL1358924,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
56,CHEMBL236,Delta opioid receptor,CHEMBL1358924,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
570,CHEMBL236,Delta opioid receptor,CHEMBL1276308,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
571,CHEMBL236,Delta opioid receptor,CHEMBL1276308,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1656,CHEMBL236,Delta opioid receptor,CHEMBL1492017,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1657,CHEMBL236,Delta opioid receptor,CHEMBL1492017,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1658,CHEMBL236,Delta opioid receptor,CHEMBL1492017,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1659,CHEMBL236,Delta opioid receptor,CHEMBL1492017,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1366,CHEMBL236,Delta opioid receptor,CHEMBL1387605,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1370,CHEMBL236,Delta opioid receptor,CHEMBL1387605,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
59,CHEMBL236,Delta opioid receptor,CHEMBL1358924,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
1372,CHEMBL236,Delta opioid receptor,CHEMBL1387605,504900,Inactive,luminescence based cell based high throughput confirmation assay for inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1086,CHEMBL236,Delta opioid receptor,CHEMBL1477197,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
73,CHEMBL236,Delta opioid receptor,CHEMBL1412822,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1085,CHEMBL236,Delta opioid receptor,CHEMBL1477197,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1084,CHEMBL236,Delta opioid receptor,CHEMBL1477197,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1083,CHEMBL236,Delta opioid receptor,CHEMBL1477197,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1082,CHEMBL236,Delta opioid receptor,CHEMBL1477197,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
72,CHEMBL236,Delta opioid receptor,CHEMBL1412822,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
71,CHEMBL236,Delta opioid receptor,CHEMBL1412822,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1480,CHEMBL236,Delta opioid receptor,CHEMBL1574879,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1481,CHEMBL236,Delta opioid receptor,CHEMBL1574879,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1482,CHEMBL236,Delta opioid receptor,CHEMBL1574879,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1483,CHEMBL236,Delta opioid receptor,CHEMBL1574879,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1484,CHEMBL236,Delta opioid receptor,CHEMBL1574879,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
1485,CHEMBL236,Delta opioid receptor,CHEMBL1574879,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
75,CHEMBL236,Delta opioid receptor,CHEMBL1412822,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
76,CHEMBL236,Delta opioid receptor,CHEMBL1412822,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
60,CHEMBL236,Delta opioid receptor,CHEMBL1358924,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
1660,CHEMBL236,Delta opioid receptor,CHEMBL1492017,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
1373,CHEMBL236,Delta opioid receptor,CHEMBL1387605,504914,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
1371,CHEMBL236,Delta opioid receptor,CHEMBL1387605,504900,Inactive,luminescence based cell based high throughput confirmation assay for inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
572,CHEMBL236,Delta opioid receptor,CHEMBL1276308,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
74,CHEMBL236,Delta opioid receptor,CHEMBL1412822,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
262,CHEMBL236,Delta opioid receptor,CHEMBL1331866,588435,Active,counterscreen for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors: luminescence based cell based high throughput dose response assay to identify agonists of oprm1 homodimerization
250,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
249,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
574,CHEMBL236,Delta opioid receptor,CHEMBL1276308,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
1661,CHEMBL236,Delta opioid receptor,CHEMBL1492017,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
1287,CHEMBL236,Delta opioid receptor,CHEMBL219916,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
575,CHEMBL236,Delta opioid receptor,CHEMBL1276308,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
134,CHEMBL236,Delta opioid receptor,CHEMBL1461585,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
133,CHEMBL236,Delta opioid receptor,CHEMBL1461585,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
251,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
132,CHEMBL236,Delta opioid receptor,CHEMBL1461585,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
55,CHEMBL236,Delta opioid receptor,CHEMBL1358924,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
130,CHEMBL236,Delta opioid receptor,CHEMBL1461585,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
129,CHEMBL236,Delta opioid receptor,CHEMBL1461585,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
573,CHEMBL236,Delta opioid receptor,CHEMBL1276308,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1283,CHEMBL236,Delta opioid receptor,CHEMBL219916,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1284,CHEMBL236,Delta opioid receptor,CHEMBL219916,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1285,CHEMBL236,Delta opioid receptor,CHEMBL219916,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1288,CHEMBL236,Delta opioid receptor,CHEMBL219916,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
131,CHEMBL236,Delta opioid receptor,CHEMBL1461585,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
252,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1286,CHEMBL236,Delta opioid receptor,CHEMBL219916,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
253,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
254,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
261,CHEMBL236,Delta opioid receptor,CHEMBL1331866,588411,Inactive,counterscreen for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors: luminescence based cell based high throughput dose response assay to identify agonists of oprd1 homodimerization
255,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504904,Active,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
260,CHEMBL236,Delta opioid receptor,CHEMBL1331866,588408,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput dose response assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
259,CHEMBL236,Delta opioid receptor,CHEMBL1331866,588407,Active,luminescence based cell based high throughput dose response assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
258,CHEMBL236,Delta opioid receptor,CHEMBL1331866,588407,Active,luminescence based cell based high throughput dose response assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
256,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504904,Active,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
257,CHEMBL236,Delta opioid receptor,CHEMBL1331866,504905,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
2261,CHEMBL238,Dopamine transporter,CHEMBL450769,393256,Active,inhibition of [3h]dopamine reuptake at human dat expressed in hek cells
1519,CHEMBL238,Dopamine transporter,CHEMBL3085032,257284,Active,displacement of [3h]win from dat in rat brain membrane
2262,CHEMBL238,Dopamine transporter,CHEMBL450769,393257,Active,displacement of [125i]rti55 from human dat expressed in hek cells
1457,CHEMBL238,Dopamine transporter,CHEMBL399147,309353,Active,inhibition of dat
1479,CHEMBL238,Dopamine transporter,CHEMBL396754,296170,Active,displacement of [125i]rti55 from human dat expressed in cos1 cell membrane
432,CHEMBL238,Dopamine transporter,CHEMBL562476,431885,Active,inhibition of [3h]win 35428 binding to human recombinant dat expressed in cho cells by scintillation counting
1538,CHEMBL238,Dopamine transporter,CHEMBL450987,393256,Active,inhibition of [3h]dopamine reuptake at human dat expressed in hek cells
2044,CHEMBL238,Dopamine transporter,CHEMBL257593,331704,Active,inhibition of [3h]da uptake at human recombinant dat expressed in hek293 cells
822,CHEMBL238,Dopamine transporter,CHEMBL460406,393257,Active,displacement of [125i]rti55 from human dat expressed in hek cells
821,CHEMBL238,Dopamine transporter,CHEMBL460406,393256,Active,inhibition of [3h]dopamine reuptake at human dat expressed in hek cells
2156,CHEMBL238,Dopamine transporter,CHEMBL4094047,1439846,Active,inhibition of [3h] 5 dopamine reuptake in human dat expressed in hek293 cells by microbeta liquid scintillation counting method
61,CHEMBL238,Dopamine transporter,CHEMBL3085027,257284,Active,displacement of [3h]win from dat in rat brain membrane
1259,CHEMBL238,Dopamine transporter,CHEMBL1201066,1164249,Active,inhibition of human dat expressed in hek293 cells at incubated for 15 mins by neurotransmitter reuptake assay
1428,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,456513,Active,inhibition of mouse full length gst tagged b raf v600e mutant assessed as mek1 phosphorylation by [32p]atp sds page gel kinase assay
1429,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,632311,Active,inhibition of wild type b raf assessed as inhibition of mek1 phosphorylation using [gamma 33p]atp by beta counting
1439,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1388685,Active,inhibition of recombinant braf  409 to 765 residues  unknown origin expressed in baculovirus expression system using mek1 as substrate after 25 mins in presence of [gamma33p]atp by beta plate counting method
1431,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,665515,Active,inhibition of mouse full length gst tagged braf v600e mutant mediated mek1 phosphorylation preincubated for 1 hr prior to substrate addition measured after 25 mins by page analysis
1437,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1380299,Active,inhibition of recombinant braf  409 to 765 residues  unknown origin using mek1 as substrate after 25 mins in presence of gamma [33p]atp
1436,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1175979,Active,inhibition of full length gst tagged mouse braf v600e mutant using mek1 as substrate preincubated for 1 hr
1440,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1388686,Active,inhibition of recombinant braf  409 to 765 residues v599e mutant  unknown origin expressed in baculovirus expression system using mek1 as substrate after 25 mins in presence of [gamma33p]atp by beta plate counting method
1435,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1174653,Active,inhibition of human gst tagged full length b raf v600e mutant  unknown origin using his6 tagged full length human mek1  k97r substrate and [33p] gamma atp incubated for 120 mins by by filter binding method
1441,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1391412,Active,inhibition of mouse full length gst tagged braf v600e mutant using recombinant human full length n terminal his tagged mek1 as substrate preincubated for 1 hr followed by substrate addition measured after 25 mins by nu page gel based phosphor screen analysis
1434,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,756116,Active,inhibition of full length recombinant c raf  unknown origin using mek1 as substrate after 1 hr by luminescence assay
1430,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,645015,Active,inhibition of mouse full length gst tagged b raf v600e mutant mediated human mek1 phosphorylation after 1 hr preincubation
1443,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1391837,Active,inhibition of b raf v600e mutant  unknown origin using mek1 as substrate measured after 2 hrs by elisa
1433,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,756111,Active,inhibition of b raf v600e mutant  unknown origin using mek1 as substrate
1445,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1480958,Active,inhibition of araf  unknown origin using human his6 tagged mek1 k97r mutant as substrate pretreated for 20 mins followed by [33p] atp addition measured after 2 hrs by filter binding method
1446,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1480959,Active,inhibition of wild type braf  unknown origin using human his6 tagged mek1 k97r mutant as substrate pretreated for 20 mins followed by [33p] atp addition measured after 2 hrs by filter binding method
1447,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1480960,Active,inhibition of craf  unknown origin using human his6 tagged mek1 k97r mutant as substrate pretreated for 20 mins followed by [33p] atp addition measured after 2 hrs by filter binding method
1438,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1388684,Active,inhibition of recombinant raf 1  305 to 648 residues  unknown origin expressed in baculovirus expression system using mek1 as substrate after 25 mins in presence of [gamma33p]atp by beta plate counting method
1432,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,695963,Active,inhibition of mouse full length gst tagged braf v600e mutant using mek1 as substrate incubated for 1 hr prior to substrate addition measured after 25 min by gel electrophoresis
1444,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1480956,Active,inhibition of recombinant human n terminal gst tagged braf catalytic domain  416 to 766 residues v600e mutant expressed in baculovirus expression system using human his6 tagged mek1 k97r mutant as substrate pretreated for 20 mins followed by [33p] atp addition measured after 2 hrs by filter binding method
1442,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL1336,1391836,Active,inhibition of b raf  unknown origin using mek1 as substrate measured after 2 hrs by elisa
1596,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL553,1394813,Active,inhibition of recombinant full length gst tagged human b raf v600e mutant  417 to 766 residues expressed in baculovirus infected sf9 cells using n terminal his tagged human mek1 as substrate by nu page gel based phosphor screen analysis
1593,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL553,687332,Active,inhibition of full length gst tagged mouse b raf v600e mutant mediated mek1 phosphorylation after 1 hr by gel electrophoresis
1594,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL553,1301358,Active,inhibition of mouse full length gst tagged braf v600e mutant assessed as reduction in human full length n terminal his tagged mek1 phosphorylation pre incubated for 1 hr before mek1 addition and measured after 25 mins
1595,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL553,1381596,Active,inhibition of mouse full length gst tagged braf v600e mutant using recombinant human full length n terminal his tagged mek1 as substrate preincubated for 60 mins followed by substrate addition and measured after 25 mins by elisa
1597,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL553,1452455,Active,inhibition of full length gst tagged mouse braf v600e mutant using recombinant full length human n terminal his tagged mek1 as substrate preincubated for 60 mins followed by substrate addition measured after 25 mins in presence of atp addition by electrophoresis method
1592,CHEMBL3587,Dual specificity mitogen-activated protein kinase kinase 1,CHEMBL553,687251,Active,inhibition of mouse full length gst tagged braf v600e mutant using n terminal his tagged mek1 as substrate incubated for 1 hr prior to substrate addition measured for 25 mins by page analysis
2482,CHEMBL2363049,Epidermal growth factor receptor,CHEMBL291986,68095,Active,in vitro inhibition of erbb2 receptor kinase autophosphorylation 
2467,CHEMBL2363049,Epidermal growth factor receptor,CHEMBL1958220,649306,Active,inhibition of histidine tagged human recombinant cytoplasmic domain of her2 expressed in baculovirus infected insect sf9 cells after 1 hr by delfia/time resolved fluorometric analysis
2479,CHEMBL2363049,Epidermal growth factor receptor,CHEMBL398793,295195,Active,inhibition of human her2
2431,CHEMBL2363049,Epidermal growth factor receptor,CHEMBL230011,624804,Active,binding constant for erbb2 kinase domain
2409,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426286,770082,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
468,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3425671,1365576,Active,inhibition of egfr e746_a750 deletion mutant in human pc9 cells assessed as reduction in cell viability after 72 hrs by mtt assay
467,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3425671,1204630,Active,inhibition of gst tagged human recombinant egfr catalytic domain  668 to 1210 amino acids t790m/l858r mutant expressed in sf9 cells pre incubated for 30 mins before atp and substrate addition by homogeneous time resolved fret assay
466,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3425671,1204630,Active,inhibition of gst tagged human recombinant egfr catalytic domain  668 to 1210 amino acids t790m/l858r mutant expressed in sf9 cells pre incubated for 30 mins before atp and substrate addition by homogeneous time resolved fret assay
464,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3425671,1204630,Active,inhibition of gst tagged human recombinant egfr catalytic domain  668 to 1210 amino acids t790m/l858r mutant expressed in sf9 cells pre incubated for 30 mins before atp and substrate addition by homogeneous time resolved fret assay
463,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3425671,1204629,Active,inhibition of gst tagged human recombinant egfr catalytic domain  668 to 1210 amino acids l858r mutant expressed in sf9 cells pre incubated for 30 mins before atp and substrate addition by homogeneous time resolved fret assay
462,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3425671,1204629,Active,inhibition of gst tagged human recombinant egfr catalytic domain  668 to 1210 amino acids l858r mutant expressed in sf9 cells pre incubated for 30 mins before atp and substrate addition by homogeneous time resolved fret assay
461,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3425671,1204629,Active,inhibition of gst tagged human recombinant egfr catalytic domain  668 to 1210 amino acids l858r mutant expressed in sf9 cells pre incubated for 30 mins before atp and substrate addition by homogeneous time resolved fret assay
460,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3425671,1204629,Active,inhibition of gst tagged human recombinant egfr catalytic domain  668 to 1210 amino acids l858r mutant expressed in sf9 cells pre incubated for 30 mins before atp and substrate addition by homogeneous time resolved fret assay
1241,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3919051,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
1251,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090361,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
743,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant
465,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3425671,1204630,Active,inhibition of gst tagged human recombinant egfr catalytic domain  668 to 1210 amino acids t790m/l858r mutant expressed in sf9 cells pre incubated for 30 mins before atp and substrate addition by homogeneous time resolved fret assay
469,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3425671,1365577,Active,inhibition of egfr e746_a750 deletion/t790m mutant in human growth resistant pc9 cells assessed as reduction in cell viability after 72 hrs by mtt assay
742,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant
732,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1922898,632227,Active,inhibition of human n terminus peptide  dykdddd  tagged egfr expressed in baculovirus infected insect cells using [gamma 32p]atp as substrate after 60 mins by scintillation counting
2408,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426286,770081,Active,inhibition of wild type egfr phosphorylation in human lovo cells after 2 hrs by fluorescence assay
2468,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3982666,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
731,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1922898,632227,Active,inhibition of human n terminus peptide  dykdddd  tagged egfr expressed in baculovirus infected insect cells using [gamma 32p]atp as substrate after 60 mins by scintillation counting
1181,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2436978,775356,Inactive,inhibition of human wild type egfr at 1 um by qpcr analysis
748,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant
747,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant
746,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant
1119,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL437584,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
1118,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL437584,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
1117,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL437584,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
745,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant
1116,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL437584,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
1253,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090361,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
741,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant
744,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256426,517320,Active,inhibition of egfr l858 mutant
730,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1922898,632227,Active,inhibition of human n terminus peptide  dykdddd  tagged egfr expressed in baculovirus infected insect cells using [gamma 32p]atp as substrate after 60 mins by scintillation counting
1252,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090361,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
729,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1922898,632227,Active,inhibition of human n terminus peptide  dykdddd  tagged egfr expressed in baculovirus infected insect cells using [gamma 32p]atp as substrate after 60 mins by scintillation counting
705,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3952465,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
470,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3425671,1365578,Active,inhibition of egfr in human nci h460 cells assessed as reduction in cell viability after 72 hrs by mtt assay
1254,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090361,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
917,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL249496,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
784,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3945072,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
943,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770082,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
815,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354187,1170825,Active,inhibition of egfr t790m/del746 to 750 mutant  unknown origin by high throughput biochemical screening
942,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770082,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
816,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354187,1170825,Active,inhibition of egfr t790m/del746 to 750 mutant  unknown origin by high throughput biochemical screening
817,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354187,1170825,Active,inhibition of egfr t790m/del746 to 750 mutant  unknown origin by high throughput biochemical screening
818,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354187,1170825,Active,inhibition of egfr t790m/del746 to 750 mutant  unknown origin by high throughput biochemical screening
576,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3736480,1261426,Active,inhibition of human egfr t790m/l858r double mutant using fl eeplywsfpakkk conh2 as substrate preincubated for 30 mins followed by addition of substrate measured after 30 mins by morrison plot analysis
577,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3736480,1261426,Active,inhibition of human egfr t790m/l858r double mutant using fl eeplywsfpakkk conh2 as substrate preincubated for 30 mins followed by addition of substrate measured after 30 mins by morrison plot analysis
578,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3736480,1261426,Active,inhibition of human egfr t790m/l858r double mutant using fl eeplywsfpakkk conh2 as substrate preincubated for 30 mins followed by addition of substrate measured after 30 mins by morrison plot analysis
579,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3736480,1261426,Active,inhibition of human egfr t790m/l858r double mutant using fl eeplywsfpakkk conh2 as substrate preincubated for 30 mins followed by addition of substrate measured after 30 mins by morrison plot analysis
941,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770082,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
584,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090355,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
585,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090355,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
944,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770083,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
606,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3916828,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
905,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1258231,517320,Active,inhibition of egfr l858 mutant
587,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090355,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
940,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770082,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
939,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770081,Active,inhibition of wild type egfr phosphorylation in human lovo cells after 2 hrs by fluorescence assay
906,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1258231,517320,Active,inhibition of egfr l858 mutant
907,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1258231,517320,Active,inhibition of egfr l858 mutant
938,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770071,Active,cytotoxicity against human nci h1975 cells harboring egfr l858r/t970m double mutant assessed as growth inhibition after 72 hrs by sytox green nucleic acid staining based fluorescence assay
908,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1258231,517320,Active,inhibition of egfr l858 mutant
937,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770070,Active,cytotoxicity against human pc9 cells harboring egfr exon 19 deletion activating mutant assessed as growth inhibition after 72 hrs by sytox green nucleic acid staining based fluorescence assay
42,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3905501,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
919,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL249496,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
913,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1241675,507084,Active,inhibition of recombinant egfr by radioactive phosphotransfer assay in presence of 10 um atp
918,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL249496,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
586,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090355,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
2410,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426286,770082,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
945,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770083,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
814,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354187,1170824,Active,inhibition of egfr t790m/l858r mutant  unknown origin by high throughput biochemical screening
2411,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426286,770082,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
1012,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3971560,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
2412,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426286,770082,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
2413,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426286,770083,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
916,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL249496,418918,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
2415,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426286,770083,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
2416,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426286,770083,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
798,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3759696,1274037,Active,inhibition of egfr t790m/l858r mutant  unknown origin 
799,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3759696,1274037,Active,inhibition of egfr t790m/l858r mutant  unknown origin 
800,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3759696,1274037,Active,inhibition of egfr t790m/l858r mutant  unknown origin 
801,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3759696,1274037,Active,inhibition of egfr t790m/l858r mutant  unknown origin 
961,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3958678,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
959,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090359,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
946,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770083,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
958,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090359,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
956,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090359,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
955,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167102,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
954,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167102,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
811,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354187,1170824,Active,inhibition of egfr t790m/l858r mutant  unknown origin by high throughput biochemical screening
953,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167102,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
952,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167102,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
951,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167101,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
812,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354187,1170824,Active,inhibition of egfr t790m/l858r mutant  unknown origin by high throughput biochemical screening
950,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167101,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
813,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3354187,1170824,Active,inhibition of egfr t790m/l858r mutant  unknown origin by high throughput biochemical screening
949,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167101,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
948,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,1167101,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
947,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426288,770083,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
957,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090359,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
2414,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2426286,770083,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
2169,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3353403,1167101,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
1273,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3623281,1250380,Active,inhibition of egfr l858r mutant phosphorylation in human h3255 cells
2330,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3623282,1250380,Active,inhibition of egfr l858r mutant phosphorylation in human h3255 cells
1456,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL119385,256664,Inactive,average binding constant for egfr nanot active at 10 um
2331,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3623282,1250380,Active,inhibition of egfr l858r mutant phosphorylation in human h3255 cells
2332,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3623282,1250380,Active,inhibition of egfr l858r mutant phosphorylation in human h3255 cells
2334,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1242380,507084,Active,inhibition of recombinant egfr by radioactive phosphotransfer assay in presence of 10 um atp
139,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3087197,1053617,Active,antiproliferative activity against human nci h1975 cells expressing egfr l858r/t790m double mutant after 72 hrs by mts assay
140,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3087197,1053618,Active,inhibition of egfr l858r/t790m double mutant  unknown origin after 1 5 hrs by fret based z' lyte assay
141,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3087197,1053618,Active,inhibition of egfr l858r/t790m double mutant  unknown origin after 1 5 hrs by fret based z' lyte assay
143,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3087197,1053618,Active,inhibition of egfr l858r/t790m double mutant  unknown origin after 1 5 hrs by fret based z' lyte assay
378,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL373882,277404,Active,inhibition of egfr
1973,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL438536,320573,Active,inhibition of egfr
2063,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090363,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
2064,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090363,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
2065,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090363,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
2066,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1090363,474118,Active,inhibition of egfr l858r mutant by time resolved fluorescence assay
2329,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3623282,1250380,Active,inhibition of egfr l858r mutant phosphorylation in human h3255 cells
1648,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3981432,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
276,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3923645,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
1631,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3934134,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
308,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3928883,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
1548,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3893058,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
92,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3947643,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
319,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775622,Active,inhibition of egfr t790m/l858r double mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay
320,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775622,Active,inhibition of egfr t790m/l858r double mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay
321,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775622,Active,inhibition of egfr t790m/l858r double mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay
322,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775622,Active,inhibition of egfr t790m/l858r double mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay
2175,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3353403,1167116,Active,cytotoxicity against human pc9 cells harboring egfr exon 19 deletion activating mutant assessed as growth inhibition after 72 hrs by sytox green nucleic acid staining based fluorescence assay
323,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775623,Active,inhibition of egfr l858r mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay
1615,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3780175,1286789,Active,inhibition of human egfr catalytic domain  668 to 1210 residues t790m/l858r double mutant using fl eeplywsfpakkk conh2 peptide substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay
324,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775623,Active,inhibition of egfr l858r mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay
325,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775623,Active,inhibition of egfr l858r mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay
326,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775623,Active,inhibition of egfr l858r mutant  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay
327,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2437474,775624,Active,inhibition of wild type egfr  unknown origin using tyr 4 peptide as substrate after 1 5 hrs by fret based z' lyte assay
1616,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3780175,1286789,Active,inhibition of human egfr catalytic domain  668 to 1210 residues t790m/l858r double mutant using fl eeplywsfpakkk conh2 peptide substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay
1617,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3780175,1286789,Active,inhibition of human egfr catalytic domain  668 to 1210 residues t790m/l858r double mutant using fl eeplywsfpakkk conh2 peptide substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay
1614,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3780175,1286789,Active,inhibition of human egfr catalytic domain  668 to 1210 residues t790m/l858r double mutant using fl eeplywsfpakkk conh2 peptide substrate preincubated for 30 mins followed by substrate addition measured after 30 mins by caliper mobility shift assay
2174,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3353403,1167115,Active,cytotoxicity against human nci h1975 cells harboring egfr l858r/t970m double mutant assessed as growth inhibition after 72 hrs by sytox green nucleic acid staining based fluorescence assay
142,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3087197,1053618,Active,inhibition of egfr l858r/t790m double mutant  unknown origin after 1 5 hrs by fret based z' lyte assay
1540,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1240565,507084,Active,inhibition of recombinant egfr by radioactive phosphotransfer assay in presence of 10 um atp
2127,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL276711,650456,Active,cytotoxicity against human a431 cells overexpressing egfr incubated for 12 hrs measured after 36 hrs by cyquant assay
1357,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant
1354,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3959160,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
1358,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant
1359,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant
1360,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant
1361,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant
1362,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant
1363,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant
2147,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2386993,748805,Active,inhibition of human egfr extracellular domain/tie2 intracellular domain transfected in mouse nih/3t3 cells assessed as phosphotyrosine level preincubated for 60 mins followed by egf stimulation by delfia assay
1364,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL1256425,517320,Active,inhibition of egfr l858 mutant
2146,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2386993,748805,Active,inhibition of human egfr extracellular domain/tie2 intracellular domain transfected in mouse nih/3t3 cells assessed as phosphotyrosine level preincubated for 60 mins followed by egf stimulation by delfia assay
2149,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2386993,748805,Active,inhibition of human egfr extracellular domain/tie2 intracellular domain transfected in mouse nih/3t3 cells assessed as phosphotyrosine level preincubated for 60 mins followed by egf stimulation by delfia assay
2148,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL2386993,748805,Active,inhibition of human egfr extracellular domain/tie2 intracellular domain transfected in mouse nih/3t3 cells assessed as phosphotyrosine level preincubated for 60 mins followed by egf stimulation by delfia assay
2172,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3353403,1167102,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
1274,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3623281,1250380,Active,inhibition of egfr l858r mutant phosphorylation in human h3255 cells
2173,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3353403,1167102,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
389,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3968233,1342636,Active,inhibition of recombinant human n terminal gst his6 tagged thrombin cleavage site fused egfr  h672 to a1210 residues expressed in baculovirus using poly ey as substrate after 210 mins by luciferase coupled chemiluminescence assay
1276,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3623281,1250380,Active,inhibition of egfr l858r mutant phosphorylation in human h3255 cells
2168,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3353403,1167101,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
1275,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3623281,1250380,Active,inhibition of egfr l858r mutant phosphorylation in human h3255 cells
2167,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3353403,1167101,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
2166,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3353403,1167101,Active,inhibition of egfr l858r/t970m double mutant phosphorylation in human nci h1975 cells after 2 hrs by fluorescence assay
2171,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3353403,1167102,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
2170,CHEMBL203,Epidermal growth factor receptor erbB1,CHEMBL3353403,1167102,Active,inhibition of egfr exon 19 deletion activating mutant phosphorylation in human pc9 cells after 2 hrs by fluorescence assay
305,CHEMBL206,Estrogen receptor alpha,CHEMBL1084534,482352,Active,agonist activity at eralpha expressed in yeast assessed as alpha galactosidase activity
2407,CHEMBL206,Estrogen receptor alpha,CHEMBL204222,262172,Active,binding affinity to eralpha
1629,CHEMBL206,Estrogen receptor alpha,CHEMBL1082422,482352,Active,agonist activity at eralpha expressed in yeast assessed as alpha galactosidase activity
1630,CHEMBL206,Estrogen receptor alpha,CHEMBL1082422,482353,Active,agonist activity at eralpha expressed in yeast assessed as alpha galactosidase activity relative to e2
315,CHEMBL206,Estrogen receptor alpha,CHEMBL3234627,1127147,Inactive,agonist activity at eralpha  unknown origin harboring n terminal af1 domain deleted mutant expressed in human hepg2 cells assessed as transcriptional activation after 24 hrs by ere luciferase reporter gene assay
1818,CHEMBL242,Estrogen receptor beta,CHEMBL2401848,759301,Active,cytotoxicity against human mcf7 cells expressing eralpha and erbeta assessed as growth inhibition after 72 hrs by mtt assay
1819,CHEMBL242,Estrogen receptor beta,CHEMBL2401848,759311,Active,cytotoxicity against eralpha deficient human du145 cells expressing erbeta assessed as growth inhibition after 72 hrs by mtt assay
1817,CHEMBL242,Estrogen receptor beta,CHEMBL2401848,759300,Active,cytotoxicity against eralpha and erbeta deficient human mda mb 231 cells assessed as growth inhibition after 72 hrs by mtt assay
1034,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3961994,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
1035,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3961994,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
1036,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3961994,1344881,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
971,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL428690,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um
1037,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3961994,1344882,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
2241,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL941,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um
1051,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3913492,1340075,Active,inhibition of fgfr1  unknown origin transfected in mouse ba/f3 cells assessed as decrease in cell proliferation in absence of mouse il3 after 24 hrs by alamar blue assay
2182,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL3914013,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
625,CHEMBL3650,Fibroblast growth factor receptor 1,CHEMBL607707,256653,Inactive,average binding constant for fgfr1 nanot active at 10 um
1545,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3944659,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
677,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3952638,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
26,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3900101,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
1853,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL4064081,1446141,Active,antiproliferative activity against human snu16 cells over expressing fgfr2 after 72 hrs by presto blue assay
27,CHEMBL4142,Fibroblast growth factor receptor 2,CHEMBL3900101,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
237,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3937344,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
766,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3941999,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
964,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3957409,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
965,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3957409,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
765,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3941999,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
2210,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3900101,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
764,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3941999,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
2144,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3982659,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
1182,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3927229,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
1296,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3944659,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
2211,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3900101,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
1112,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3787112,1291012,Active,inhibition of fgfr3 k650e mutant  unknown origin in presence of [gamma33p]atp
2145,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3982659,1344880,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
596,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3401370,1193341,Active,inhibition of fgfr3  unknown origin after 90 mins by tr fret assay
1013,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL103667,256624,Inactive,average binding constant for fgfr3 nanot active at 10 um
1462,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3911943,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
1463,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3914013,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
236,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3937344,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
248,CHEMBL2742,Fibroblast growth factor receptor 3,CHEMBL3976424,1344879,Active,kinase hotspot xe2 xbf xa2 assay: compounds were profiled for fgfr inhibition activity at reaction biology corporation  malvern pa with their kinase hotspot assay see anastassiadis et al 2011 comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity nat biotechnol 29 1039 1045 recombinant fgfr1  2 5 nm fgfr2  1 nm fgfr3  5 nm or fgfr4  12 nm  invitrogen was prepared as a mixture with substrate kkkspgeyvniefg  seq id no:1  20 um fgfr1 substrate and poly [e y]4:1  0 2 mg/ml fgfr2 3 4 substrate ] in kinase reaction buffer  20 mm hepes hcl ph 7 5 10 mm mgcl2 2 mm mncl2 1 mm egta 0 02% brij35 0 1 mm na3vo4 0 02 mg/ml bsa 2 mm dtt and 1% dmso compound was added to the enzyme/substrate mixture using acoustic technology  labcyte echo 550 sunnyvale calif  see olechno et al 2006 improving ic50 results with acoustic droplet ejection jala 11 240 246 and pre incubated for 0 15 or 60 minutes at room temperat
2473,CHEMBL2695,Focal adhesion kinase 1,CHEMBL3935745,1257456,Active,in vitro enzyme assay: the ability of compounds to inhibit the kinase activity of baculovirus expressed human fak and jak kinase using the time resolved fluorescence  trf assay system 
2472,CHEMBL2695,Focal adhesion kinase 1,CHEMBL3935745,1257455,Active,in vitro enzyme assay: the ability of compounds to inhibit the kinase activity of baculovirus expressed human fak and jak kinase using the time resolved fluorescence  trf assay system 
1604,CHEMBL2695,Focal adhesion kinase 1,CHEMBL1336,1299346,Inactive,inhibition of fak  unknown origin 
1603,CHEMBL2695,Focal adhesion kinase 1,CHEMBL1336,256640,Inactive,average binding constant for ptk2 nanot active at 10 um
2474,CHEMBL2695,Focal adhesion kinase 1,CHEMBL3935745,1257457,Active,in vitro enzyme assay: the ability of compounds to inhibit the kinase activity of baculovirus expressed human fak and jak kinase using the time resolved fluorescence  trf assay system 
287,CHEMBL2695,Focal adhesion kinase 1,CHEMBL124660,256640,Inactive,average binding constant for ptk2 nanot active at 10 um
1539,CHEMBL2695,Focal adhesion kinase 1,CHEMBL24828,256640,Inactive,average binding constant for ptk2 nanot active at 10 um
286,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL553,1117336,Active,gsk3b pretreated hct116 viability from cell titerglo screen
264,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL1289926,1117355,Inactive,human gsk3b kinase inhibition screen
263,CHEMBL262,Glycogen synthase kinase-3 beta,CHEMBL1289926,1117336,Inactive,gsk3b pretreated hct116 viability from cell titerglo screen
98,CHEMBL240,HERG,CHEMBL496,1511,Inactive,primary cell based high throughput screening assay for identification of compounds that protect herg from block by proarrhythmic agents
707,CHEMBL240,HERG,CHEMBL1255837,624246,Inactive,qhts for small molecule inhibitors of the erg ets/dna interaction
100,CHEMBL240,HERG,CHEMBL496,588834,Inactive,qhts assay for small molecule inhibitors of the human herg channel activity
1836,CHEMBL240,HERG,CHEMBL51,588834,Active,qhts assay for small molecule inhibitors of the human herg channel activity
671,CHEMBL240,HERG,CHEMBL1200406,588834,Active,qhts assay for small molecule inhibitors of the human herg channel activity
99,CHEMBL240,HERG,CHEMBL496,588834,Inactive,qhts assay for small molecule inhibitors of the human herg channel activity
101,CHEMBL240,HERG,CHEMBL496,624246,Inactive,qhts for small molecule inhibitors of the erg ets/dna interaction
706,CHEMBL240,HERG,CHEMBL1255837,1511,Inactive,primary cell based high throughput screening assay for identification of compounds that protect herg from block by proarrhythmic agents
1413,CHEMBL2093865,Histone deacetylase,CHEMBL3884118,1336913,Active,inhibition of hdac1  unknown origin after 24 hrs by samdi mass spectroscopic analysis
826,CHEMBL2093865,Histone deacetylase,CHEMBL3655963,1257730,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
827,CHEMBL2093865,Histone deacetylase,CHEMBL3655963,1257731,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
1130,CHEMBL2093865,Histone deacetylase,CHEMBL2177582,706268,Active,inhibition of hdac1 using p53  379 to 382 residues based fluorogenic peptide substrate
828,CHEMBL2093865,Histone deacetylase,CHEMBL3655963,1257732,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
1861,CHEMBL2093865,Histone deacetylase,CHEMBL55895,569928,Active,inhibition of human recombinant hdac1
491,CHEMBL2093865,Histone deacetylase,CHEMBL4095245,1466382,Active,inhibition of hdac1  unknown origin using boc lys  acetyl  amc as substrate incubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence assay
2059,CHEMBL2093865,Histone deacetylase,CHEMBL485968,345180,Active,inhibition of hdac1 purified from hek293 cells by western blot
867,CHEMBL2093865,Histone deacetylase,CHEMBL2407723,762201,Active,inhibition of recombinant c terminal flag tagged hdac1  unknown origin expressed in escherichia coli bl21 using mal as substrate incubated for 1 hr prior to substrate addition measured after 60 mins by fluorescence plate reader analysis
28,CHEMBL2093865,Histone deacetylase,CHEMBL3311465,1178595,Active,inhibition of human hdac1 pre incubated for 30 mins before substrate addition and measured after 30 mins by hdac glo i/ii assay
894,CHEMBL2093865,Histone deacetylase,CHEMBL3656020,1257730,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
895,CHEMBL2093865,Histone deacetylase,CHEMBL3656020,1257731,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
896,CHEMBL2093865,Histone deacetylase,CHEMBL3656020,1257732,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
897,CHEMBL2093865,Histone deacetylase,CHEMBL3656020,1257733,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
901,CHEMBL2093865,Histone deacetylase,CHEMBL2442696,780588,Active,inhibition of human recombinant hdac1 expressed in baculovirus infected insect high5 cells using ac lys tyr lys  epsilon acetyl  amc as substrate after 3 to 24 hrs by fluorescence assay
903,CHEMBL2093865,Histone deacetylase,CHEMBL3925939,1326509,Active,inhibition of c terminal his/flag tagged full length recombinant human hdac1 expressed in baculovirus expression system assessed as release of 7 amino 4 methylcoumarin by fluorogenic assay
829,CHEMBL2093865,Histone deacetylase,CHEMBL3655963,1257733,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
384,CHEMBL2093865,Histone deacetylase,CHEMBL3655934,1257730,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
1537,CHEMBL2093865,Histone deacetylase,CHEMBL405072,320808,Active,inhibition of hdac1
385,CHEMBL2093865,Histone deacetylase,CHEMBL3655934,1257731,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
2483,CHEMBL2093865,Histone deacetylase,CHEMBL3287016,1156054,Active,inhibition of recombinant human hdac1 using ac lys tyr lys epsilon acetyl  amc as substrate after 24 hrs by fluorescence assay
90,CHEMBL2093865,Histone deacetylase,CHEMBL406927,328793,Active,inhibition of hdac1
674,CHEMBL2093865,Histone deacetylase,CHEMBL4070232,1459953,Active,inhibition of recombinant human hdac1 using fluorogenic substrate by fluorescence assay
1280,CHEMBL2093865,Histone deacetylase,CHEMBL520056,408880,Active,inhibition of hdac1
2475,CHEMBL2093865,Histone deacetylase,CHEMBL3314869,1181303,Active,inhibition of human recombinant hdac1 using histone h3 substrate pre incubated at room temperature for 15 mins before substrate addition by fluorimetric assay
428,CHEMBL2093865,Histone deacetylase,CHEMBL3885496,1336913,Active,inhibition of hdac1  unknown origin after 24 hrs by samdi mass spectroscopic analysis
419,CHEMBL2093865,Histone deacetylase,CHEMBL3356924,1164780,Active,inhibition of hdac1  unknown origin using fluorogenic tetrapeptide rhkk ac substrate by fluorescence assay
1299,CHEMBL2093865,Histone deacetylase,CHEMBL3356934,1164780,Active,inhibition of hdac1  unknown origin using fluorogenic tetrapeptide rhkk ac substrate by fluorescence assay
2484,CHEMBL2093865,Histone deacetylase,CHEMBL3287016,1343566,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
399,CHEMBL2093865,Histone deacetylase,CHEMBL3415959,1202602,Active,inhibition of hdac1 in human kb cells assessed as increase in histone h4 acetylation at 100 um after 24 hrs by western blotting analysis
398,CHEMBL2093865,Histone deacetylase,CHEMBL3415959,1202583,Active,inhibition of his tagged hdac1  unknown origin expressed in escherichia coli bl21 de3 after 60 mins by maldi mass spectrometry
2141,CHEMBL2093865,Histone deacetylase,CHEMBL3287263,1343568,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
2140,CHEMBL2093865,Histone deacetylase,CHEMBL3287263,1343567,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
2139,CHEMBL2093865,Histone deacetylase,CHEMBL3287263,1343566,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
2138,CHEMBL2093865,Histone deacetylase,CHEMBL3287263,1156054,Active,inhibition of recombinant human hdac1 using ac lys tyr lys epsilon acetyl  amc as substrate after 24 hrs by fluorescence assay
392,CHEMBL2093865,Histone deacetylase,CHEMBL3415968,1202583,Active,inhibition of his tagged hdac1  unknown origin expressed in escherichia coli bl21 de3 after 60 mins by maldi mass spectrometry
2461,CHEMBL2093865,Histone deacetylase,CHEMBL4069152,1452273,Active,inhibition of hdac1  unknown origin preincubated for 15 mins followed by substrate addition measured after 60 mins by fluorescence assay
387,CHEMBL2093865,Histone deacetylase,CHEMBL3655934,1257733,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
386,CHEMBL2093865,Histone deacetylase,CHEMBL3655934,1257732,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
78,CHEMBL2093865,Histone deacetylase,CHEMBL3736100,1263052,Active,inhibition of recombinant hdac1  unknown origin expressed in escherichia coli bl21 de3 after 60 mins using trichostatin a by label free mass spectrometry based samdi assay
2179,CHEMBL2093865,Histone deacetylase,CHEMBL3339031,1166496,Active,inhibition of human recombinant full length hdac1 using  ac  lys tyr lys  acetyl  amc substrate after 30 mins
850,CHEMBL2093865,Histone deacetylase,CHEMBL3309291,1178595,Active,inhibition of human hdac1 pre incubated for 30 mins before substrate addition and measured after 30 mins by hdac glo i/ii assay
2212,CHEMBL2093865,Histone deacetylase,CHEMBL483495,408880,Active,inhibition of hdac1
115,CHEMBL2093865,Histone deacetylase,CHEMBL487742,408880,Active,inhibition of hdac1
1005,CHEMBL2093865,Histone deacetylase,CHEMBL3317817,1185952,Active,inhibition of hdac1  unknown origin incubated at 37 degc for 30 mins
1478,CHEMBL2093865,Histone deacetylase,CHEMBL3339018,1166496,Active,inhibition of human recombinant full length hdac1 using  ac  lys tyr lys  acetyl  amc substrate after 30 mins
1026,CHEMBL2093865,Histone deacetylase,CHEMBL3339017,1166496,Active,inhibition of human recombinant full length hdac1 using  ac  lys tyr lys  acetyl  amc substrate after 30 mins
1047,CHEMBL2093865,Histone deacetylase,CHEMBL2396902,756022,Active,inhibition of hdac1  unknown origin after 30 mins by fluorometric analysis
1860,CHEMBL2093865,Histone deacetylase,CHEMBL55895,496801,Active,inhibition of human hdac1
580,CHEMBL2093865,Histone deacetylase,CHEMBL3885011,1336913,Active,inhibition of hdac1  unknown origin after 24 hrs by samdi mass spectroscopic analysis
1717,CHEMBL2093865,Histone deacetylase,CHEMBL3356930,1164780,Active,inhibition of hdac1  unknown origin using fluorogenic tetrapeptide rhkk ac substrate by fluorescence assay
1719,CHEMBL2093865,Histone deacetylase,CHEMBL3415965,1202583,Active,inhibition of his tagged hdac1  unknown origin expressed in escherichia coli bl21 de3 after 60 mins by maldi mass spectrometry
2219,CHEMBL2093865,Histone deacetylase,CHEMBL3884044,1336913,Active,inhibition of hdac1  unknown origin after 24 hrs by samdi mass spectroscopic analysis
2485,CHEMBL2093865,Histone deacetylase,CHEMBL3287016,1343567,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
911,CHEMBL2093865,Histone deacetylase,CHEMBL3907730,1321715,Active,inhibition of full length recombinant human c terminal his/flag tagged hdac1 expressed in baculovirus infected sf9 cells using fluorogenic hdac substrate after 30 mins by fluorescence analysis
1091,CHEMBL2093865,Histone deacetylase,CHEMBL3287008,1343567,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
1090,CHEMBL2093865,Histone deacetylase,CHEMBL3287008,1343566,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
1089,CHEMBL2093865,Histone deacetylase,CHEMBL3287008,1156054,Active,inhibition of recombinant human hdac1 using ac lys tyr lys epsilon acetyl  amc as substrate after 24 hrs by fluorescence assay
1092,CHEMBL2093865,Histone deacetylase,CHEMBL3287008,1343568,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
1418,CHEMBL2093865,Histone deacetylase,CHEMBL3775409,1282229,Active,inhibition of human recombinant hdac1 using amc labeled ac peptide as substrate incubated for 1 hr by fluorescence analysis
2481,CHEMBL325,Histone deacetylase 1,CHEMBL123626,90212,Active,inhibitory activity against histone deacetylase  hdac1 and hdac2 isolated from k562 erythroleukemia cells
1356,CHEMBL325,Histone deacetylase 1,CHEMBL455735,1263052,Active,inhibition of recombinant hdac1  unknown origin expressed in escherichia coli bl21 de3 after 60 mins using trichostatin a by label free mass spectrometry based samdi assay
1232,CHEMBL325,Histone deacetylase 1,CHEMBL3640659,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1094,CHEMBL325,Histone deacetylase 1,CHEMBL3692601,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control 
1353,CHEMBL325,Histone deacetylase 1,CHEMBL4099064,1472133,Active,inhibition of recombinant human full length c terminal flag tagged hdac1 expressed in fall armyworm sf9 cells using fluorogenic zmal as substrate after 90 mins by fluorimetric analysis
1525,CHEMBL325,Histone deacetylase 1,CHEMBL3693702,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1486,CHEMBL325,Histone deacetylase 1,CHEMBL3640654,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1524,CHEMBL325,Histone deacetylase 1,CHEMBL3693702,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1487,CHEMBL325,Histone deacetylase 1,CHEMBL3640654,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
2161,CHEMBL325,Histone deacetylase 1,CHEMBL3692685,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control 
1297,CHEMBL325,Histone deacetylase 1,CHEMBL1214763,499814,Active,inhibition of plasmodium falciparum hdac1
728,CHEMBL325,Histone deacetylase 1,CHEMBL3693734,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
727,CHEMBL325,Histone deacetylase 1,CHEMBL3693734,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
2423,CHEMBL325,Histone deacetylase 1,CHEMBL3693727,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1022,CHEMBL325,Histone deacetylase 1,CHEMBL2046613,670970,Active,inhibition of human recombinant his6 tagged and gst fuses hdac1 expressed in insect high5 cells using ac lys tyr lys e acetyl  amc as substrate after 24 hrs by fluorescence assay
1277,CHEMBL325,Histone deacetylase 1,CHEMBL3692625,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control 
2287,CHEMBL325,Histone deacetylase 1,CHEMBL439842,343687,Active,inhibition of recombinant hdac1 expressed in hek293 cells
1610,CHEMBL325,Histone deacetylase 1,CHEMBL564916,434540,Active,inhibition of human hdac1 by fluorimetry
1520,CHEMBL325,Histone deacetylase 1,CHEMBL3693749,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
702,CHEMBL325,Histone deacetylase 1,CHEMBL506834,1371037,Active,inhibition of recombinant plasmodium falciparum hdac1 using hdac substrate 3 after 30 mins by fluorescence assay
701,CHEMBL325,Histone deacetylase 1,CHEMBL506834,1263052,Active,inhibition of recombinant hdac1  unknown origin expressed in escherichia coli bl21 de3 after 60 mins using trichostatin a by label free mass spectrometry based samdi assay
1521,CHEMBL325,Histone deacetylase 1,CHEMBL3693749,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1278,CHEMBL325,Histone deacetylase 1,CHEMBL3692625,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control 
2480,CHEMBL325,Histone deacetylase 1,CHEMBL123626,90212,Active,inhibitory activity against histone deacetylase  hdac1 and hdac2 isolated from k562 erythroleukemia cells
1095,CHEMBL325,Histone deacetylase 1,CHEMBL3692601,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control 
2403,CHEMBL325,Histone deacetylase 1,CHEMBL3652240,1257730,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
830,CHEMBL325,Histone deacetylase 1,CHEMBL3640648,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1041,CHEMBL325,Histone deacetylase 1,CHEMBL3692687,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control 
831,CHEMBL325,Histone deacetylase 1,CHEMBL3640648,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1474,CHEMBL325,Histone deacetylase 1,CHEMBL3693796,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1736,CHEMBL325,Histone deacetylase 1,CHEMBL3692675,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control 
1473,CHEMBL325,Histone deacetylase 1,CHEMBL406800,316892,Inactive,inhibition of hdac1
2225,CHEMBL325,Histone deacetylase 1,CHEMBL3693790,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1695,CHEMBL325,Histone deacetylase 1,CHEMBL3693764,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1975,CHEMBL325,Histone deacetylase 1,CHEMBL3771174,1280259,Active,inhibition of human hdac1 using  z  ac lys amc as substrate after 90 mins by fluorescence analysis
1475,CHEMBL325,Histone deacetylase 1,CHEMBL3693796,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
2051,CHEMBL325,Histone deacetylase 1,CHEMBL2337872,734736,Active,inhibition of hdac1  unknown origin at 10 um after 60 mins by samdi spectrophotometric analysis relative to control
1050,CHEMBL325,Histone deacetylase 1,CHEMBL3589699,1233250,Inactive,inhibition of human recombinant hdac1 after 15 mins by fluorogenic assay
1405,CHEMBL325,Histone deacetylase 1,CHEMBL3693758,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
2424,CHEMBL325,Histone deacetylase 1,CHEMBL3693727,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1694,CHEMBL325,Histone deacetylase 1,CHEMBL3693764,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1693,CHEMBL325,Histone deacetylase 1,CHEMBL3692655,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control 
2097,CHEMBL325,Histone deacetylase 1,CHEMBL493782,404170,Inactive,inhibition of hdac1 at 10 um
1692,CHEMBL325,Histone deacetylase 1,CHEMBL3692655,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control 
2406,CHEMBL325,Histone deacetylase 1,CHEMBL3652240,1257733,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
2405,CHEMBL325,Histone deacetylase 1,CHEMBL3652240,1257732,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
1688,CHEMBL325,Histone deacetylase 1,CHEMBL3640675,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
2404,CHEMBL325,Histone deacetylase 1,CHEMBL3652240,1257731,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
1687,CHEMBL325,Histone deacetylase 1,CHEMBL3640675,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
775,CHEMBL325,Histone deacetylase 1,CHEMBL3894057,1321715,Active,inhibition of full length recombinant human c terminal his/flag tagged hdac1 expressed in baculovirus infected sf9 cells using fluorogenic hdac substrate after 30 mins by fluorescence analysis
2226,CHEMBL325,Histone deacetylase 1,CHEMBL3693790,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1046,CHEMBL325,Histone deacetylase 1,CHEMBL3692610,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control 
1651,CHEMBL325,Histone deacetylase 1,CHEMBL4094909,1432957,Active,inhibition of human hdac1 using rhkkac as substrate by fluorescence assay
1045,CHEMBL325,Histone deacetylase 1,CHEMBL3692610,1258949,Active,inhibition assay: a similar assay procedure as described in test 2 was used for hdac6 human recombinant full length hdac6 expressed in a baculovirus expression system was purchased from bps biosciences  san diego calif u s a the substrate used in the hdac1 assay was 5 um of acetyl gly ala lys acetyl  amc test 2: human recombinant hdac4 was expressed in full length form  aa 2 1084 in sf9 insect cells  obtained from atcc using baculovirus generated with bac to bac system  invitrogen test compounds were serially diluted to reach final test concentrations from 0 000128 um to 10 um hdac4 and test compounds were incubated in 25 mm tris buffer ph 8 0 containing 137 mm nacl 2 7 mm kcl 1 mm mgcl2 0 05%  w/v bovine serum albumine and 0 005%  v/v triton x 100 for 2 hours at room temperature in presence of 5 um of acetyl gly ala lys e trifluoroacetyl  amc  amc7 amino 4 methyl coumarin in a final volume of 9 ul control wells with hdac4 only  positive control 
1231,CHEMBL325,Histone deacetylase 1,CHEMBL3640659,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1404,CHEMBL325,Histone deacetylase 1,CHEMBL3693758,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1242,CHEMBL325,Histone deacetylase 1,CHEMBL2018297,655909,Active,inhibition of human recombinant hdac1 using rhkkac peptide as substrate incubated for 5 to mins prior to substrate addition measured after 2 hrs
240,CHEMBL325,Histone deacetylase 1,CHEMBL1214759,499814,Active,inhibition of plasmodium falciparum hdac1
20,CHEMBL325,Histone deacetylase 1,CHEMBL3797516,1472133,Active,inhibition of recombinant human full length c terminal flag tagged hdac1 expressed in fall armyworm sf9 cells using fluorogenic zmal as substrate after 90 mins by fluorimetric analysis
204,CHEMBL325,Histone deacetylase 1,CHEMBL2431901,772647,Active,inhibition of full length gst tagged recombinant human hdac1 expressed in baculovirus using arg his lys lys  ac as substrate after 1 hr by fluorescence plate reader analysis
311,CHEMBL325,Histone deacetylase 1,CHEMBL3415449,1200977,Inactive,inhibition of hdac1/hdac2/hdac3 in human hela cells assessed as induction of p21 gene expression at 10 um after 15 hrs by luciferase reporter gene assay relative to hdac1 inhibitor sndx 275
29,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343397,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
30,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343401,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
31,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343403,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
32,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343405,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
312,CHEMBL325,Histone deacetylase 1,CHEMBL3415449,1200977,Inactive,inhibition of hdac1/hdac2/hdac3 in human hela cells assessed as induction of p21 gene expression at 10 um after 15 hrs by luciferase reporter gene assay relative to hdac1 inhibitor sndx 275
313,CHEMBL325,Histone deacetylase 1,CHEMBL3415449,1200977,Inactive,inhibition of hdac1/hdac2/hdac3 in human hela cells assessed as induction of p21 gene expression at 10 um after 15 hrs by luciferase reporter gene assay relative to hdac1 inhibitor sndx 275
314,CHEMBL325,Histone deacetylase 1,CHEMBL3415449,1200977,Inactive,inhibition of hdac1/hdac2/hdac3 in human hela cells assessed as induction of p21 gene expression at 10 um after 15 hrs by luciferase reporter gene assay relative to hdac1 inhibitor sndx 275
205,CHEMBL325,Histone deacetylase 1,CHEMBL2431901,1173499,Active,inhibition of full length gst tagged human hdac1 using arg his lys lys ac substrate incubated for 2 hrs by fluorescence assay
95,CHEMBL325,Histone deacetylase 1,CHEMBL2337875,734736,Active,inhibition of hdac1  unknown origin at 10 um after 60 mins by samdi spectrophotometric analysis relative to control
285,CHEMBL325,Histone deacetylase 1,CHEMBL481131,343687,Active,inhibition of recombinant hdac1 expressed in hek293 cells
282,CHEMBL325,Histone deacetylase 1,CHEMBL3770180,1280259,Active,inhibition of human hdac1 using  z  ac lys amc as substrate after 90 mins by fluorescence analysis
47,CHEMBL325,Histone deacetylase 1,CHEMBL2178342,711159,Active,inhibition of hdac1 by fluorometric assay
278,CHEMBL325,Histone deacetylase 1,CHEMBL2337867,734736,Active,inhibition of hdac1  unknown origin at 10 um after 60 mins by samdi spectrophotometric analysis relative to control
70,CHEMBL325,Histone deacetylase 1,CHEMBL2337864,734736,Active,inhibition of hdac1  unknown origin at 10 um after 60 mins by samdi spectrophotometric analysis relative to control
19,CHEMBL325,Histone deacetylase 1,CHEMBL3797516,1472115,Inactive,inhibition of hdac1 in human be 2  c cells assessed as effect on histone h3 acetylation at 10 um after 6 hrs by western blot analysis
18,CHEMBL325,Histone deacetylase 1,CHEMBL3797516,1296348,Active,inhibition of recombinant human hdac1 using cbz  ac lys amc as substrate preincubated for 90 mins followed by trypsin addition measured after 20 mins by fluorescence assay
33,CHEMBL325,Histone deacetylase 1,CHEMBL3911566,1343406,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
672,CHEMBL325,Histone deacetylase 1,CHEMBL3338404,1164906,Active,inhibition of hdac1  unknown origin using fluorogenic peptide as substrate by fluorescence assay
242,CHEMBL325,Histone deacetylase 1,CHEMBL3617543,1246507,Active,inhibition of hdac1  unknown origin using rhkk ac fluorogenic acetylated peptide substrate by fluorometric assay
870,CHEMBL1937,Histone deacetylase 2,CHEMBL4104117,1473145,Active,inhibition of full length recombinant human c terminal gst tagged hdac2 expressed in baculovirus infected insect cells using rhk k ac  amc as substrate after 60 mins by fluorescence assay
1114,CHEMBL1937,Histone deacetylase 2,CHEMBL1095719,480050,Active,inhibition of human recombinant hdac2
1409,CHEMBL1937,Histone deacetylase 2,CHEMBL1095764,480050,Active,inhibition of human recombinant hdac2
891,CHEMBL1937,Histone deacetylase 2,CHEMBL470843,417645,Active,inhibition of human hdac2
458,CHEMBL1937,Histone deacetylase 2,CHEMBL3693708,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
699,CHEMBL1937,Histone deacetylase 2,CHEMBL1094085,480050,Active,inhibition of human recombinant hdac2
368,CHEMBL1937,Histone deacetylase 2,CHEMBL1096433,480050,Active,inhibition of human recombinant hdac2
1343,CHEMBL1937,Histone deacetylase 2,CHEMBL3640660,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1636,CHEMBL1937,Histone deacetylase 2,CHEMBL3693758,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1635,CHEMBL1937,Histone deacetylase 2,CHEMBL3693758,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
394,CHEMBL1937,Histone deacetylase 2,CHEMBL1098067,480050,Active,inhibition of human recombinant hdac2
779,CHEMBL1937,Histone deacetylase 2,CHEMBL3693765,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
780,CHEMBL1937,Histone deacetylase 2,CHEMBL3693765,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1344,CHEMBL1937,Histone deacetylase 2,CHEMBL3640660,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1031,CHEMBL1937,Histone deacetylase 2,CHEMBL4104247,1452864,Active,inhibition of hdac2  unknown origin 
2422,CHEMBL1937,Histone deacetylase 2,CHEMBL1095437,480050,Active,inhibition of human recombinant hdac2
459,CHEMBL1937,Histone deacetylase 2,CHEMBL3693708,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
2328,CHEMBL1937,Histone deacetylase 2,CHEMBL3640694,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
494,CHEMBL1937,Histone deacetylase 2,CHEMBL1099048,480050,Active,inhibition of human recombinant hdac2
2327,CHEMBL1937,Histone deacetylase 2,CHEMBL3640694,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
2025,CHEMBL1829,Histone deacetylase 3,CHEMBL4087539,1466384,Active,inhibition of hdac3  unknown origin using boc lys  acetyl  amc as substrate incubated for 10 mins followed by substrate addition measured after 30 mins by fluorescence assay
1878,CHEMBL1829,Histone deacetylase 3,CHEMBL2407725,762203,Active,inhibition of recombinant hdac3 ncor1  unknown origin using mal as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis
2194,CHEMBL1829,Histone deacetylase 3,CHEMBL3655978,1257730,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
1271,CHEMBL1829,Histone deacetylase 3,CHEMBL3640686,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
238,CHEMBL1829,Histone deacetylase 3,CHEMBL2407718,762203,Active,inhibition of recombinant hdac3 ncor1  unknown origin using mal as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis
1771,CHEMBL1829,Histone deacetylase 3,CHEMBL3693793,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
2183,CHEMBL1829,Histone deacetylase 3,CHEMBL475692,392642,Active,inhibition of c terminal flag tagged human hdac3 overexpressed in mammalian cells by plate reader method
2326,CHEMBL1829,Histone deacetylase 3,CHEMBL3640664,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1879,CHEMBL1829,Histone deacetylase 3,CHEMBL2407725,762203,Active,inhibition of recombinant hdac3 ncor1  unknown origin using mal as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis
2325,CHEMBL1829,Histone deacetylase 3,CHEMBL3640664,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
473,CHEMBL1829,Histone deacetylase 3,CHEMBL3911566,1343403,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
1772,CHEMBL1829,Histone deacetylase 3,CHEMBL3693793,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
472,CHEMBL1829,Histone deacetylase 3,CHEMBL3911566,1343401,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
279,CHEMBL1829,Histone deacetylase 3,CHEMBL3640692,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
280,CHEMBL1829,Histone deacetylase 3,CHEMBL3640692,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
475,CHEMBL1829,Histone deacetylase 3,CHEMBL3911566,1343406,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
239,CHEMBL1829,Histone deacetylase 3,CHEMBL2407718,762203,Active,inhibition of recombinant hdac3 ncor1  unknown origin using mal as substrate incubated for 3 hrs prior to substrate addition measured after 60 mins by fluorescence plate reader analysis
2420,CHEMBL1829,Histone deacetylase 3,CHEMBL3640656,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
471,CHEMBL1829,Histone deacetylase 3,CHEMBL3911566,1343397,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
2195,CHEMBL1829,Histone deacetylase 3,CHEMBL3655978,1257731,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
1321,CHEMBL1829,Histone deacetylase 3,CHEMBL3356525,1164782,Active,inhibition of hdac3  unknown origin using fluorogenic tetrapeptide rhkk ac substrate by fluorescence assay
2197,CHEMBL1829,Histone deacetylase 3,CHEMBL3655978,1257733,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
1477,CHEMBL1829,Histone deacetylase 3,CHEMBL3793310,1293565,Active,inhibition of full length human recombinant c terminal his tagged hdac3  1 to 428 residues /human recombinant n terminal gst tagged ncor2  395 to 489 residues expressed in insect cells using rhk k ac  amc as substrate incubated for 60 mins by fluorescence assay
2028,CHEMBL1829,Histone deacetylase 3,CHEMBL343448,1188979,Active,inhibition of hdac3  unknown origin incubated for 30 mins in presence of bsa and dtt by fluorescence assay
2196,CHEMBL1829,Histone deacetylase 3,CHEMBL3655978,1257732,Active,enzyme assay: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 five ul of compounds and 20 ul of enzyme were added to wells of a black opaque 384 well plate in duplicate enzyme and compound were incubated together at room temperature 
2029,CHEMBL1829,Histone deacetylase 3,CHEMBL343448,1250642,Active,inhibition of recombinant human hdac3 after 60 mins by fluorescence assay
128,CHEMBL1829,Histone deacetylase 3,CHEMBL3110003,1065634,Active,inhibition of human recombinant full length hdac3 ncor2 using lys_ac_amc as substrate after 60 mins by fluorescence assay
1269,CHEMBL1829,Histone deacetylase 3,CHEMBL3640698,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
2027,CHEMBL1829,Histone deacetylase 3,CHEMBL343448,496803,Active,inhibition of human hdac3
1281,CHEMBL1829,Histone deacetylase 3,CHEMBL3417211,1201721,Active,inhibition of recombinant human hdac3 expressed in baculovirus infected insect high5 cells using ac lys tyr lys  epsilon acetyl  amc as substrate after 3 hrs by fluorescence assay
1476,CHEMBL1829,Histone deacetylase 3,CHEMBL3793310,1293565,Active,inhibition of full length human recombinant c terminal his tagged hdac3  1 to 428 residues /human recombinant n terminal gst tagged ncor2  395 to 489 residues expressed in insect cells using rhk k ac  amc as substrate incubated for 60 mins by fluorescence assay
2421,CHEMBL1829,Histone deacetylase 3,CHEMBL3640656,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1270,CHEMBL1829,Histone deacetylase 3,CHEMBL3640686,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
1268,CHEMBL1829,Histone deacetylase 3,CHEMBL3640698,1257705,Active,enzyme assays: compounds for testing were diluted in dmso to 50 fold the final concentration and a ten point three fold dilution series was made the compounds were diluted in assay buffer  50 mm hepes ph 7 4 100 mm kcl 0 001% tween 20 0 05% bsa 20 um tcep to 6 fold their final concentration the hdac enzymes  purchased from bps biosciences were diluted to 1 5 fold their final concentration in assay buffer the tripeptide substrate and trypsin at 0 05 um final concentration were diluted in assay buffer at 6 fold their final concentration the final enzyme concentrations used in these assays were 3 3 ng/ml  hdac1 0 2 ng/ml  hdac2 0 08 ng/ml  hdac3 and 2 ng/ml  hdac6 the final substrate concentrations used were 16 um  hdac1 10 um  hdac2 17 um  hdac3 and 14 um  hdac6 
474,CHEMBL1829,Histone deacetylase 3,CHEMBL3911566,1343405,Active,inhibition assay: the inhibitions of activities of hdac enzymes by the compounds n1' [3 fluoro 4 [[7 [4  hydroxyamino  4 oxobutoxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluoro phenyl cyclopropane 1 1 dicarboxamide prepared in example 9 and n1' [3 fluoro 4 [[7 [6  hydroxyamino  6 oxohexyloxy] 6 methoxy 4 quinolyl]oxy]phenyl] n1  4 fluo rophenyl cyclopropane 1 1 dicarboxamide prepared in example 13 were measured by reaction biology corporation  reaction biology corp one great valley parkway suite 2 malvern pa 19355 usa  http://www reactionbiology com/pages/hdac htm the hdac enzymes tested include the following 11 hdac isoforms: hdac1 hdac2 hdac3 hdac4 hdac5 hdac6 hdac7 hdac8 hdac9 hdac10 and hdac11 specific steps were as follows: the compound of the present invention was dissolved in dimethyl sulfoxide  dmso to make a stock solution of 10 mm the stock solution was diluted in 4 fold series starting from 10 mm to prepare 10 different dosages 
1528,CHEMBL1865,Histone deacetylase 6,CHEMBL551151,420642,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic80 after 24 hrs by western blot
1527,CHEMBL1865,Histone deacetylase 6,CHEMBL551151,420641,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic50 after 48 hrs by western blot
1338,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,1324233,Active,inhibition of hdac6 in human lncap cells assessed as inhibition of dht induced alpha tubulin deacetylation by measuring increase in alpha tubulin acetylation at 10 um measured after 24 hrs relative to control
1994,CHEMBL1865,Histone deacetylase 6,CHEMBL3287016,1156059,Inactive,inhibition of recombinant human hdac6 using boc lys epsilon acetyl  amc as substrate at 20 ug/ml after 3 hrs by fluorescence assay
1526,CHEMBL1865,Histone deacetylase 6,CHEMBL551151,420640,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic50 after 24 hrs by western blot
1339,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,1380965,Inactive,inhibition of hdac6 in human hela cells assessed as increase in intracellular acetyl tubulin levels at 1 um after 6 hrs by western blot analysis
2067,CHEMBL1865,Histone deacetylase 6,CHEMBL3918869,1343566,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
892,CHEMBL1865,Histone deacetylase 6,CHEMBL1093713,473174,Active,ex vivo inhibition of human hdac6 in human caco 2 cells by fluorometric cellular activity assay
1996,CHEMBL1865,Histone deacetylase 6,CHEMBL3287016,1343567,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
1340,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,1401904,Active,inhibition of human recombinant hdac6 using fluor de lys green as substrate preincubated for 5 mins followed by substrate addition and measured after 1 hr by fluorescence assay
1341,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,1449332,Inactive,inhibition of hdac6 in human cal27 cells assessed as accumulation of acetylated alpha tubulin at 1 um after 24 hrs by immunoblot analysis
1342,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,1449333,Inactive,inhibition of hdac6 in human cal27cisr cells assessed accumulation of acetylated alpha tubulin at 1 um after 24 hrs by immunoblot analysis
1529,CHEMBL1865,Histone deacetylase 6,CHEMBL551151,420643,Active,inhibition of hdac6 in human igrov1 cells assessed as alpha tubulin acetylation at ic80 after 48 hrs by western blot
2375,CHEMBL1865,Histone deacetylase 6,CHEMBL4105617,1452911,Active,inhibition of hdac6  unknown origin by fluorescence assay
2068,CHEMBL1865,Histone deacetylase 6,CHEMBL3918869,1343567,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
893,CHEMBL1865,Histone deacetylase 6,CHEMBL235917,302799,Active,inhibition of mouse recombinant hdac6 expressed in 293 cells
1168,CHEMBL1865,Histone deacetylase 6,CHEMBL4063938,1469192,Inactive,inhibition of hdac6 in human pc3 cells assessed as increase in acetylated tubulin level at 1 to 2 um after 24 hrs by western blot method
356,CHEMBL1865,Histone deacetylase 6,CHEMBL1934896,1439777,Active,inhibition of human hdac6 using boc lys ac  amc as substrate preincubated for 30 mins followed by substrate addition measured after 60 mins by trypsin based fluorescence assay
1167,CHEMBL1865,Histone deacetylase 6,CHEMBL4063938,1469191,Inactive,downregulation of hdac6 protein expression in human pc3 cells at 1 to 2 um after 24 hrs by western blot method
355,CHEMBL1865,Histone deacetylase 6,CHEMBL1934896,637889,Active,inhibition of recombinant human hdac6 using boc l lys acetyl  mca as substrate by fluorogenic enzymatic assay
1165,CHEMBL1865,Histone deacetylase 6,CHEMBL4063938,1469138,Active,downregulation of hdac6 protein expression in human mv4 11 cells at > 0 5 um after 24 hrs by western blot analysis
912,CHEMBL1865,Histone deacetylase 6,CHEMBL2170019,700671,Inactive,inhibition of hdac6 in human jurkat cells assessed as increase of acetylated alpha tubulin level at 2 to 20 um after 24 hrs by western blot analysis
1166,CHEMBL1865,Histone deacetylase 6,CHEMBL4063938,1469177,Active,inhibition of hdac6 in human mv4 11 cells assessed as increase in acetylated tubulin level at 0 25 to 2 um after 24 hrs by western blot analysis
1995,CHEMBL1865,Histone deacetylase 6,CHEMBL3287016,1343566,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
1466,CHEMBL1865,Histone deacetylase 6,CHEMBL1093041,473174,Active,ex vivo inhibition of human hdac6 in human caco 2 cells by fluorometric cellular activity assay
703,CHEMBL1865,Histone deacetylase 6,CHEMBL3735770,1263145,Active,inhibition of human recombinant hdac6 using boc lys ac  amc as substrate after 30 mins by fluorescence assay
777,CHEMBL1865,Histone deacetylase 6,CHEMBL3628323,1254048,Active,inhibition of hdac6  unknown origin incubated for 1 hr by fluor de lys substrate based fluorescence method
1674,CHEMBL1865,Histone deacetylase 6,CHEMBL3287019,1343567,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
1673,CHEMBL1865,Histone deacetylase 6,CHEMBL3287019,1343566,Active,enzyme assay: enzyme activity of hdac1 3 is determined using the substrate ac lys tyr lys ac  amc while the enzyme activity of hdac6 is assayed using the substrate boc lys ac  amc the reaction is carried out in flat bottom 96 well or 384 well microplates after the substrate was deacetylated by hdacs the product amc which was obtained from hydrolysis by trypsin can generate fluorescence signal measurement is taken in using an multilabe plate reader a 355 nm excitation filter and a 460 nm emission filter the initial rate of fluorescence should accurately reflect the rate of product formation and enzyme activity sample processing: the sample was dissolved in dmso and kept at a low temperature dmso in the final system is limited under a low concentration which won't affect the enzyme activity 
1672,CHEMBL1865,Histone deacetylase 6,CHEMBL3287019,1156059,Inactive,inhibition of recombinant human hdac6 using boc lys epsilon acetyl  amc as substrate at 20 ug/ml after 3 hrs by fluorescence assay
1337,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,607635,Inactive,inhibition of hdac6 in human hela cells assessed as increase in alpha tubulin acetylation at 0 6 um after 16 hrs by immunofluorescence microscopy
1336,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,607634,Active,inhibition of hdac6 in human hela cells assessed as increase in total lysine acetylation at 0 6 um after 16 hrs by immunofluorescence microscopy
1334,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,324957,Inactive,inhibition of hdac6 in hek293 cells at 10 um
1042,CHEMBL1865,Histone deacetylase 6,CHEMBL513568,345082,Inactive,inhibition of human hdac6 expressed in mammalian cells
1335,CHEMBL1865,Histone deacetylase 6,CHEMBL27759,488276,Active,inhibition of hdac6
333,CHEMBL3192,Histone deacetylase 8,CHEMBL3770484,1280261,Active,inhibition of human hdac8 using z l lys eta trifluoroacetyl  amc as substrate after 90 mins by fluorescence analysis
1400,CHEMBL3192,Histone deacetylase 8,CHEMBL3352823,1170743,Inactive,inhibition of human recombinant hdac8 using [ac leu gly lys ac  amc substrate incubated for 15 to 30 mins
277,CHEMBL3192,Histone deacetylase 8,CHEMBL2407720,762202,Active,inhibition of recombinant hdac8  unknown origin expressed in escherichia coli bl21 using mal as substrate incubated for 15 mins prior to substrate addition measured after 60 mins by fluorescence plate reader analysis
2286,CHEMBL3192,Histone deacetylase 8,CHEMBL2401843,759303,Active,inhibition of human recombinant hdac8 after 30 mins by fluorescence assay
1618,CHEMBL4040,MAP kinase ERK2,CHEMBL535,479526,Inactive,inhibition of erk2
1974,CHEMBL4204,MAP kinase signal-integrating kinase 2,CHEMBL124660,256576,Inactive,average binding constant for mknk2 nanot active at 10 um
1706,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL2086760,1345520,Active,human fms related tyrosine kinase 4  type iv rtks: vegf  vascular endothelial growth factor receptor family 
145,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL1289494,1345548,Active,human fms related tyrosine kinase 1  type iv rtks: vegf  vascular endothelial growth factor receptor family 
144,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL1289494,1345520,Active,human fms related tyrosine kinase 4  type iv rtks: vegf  vascular endothelial growth factor receptor family 
1707,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL2086760,1345548,Active,human fms related tyrosine kinase 1  type iv rtks: vegf  vascular endothelial growth factor receptor family 
1125,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL1084546,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family 
1705,CHEMBL1844,Macrophage colony stimulating factor receptor,CHEMBL2086760,1345503,Active,human fms related tyrosine kinase 3  type iii rtks: pdgfr csfr kit flt3 receptor family 
2292,CHEMBL280,Matrix metalloproteinase 13,CHEMBL151,670315,Active,inhibition of human recombinant mmp13 catalytic domain incubated for 20 mins by fluorimetric assay
1472,CHEMBL280,Matrix metalloproteinase 13,CHEMBL1078396,464405,Active,inhibition of mmp13
246,CHEMBL280,Matrix metalloproteinase 13,CHEMBL1683453,580296,Active,inhibition of recombinant human mmp13 assessed as substrate cleavage by measuring increase in fluorescence after 16 hrs
750,CHEMBL280,Matrix metalloproteinase 13,CHEMBL3359091,1328774,Active,inhibition of recombinant human ampa activated mmp13 using cy3 plglk cy5q ar nh2 as substrate measured after 40 mins by spectrofluorimetric method
749,CHEMBL280,Matrix metalloproteinase 13,CHEMBL3359091,1166661,Active,inhibition of human recombinant mmp13 using cy3 plglk cy5q ar nh2 as substrate after 40 mins by spectrofluorimetry
1421,CHEMBL283,Matrix metalloproteinase 3,CHEMBL151,670312,Active,inhibition of human recombinant mmp3 catalytic domain incubated for 20 mins by fluorimetric assay
34,CHEMBL283,Matrix metalloproteinase 3,CHEMBL574370,440423,Active,inhibition of trypsin activated human pro mmp3 after 4 hrs by fluorimetry
1683,CHEMBL283,Matrix metalloproteinase 3,CHEMBL496942,349399,Inactive,inhibition of mmp3 up to 100 um
843,CHEMBL283,Matrix metalloproteinase 3,CHEMBL584122,440423,Active,inhibition of trypsin activated human pro mmp3 after 4 hrs by fluorimetry
1709,CHEMBL283,Matrix metalloproteinase 3,CHEMBL452083,362876,Active,inhibition of human recombinant mmp3
415,CHEMBL321,Matrix metalloproteinase 9,CHEMBL3648904,1344400,Active,inhibition assay: the molecules are dose response tested on the following enzymes: mmp1 mmp3 mmp9 adam9 and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d systems reference: p126 990 and adam r d systems reference: es003 
1663,CHEMBL321,Matrix metalloproteinase 9,CHEMBL3959985,1344400,Active,inhibition assay: the molecules are dose response tested on the following enzymes: mmp1 mmp3 mmp9 adam9 and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d systems reference: p126 990 and adam r d systems reference: es003 
1137,CHEMBL321,Matrix metalloproteinase 9,CHEMBL2151350,693529,Active,inhibition of recombinant mmp9 catalytic site using mca pro leu gly leu dpa ala arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay
1499,CHEMBL321,Matrix metalloproteinase 9,CHEMBL104022,259187,Active,binding affinity to mmp9
1662,CHEMBL321,Matrix metalloproteinase 9,CHEMBL3959985,1344399,Active,inhibition assay: the molecules are dose response tested on the following enzymes: mmp1 mmp3 mmp9 adam9 and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d systems reference: p126 990 and adam r d systems reference: es003 
621,CHEMBL321,Matrix metalloproteinase 9,CHEMBL1779630,598240,Active,inhibition of mmp9
414,CHEMBL321,Matrix metalloproteinase 9,CHEMBL3648904,1344399,Active,inhibition assay: the molecules are dose response tested on the following enzymes: mmp1 mmp3 mmp9 adam9 and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d systems reference: p126 990 and adam r d systems reference: es003 
806,CHEMBL321,Matrix metalloproteinase 9,CHEMBL267854,313328,Active,inhibition of human recombinant mmp9
1773,CHEMBL321,Matrix metalloproteinase 9,CHEMBL2440441,779762,Active,inhibition of mmp9 catalytic domain  unknown origin using mca pro leu gly leu dpa ala arg nh2 as substrate incubated for 30 mins prior to substrate addition measured after 2 to 4 hrs by fluorometric assay
2372,CHEMBL321,Matrix metalloproteinase 9,CHEMBL43147,310906,Active,inhibition of mmp9
2181,CHEMBL321,Matrix metalloproteinase 9,CHEMBL472915,1399117,Active,inhibition of recombinant human mmp9  phe107 to pro449 residues expressed in escherichia coli preincubated for 45 mins followed by mea pro leu gly leu dap dnp  ala arg nh2 substrate addition by fluorescence assay
1060,CHEMBL321,Matrix metalloproteinase 9,CHEMBL579068,440421,Active,inhibition of para aminophenylmercuric acetate activated human recombinant pro mmp9 catalytic domain after 4 hrs by fluorimetry
678,CHEMBL332,Matrix metalloproteinase-1,CHEMBL251917,311967,Active,inhibition of mmp1
1711,CHEMBL332,Matrix metalloproteinase-1,CHEMBL573935,440425,Active,inhibition of para aminophenylmercuric acetate activated human pro mmp1 after 4 hrs by fluorimetry
969,CHEMBL332,Matrix metalloproteinase-1,CHEMBL1795861,603756,Active,inhibition of human mmp1 by fluorometric assay
1292,CHEMBL332,Matrix metalloproteinase-1,CHEMBL561036,419737,Active,inhibition of mmp1
1203,CHEMBL332,Matrix metalloproteinase-1,CHEMBL3704903,1259199,Active,enzyme assay: the molecules are tested in dose response studies on the following enzymes mmp1 mmp3 mmp9 adams and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d system reference: p126 990 and adam r d system reference: es003 
679,CHEMBL332,Matrix metalloproteinase-1,CHEMBL251917,349373,Active,inhibition of mmp1
1070,CHEMBL332,Matrix metalloproteinase-1,CHEMBL253823,311942,Active,inhibition of mmp1
2263,CHEMBL332,Matrix metalloproteinase-1,CHEMBL445971,349395,Inactive,inhibition of mmp1 up to 25 um
1205,CHEMBL332,Matrix metalloproteinase-1,CHEMBL3704903,1259201,Active,enzyme assay: the molecules are tested in dose response studies on the following enzymes mmp1 mmp3 mmp9 adams and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d system reference: p126 990 and adam r d system reference: es003 
1155,CHEMBL332,Matrix metalloproteinase-1,CHEMBL550548,419746,Active,inhibition of mmp1 mediated collagen degradation by sds page
1154,CHEMBL332,Matrix metalloproteinase-1,CHEMBL550548,419737,Active,inhibition of mmp1
1133,CHEMBL332,Matrix metalloproteinase-1,CHEMBL127867,108894,Active,inhibitory activity against matrix metalloprotease 1  mmp1 
1206,CHEMBL332,Matrix metalloproteinase-1,CHEMBL3704903,1259202,Active,enzyme assay: the molecules are tested in dose response studies on the following enzymes mmp1 mmp3 mmp9 adams and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d system reference: p126 990 and adam r d system reference: es003 
2103,CHEMBL332,Matrix metalloproteinase-1,CHEMBL563026,419737,Active,inhibition of mmp1
1204,CHEMBL332,Matrix metalloproteinase-1,CHEMBL3704903,1259200,Active,enzyme assay: the molecules are tested in dose response studies on the following enzymes mmp1 mmp3 mmp9 adams and adam10 according to the same protocol as that described for the tace enzyme in example 28 but with different substrates  mmp r d system reference: p126 990 and adam r d system reference: es003 
164,CHEMBL333,Matrix metalloproteinase-2,CHEMBL2385445,750825,Active,inhibition of human full length mmp2 using mca pro leu gly leu dpa dnp  ala arg nh2 as substrate measured up to 120 mins by fluorescence assay
1407,CHEMBL333,Matrix metalloproteinase-2,CHEMBL495795,375766,Active,inhibition of human recombinant mmp2 catalytic domain
1467,CHEMBL333,Matrix metalloproteinase-2,CHEMBL1801046,604449,Active,inhibition of human mmp2 assessed as cleavage of fluorogenic peptide mcapro leu gly leu dpa ala arg nh2 by fluorometric assay
2384,CHEMBL333,Matrix metalloproteinase-2,CHEMBL250266,349374,Active,inhibition of mmp2
1333,CHEMBL333,Matrix metalloproteinase-2,CHEMBL98917,310905,Active,inhibition of mmp2
2383,CHEMBL333,Matrix metalloproteinase-2,CHEMBL250266,311966,Active,inhibition of mmp2
1332,CHEMBL333,Matrix metalloproteinase-2,CHEMBL2151349,693528,Active,inhibition of mmp2 using mca pro leu gly leu dpa ala arg as substrate incubated for 30 mins prior to substrate addition measured after 3 hrs by fluorimetric assay
1149,CHEMBL333,Matrix metalloproteinase-2,CHEMBL2385443,750825,Active,inhibition of human full length mmp2 using mca pro leu gly leu dpa dnp  ala arg nh2 as substrate measured up to 120 mins by fluorescence assay
1881,CHEMBL333,Matrix metalloproteinase-2,CHEMBL3622794,1251006,Active,inhibition of apma activated human recombinant mmp2 incubated for 5 mins using 4 nitrophenylacetate substrate by esterase assay
1880,CHEMBL333,Matrix metalloproteinase-2,CHEMBL3622794,1251006,Active,inhibition of apma activated human recombinant mmp2 incubated for 5 mins using 4 nitrophenylacetate substrate by esterase assay
1390,CHEMBL233,Mu opioid receptor,CHEMBL1387060,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
302,CHEMBL233,Mu opioid receptor,CHEMBL1302391,504634,Active,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
301,CHEMBL233,Mu opioid receptor,CHEMBL1302391,504357,Active,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
300,CHEMBL233,Mu opioid receptor,CHEMBL1302391,504357,Active,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2270,CHEMBL233,Mu opioid receptor,CHEMBL1384726,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2271,CHEMBL233,Mu opioid receptor,CHEMBL1384726,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1391,CHEMBL233,Mu opioid receptor,CHEMBL1387060,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
2272,CHEMBL233,Mu opioid receptor,CHEMBL1384726,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1392,CHEMBL233,Mu opioid receptor,CHEMBL1387060,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
2274,CHEMBL233,Mu opioid receptor,CHEMBL1384726,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
1867,CHEMBL233,Mu opioid receptor,CHEMBL1487635,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
2273,CHEMBL233,Mu opioid receptor,CHEMBL1384726,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1868,CHEMBL233,Mu opioid receptor,CHEMBL1487635,504900,Inactive,luminescence based cell based high throughput confirmation assay for inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1388,CHEMBL233,Mu opioid receptor,CHEMBL1387060,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1387,CHEMBL233,Mu opioid receptor,CHEMBL1387060,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
522,CHEMBL233,Mu opioid receptor,CHEMBL1545369,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1389,CHEMBL233,Mu opioid receptor,CHEMBL1387060,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2275,CHEMBL233,Mu opioid receptor,CHEMBL1384726,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
299,CHEMBL233,Mu opioid receptor,CHEMBL1302391,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
161,CHEMBL233,Mu opioid receptor,CHEMBL1572356,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
303,CHEMBL233,Mu opioid receptor,CHEMBL1302391,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
162,CHEMBL233,Mu opioid receptor,CHEMBL1572356,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
163,CHEMBL233,Mu opioid receptor,CHEMBL1572356,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
160,CHEMBL233,Mu opioid receptor,CHEMBL1572356,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
159,CHEMBL233,Mu opioid receptor,CHEMBL1572356,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2107,CHEMBL233,Mu opioid receptor,CHEMBL408980,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2108,CHEMBL233,Mu opioid receptor,CHEMBL408980,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2109,CHEMBL233,Mu opioid receptor,CHEMBL408980,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2110,CHEMBL233,Mu opioid receptor,CHEMBL408980,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
158,CHEMBL233,Mu opioid receptor,CHEMBL1572356,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2106,CHEMBL233,Mu opioid receptor,CHEMBL408980,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
991,CHEMBL233,Mu opioid receptor,CHEMBL1574879,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
990,CHEMBL233,Mu opioid receptor,CHEMBL1574879,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
989,CHEMBL233,Mu opioid receptor,CHEMBL1574879,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
988,CHEMBL233,Mu opioid receptor,CHEMBL1574879,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
987,CHEMBL233,Mu opioid receptor,CHEMBL1574879,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2111,CHEMBL233,Mu opioid receptor,CHEMBL408980,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
986,CHEMBL233,Mu opioid receptor,CHEMBL1574879,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1865,CHEMBL233,Mu opioid receptor,CHEMBL1487635,504357,Active,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1864,CHEMBL233,Mu opioid receptor,CHEMBL1487635,504357,Active,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
523,CHEMBL233,Mu opioid receptor,CHEMBL1545369,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1863,CHEMBL233,Mu opioid receptor,CHEMBL1487635,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1862,CHEMBL233,Mu opioid receptor,CHEMBL1487635,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
524,CHEMBL233,Mu opioid receptor,CHEMBL1545369,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1866,CHEMBL233,Mu opioid receptor,CHEMBL1487635,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
2070,CHEMBL233,Mu opioid receptor,CHEMBL1485010,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2073,CHEMBL233,Mu opioid receptor,CHEMBL1485010,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2074,CHEMBL233,Mu opioid receptor,CHEMBL1485010,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
2075,CHEMBL233,Mu opioid receptor,CHEMBL1485010,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
525,CHEMBL233,Mu opioid receptor,CHEMBL1545369,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
526,CHEMBL233,Mu opioid receptor,CHEMBL1545369,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
527,CHEMBL233,Mu opioid receptor,CHEMBL1545369,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
2072,CHEMBL233,Mu opioid receptor,CHEMBL1485010,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2071,CHEMBL233,Mu opioid receptor,CHEMBL1485010,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
405,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
295,CHEMBL233,Mu opioid receptor,CHEMBL1522211,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
413,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588435,Inactive,counterscreen for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors: luminescence based cell based high throughput dose response assay to identify agonists of oprm1 homodimerization
412,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588411,Active,counterscreen for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors: luminescence based cell based high throughput dose response assay to identify agonists of oprd1 homodimerization
411,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588408,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput dose response assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
292,CHEMBL233,Mu opioid receptor,CHEMBL1522211,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
410,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588407,Active,luminescence based cell based high throughput dose response assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
409,CHEMBL233,Mu opioid receptor,CHEMBL1604493,588407,Active,luminescence based cell based high throughput dose response assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
293,CHEMBL233,Mu opioid receptor,CHEMBL1522211,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
408,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504905,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
294,CHEMBL233,Mu opioid receptor,CHEMBL1522211,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2345,CHEMBL233,Mu opioid receptor,CHEMBL1411665,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
836,CHEMBL233,Mu opioid receptor,CHEMBL1565646,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
837,CHEMBL233,Mu opioid receptor,CHEMBL1565646,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
838,CHEMBL233,Mu opioid receptor,CHEMBL1565646,504357,Active,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
839,CHEMBL233,Mu opioid receptor,CHEMBL1565646,504357,Active,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
840,CHEMBL233,Mu opioid receptor,CHEMBL1565646,504634,Active,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
841,CHEMBL233,Mu opioid receptor,CHEMBL1565646,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
2344,CHEMBL233,Mu opioid receptor,CHEMBL1411665,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
296,CHEMBL233,Mu opioid receptor,CHEMBL1522211,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
407,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504904,Active,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2343,CHEMBL233,Mu opioid receptor,CHEMBL1411665,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2342,CHEMBL233,Mu opioid receptor,CHEMBL1411665,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
634,CHEMBL233,Mu opioid receptor,CHEMBL1457803,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
635,CHEMBL233,Mu opioid receptor,CHEMBL1457803,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
636,CHEMBL233,Mu opioid receptor,CHEMBL1457803,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
637,CHEMBL233,Mu opioid receptor,CHEMBL1457803,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1261,CHEMBL233,Mu opioid receptor,CHEMBL256042,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1262,CHEMBL233,Mu opioid receptor,CHEMBL256042,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1263,CHEMBL233,Mu opioid receptor,CHEMBL256042,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1264,CHEMBL233,Mu opioid receptor,CHEMBL256042,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1265,CHEMBL233,Mu opioid receptor,CHEMBL256042,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
1266,CHEMBL233,Mu opioid receptor,CHEMBL256042,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
708,CHEMBL233,Mu opioid receptor,CHEMBL140425,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
709,CHEMBL233,Mu opioid receptor,CHEMBL140425,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
710,CHEMBL233,Mu opioid receptor,CHEMBL140425,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
711,CHEMBL233,Mu opioid receptor,CHEMBL140425,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2341,CHEMBL233,Mu opioid receptor,CHEMBL1411665,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
712,CHEMBL233,Mu opioid receptor,CHEMBL140425,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
647,CHEMBL233,Mu opioid receptor,CHEMBL1457803,588435,Inactive,counterscreen for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors: luminescence based cell based high throughput dose response assay to identify agonists of oprm1 homodimerization
646,CHEMBL233,Mu opioid receptor,CHEMBL1457803,588411,Active,counterscreen for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors: luminescence based cell based high throughput dose response assay to identify agonists of oprd1 homodimerization
645,CHEMBL233,Mu opioid receptor,CHEMBL1457803,588408,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput dose response assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
644,CHEMBL233,Mu opioid receptor,CHEMBL1457803,588407,Active,luminescence based cell based high throughput dose response assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
643,CHEMBL233,Mu opioid receptor,CHEMBL1457803,588407,Active,luminescence based cell based high throughput dose response assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
642,CHEMBL233,Mu opioid receptor,CHEMBL1457803,504905,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
641,CHEMBL233,Mu opioid receptor,CHEMBL1457803,504904,Active,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
640,CHEMBL233,Mu opioid receptor,CHEMBL1457803,504904,Active,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
639,CHEMBL233,Mu opioid receptor,CHEMBL1457803,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
638,CHEMBL233,Mu opioid receptor,CHEMBL1457803,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
713,CHEMBL233,Mu opioid receptor,CHEMBL140425,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
2340,CHEMBL233,Mu opioid receptor,CHEMBL1411665,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1869,CHEMBL233,Mu opioid receptor,CHEMBL1487635,504900,Inactive,luminescence based cell based high throughput confirmation assay for inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
298,CHEMBL233,Mu opioid receptor,CHEMBL1302391,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2309,CHEMBL233,Mu opioid receptor,CHEMBL1542886,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2311,CHEMBL233,Mu opioid receptor,CHEMBL1542886,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2312,CHEMBL233,Mu opioid receptor,CHEMBL1542886,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2313,CHEMBL233,Mu opioid receptor,CHEMBL1542886,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
297,CHEMBL233,Mu opioid receptor,CHEMBL1522211,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
404,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
2314,CHEMBL233,Mu opioid receptor,CHEMBL1542886,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
403,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
402,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
1870,CHEMBL233,Mu opioid receptor,CHEMBL1487635,504914,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
401,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
406,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504904,Active,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
400,CHEMBL233,Mu opioid receptor,CHEMBL1604493,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
861,CHEMBL233,Mu opioid receptor,CHEMBL1333440,504905,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
860,CHEMBL233,Mu opioid receptor,CHEMBL1333440,504904,Inactive,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
2310,CHEMBL233,Mu opioid receptor,CHEMBL1542886,504326,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
856,CHEMBL233,Mu opioid receptor,CHEMBL1333440,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
853,CHEMBL233,Mu opioid receptor,CHEMBL1333440,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
854,CHEMBL233,Mu opioid receptor,CHEMBL1333440,504326,Active,luminescence based cell based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
855,CHEMBL233,Mu opioid receptor,CHEMBL1333440,504357,Inactive,luminescence based cell based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
858,CHEMBL233,Mu opioid receptor,CHEMBL1333440,504692,Inactive,counterscreen for agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
857,CHEMBL233,Mu opioid receptor,CHEMBL1333440,504634,Inactive,counterscreen for inverse agonists of oprm1 oprd1 heterodimerization: luminescence based cell based full deck high throughput screening assay to identify inverse agonists of 5 hydroxytryptamine  serotonin 5a receptor  htr5a 
859,CHEMBL233,Mu opioid receptor,CHEMBL1333440,504904,Inactive,luminescence based cell based high throughput confirmation assay for agonists of heterodimerization of the mu 1  oprm1 and delta 1  oprd1 opioid receptors
346,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1108,602247,Inactive,full deck counterscreen for positive allosteric modulators  pams of the human m1 muscarinic receptor  chrm1 : fluorescence based cell based high throughput screening assay to identify nonselective activators and assay artifacts using the parental chok1 cell line
347,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1108,602248,Inactive,full deck counterscreen for agonists of the human m1 muscarinic receptor  chrm1 : fluorescence based cell based high throughput screening assay to identify nonselective activators and assay artifacts using the parental chok1 cell line
2299,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1724,588814,Inactive,fluorescence based cell based primary high throughput screening assay to identify agonists of the human cholinergic receptor muscarinic 1  chrm1 
2300,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1724,588819,Inactive,fluorescence based cell based primary high throughput screening assay to identify positive allosteric modulators  pams of the human m1 muscarinic receptor  chrm1 
348,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1108,602250,Inactive,full deck counterscreen for antagonists of the human m1 muscarinic receptor  chrm1 : fluorescence based cell based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental chok1 cell line
2301,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1724,588852,Active,fluorescence based cell based primary high throughput screening assay to identify antagonists of the human m1 muscarinic receptor  chrm1 
2304,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1724,602250,Inactive,full deck counterscreen for antagonists of the human m1 muscarinic receptor  chrm1 : fluorescence based cell based high throughput screening assay to identify nonselective inhibitors and assay artifacts using the parental chok1 cell line
2303,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1724,602248,Inactive,full deck counterscreen for agonists of the human m1 muscarinic receptor  chrm1 : fluorescence based cell based high throughput screening assay to identify nonselective activators and assay artifacts using the parental chok1 cell line
343,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1108,588814,Inactive,fluorescence based cell based primary high throughput screening assay to identify agonists of the human cholinergic receptor muscarinic 1  chrm1 
2302,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1724,602247,Inactive,full deck counterscreen for positive allosteric modulators  pams of the human m1 muscarinic receptor  chrm1 : fluorescence based cell based high throughput screening assay to identify nonselective activators and assay artifacts using the parental chok1 cell line
345,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1108,588852,Inactive,fluorescence based cell based primary high throughput screening assay to identify antagonists of the human m1 muscarinic receptor  chrm1 
344,CHEMBL216,Muscarinic acetylcholine receptor M1,CHEMBL1108,588819,Inactive,fluorescence based cell based primary high throughput screening assay to identify positive allosteric modulators  pams of the human m1 muscarinic receptor  chrm1 
2222,CHEMBL2815,Nerve growth factor receptor Trk-A,CHEMBL941,256626,Inactive,average binding constant for ntrk1 nanot active at 10 um
1016,CHEMBL222,Norepinephrine transporter,CHEMBL3331504,1164248,Active,inhibition of human net expressed in hek293 cells at incubated for 15 mins by neurotransmitter reuptake assay
648,CHEMBL222,Norepinephrine transporter,CHEMBL1914693,628084,Active,displacement of [125i] inxt from net transfected in pig llc pk1 cells by radioligand competition binding assay
1052,CHEMBL222,Norepinephrine transporter,CHEMBL3126751,1075730,Active,displacement of [3h]nisoxetine from sprague dawley rat brain net after 180 mins by liquid scintillation counting analysis
1875,CHEMBL222,Norepinephrine transporter,CHEMBL3331469,1164248,Active,inhibition of human net expressed in hek293 cells at incubated for 15 mins by neurotransmitter reuptake assay
869,CHEMBL222,Norepinephrine transporter,CHEMBL3331501,1164248,Active,inhibition of human net expressed in hek293 cells at incubated for 15 mins by neurotransmitter reuptake assay
1840,CHEMBL222,Norepinephrine transporter,CHEMBL401069,309731,Active,displacement of [125i]rti55 from human net transfected in cos1 cells
1744,CHEMBL222,Norepinephrine transporter,CHEMBL4062435,1472455,Active,displacement of [3h]nisoxetine from sprague dawley rat brain net after 180 mins by liquid scintillation counting method
1419,CHEMBL222,Norepinephrine transporter,CHEMBL428408,309731,Active,displacement of [125i]rti55 from human net transfected in cos1 cells
207,CHEMBL222,Norepinephrine transporter,CHEMBL2204360,712515,Active,inhibition of net mediated [3h]ne in rat synaptosomes by scintillation counting
599,CHEMBL222,Norepinephrine transporter,CHEMBL476108,342786,Active,binding affinity to rat net
724,CHEMBL222,Norepinephrine transporter,CHEMBL3331485,1164248,Active,inhibition of human net expressed in hek293 cells at incubated for 15 mins by neurotransmitter reuptake assay
1619,CHEMBL222,Norepinephrine transporter,CHEMBL1914695,628084,Active,displacement of [125i] inxt from net transfected in pig llc pk1 cells by radioligand competition binding assay
429,CHEMBL222,Norepinephrine transporter,CHEMBL1516187,1075730,Active,displacement of [3h]nisoxetine from sprague dawley rat brain net after 180 mins by liquid scintillation counting analysis
1682,CHEMBL5113,Orexin receptor 1,CHEMBL1272150,485270,Inactive,fret based cell based primary high throughput screening assay to identify antagonists of the orexin 1 receptor  ox1r hcrtr1 
1681,CHEMBL5113,Orexin receptor 1,CHEMBL1272150,463079,Inactive,fluorescence based counterscreen for orexin 1 receptor  ox1r antagonists: cell based assay to identify antagonists of the parental cho cell line
1680,CHEMBL5113,Orexin receptor 1,CHEMBL1272150,434989,Inactive,fluorescence based cell based primary high throughput screening assay to identify antagonists of the orexin 1 receptor  ox1r hcrtr1 
1355,CHEMBL5113,Orexin receptor 1,CHEMBL3672939,1258840,Active,flipr ca2+ flux assay: the utility of the compounds in accordance with the present invention as orexin receptor ox1r and/or ox2r antagonists may be readily determined without undue experimentation by methodology well known in the art including the flipr ca2+ flux assay  okumura et al biochem biophys res comm 280:976 981 2001 in a typical experiment the ox1 and ox2 receptor antagonistic activity of the compounds of the present invention was determined in accordance with the following experimental method for intracellular calcium measurements chinese hamster ovary  cho cells expressing the rat orexin 1 receptor or the human orexin 2 receptor are grown in iscove's modified dmem containing 2 mm l glutamine 0 5 g/ml g418 1% hypoxanthine thymidine supplement 100 u/ml penicillin 100 ug/ml streptomycin and 10% heat inactivated fetal calf serum  fcs the cells are seeded at 20 000 cells/well into becton dickinson black 384 well clear bottom sterile plates coated with poly d l
1235,CHEMBL4792,Orexin receptor 2,CHEMBL1576843,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1236,CHEMBL4792,Orexin receptor 2,CHEMBL1576843,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
396,CHEMBL4792,Orexin receptor 2,CHEMBL1502109,624050,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1126,CHEMBL4792,Orexin receptor 2,CHEMBL1605702,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1132,CHEMBL4792,Orexin receptor 2,CHEMBL1532403,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1127,CHEMBL4792,Orexin receptor 2,CHEMBL1605702,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
390,CHEMBL4792,Orexin receptor 2,CHEMBL1419029,624050,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
397,CHEMBL4792,Orexin receptor 2,CHEMBL1502109,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2049,CHEMBL4792,Orexin receptor 2,CHEMBL1507474,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1984,CHEMBL4792,Orexin receptor 2,CHEMBL1583817,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1104,CHEMBL4792,Orexin receptor 2,CHEMBL1372776,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1105,CHEMBL4792,Orexin receptor 2,CHEMBL1372776,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
506,CHEMBL4792,Orexin receptor 2,CHEMBL1548353,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
507,CHEMBL4792,Orexin receptor 2,CHEMBL1548353,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1131,CHEMBL4792,Orexin receptor 2,CHEMBL1532403,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2053,CHEMBL4792,Orexin receptor 2,CHEMBL1721724,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2052,CHEMBL4792,Orexin receptor 2,CHEMBL1721724,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2050,CHEMBL4792,Orexin receptor 2,CHEMBL1507474,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1887,CHEMBL4792,Orexin receptor 2,CHEMBL1304258,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1983,CHEMBL4792,Orexin receptor 2,CHEMBL1583817,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1886,CHEMBL4792,Orexin receptor 2,CHEMBL1304258,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1349,CHEMBL4792,Orexin receptor 2,CHEMBL1496820,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1348,CHEMBL4792,Orexin receptor 2,CHEMBL1496820,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1401,CHEMBL4792,Orexin receptor 2,CHEMBL1584180,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1185,CHEMBL4792,Orexin receptor 2,CHEMBL1493746,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1186,CHEMBL4792,Orexin receptor 2,CHEMBL1493746,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1197,CHEMBL4792,Orexin receptor 2,CHEMBL1432793,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1198,CHEMBL4792,Orexin receptor 2,CHEMBL1432793,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1316,CHEMBL4792,Orexin receptor 2,CHEMBL1501678,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1315,CHEMBL4792,Orexin receptor 2,CHEMBL1501678,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1402,CHEMBL4792,Orexin receptor 2,CHEMBL1584180,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
391,CHEMBL4792,Orexin receptor 2,CHEMBL1419029,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1858,CHEMBL4792,Orexin receptor 2,CHEMBL1720383,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1043,CHEMBL4792,Orexin receptor 2,CHEMBL1301892,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1730,CHEMBL4792,Orexin receptor 2,CHEMBL1438621,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
871,CHEMBL4792,Orexin receptor 2,CHEMBL1714761,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
872,CHEMBL4792,Orexin receptor 2,CHEMBL1714761,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1044,CHEMBL4792,Orexin receptor 2,CHEMBL1301892,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
883,CHEMBL4792,Orexin receptor 2,CHEMBL1351929,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
884,CHEMBL4792,Orexin receptor 2,CHEMBL1351929,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1800,CHEMBL4792,Orexin receptor 2,CHEMBL1536921,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1801,CHEMBL4792,Orexin receptor 2,CHEMBL1536921,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1806,CHEMBL4792,Orexin receptor 2,CHEMBL1364699,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1807,CHEMBL4792,Orexin receptor 2,CHEMBL1364699,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2285,CHEMBL4792,Orexin receptor 2,CHEMBL1526293,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2284,CHEMBL4792,Orexin receptor 2,CHEMBL1526293,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1824,CHEMBL4792,Orexin receptor 2,CHEMBL1575559,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
923,CHEMBL4792,Orexin receptor 2,CHEMBL1418095,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
924,CHEMBL4792,Orexin receptor 2,CHEMBL1418095,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1825,CHEMBL4792,Orexin receptor 2,CHEMBL1575559,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
934,CHEMBL4792,Orexin receptor 2,CHEMBL1463349,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
935,CHEMBL4792,Orexin receptor 2,CHEMBL1463349,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2232,CHEMBL4792,Orexin receptor 2,CHEMBL1518032,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2231,CHEMBL4792,Orexin receptor 2,CHEMBL1518032,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
552,CHEMBL4792,Orexin receptor 2,CHEMBL1556270,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1612,CHEMBL4792,Orexin receptor 2,CHEMBL1967103,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
551,CHEMBL4792,Orexin receptor 2,CHEMBL1556270,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1613,CHEMBL4792,Orexin receptor 2,CHEMBL1967103,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2376,CHEMBL4792,Orexin receptor 2,CHEMBL1559065,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
683,CHEMBL4792,Orexin receptor 2,CHEMBL1521046,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
684,CHEMBL4792,Orexin receptor 2,CHEMBL1521046,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1679,CHEMBL4792,Orexin receptor 2,CHEMBL1418004,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1678,CHEMBL4792,Orexin receptor 2,CHEMBL1418004,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
666,CHEMBL4792,Orexin receptor 2,CHEMBL1481716,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1702,CHEMBL4792,Orexin receptor 2,CHEMBL1588256,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
665,CHEMBL4792,Orexin receptor 2,CHEMBL1481716,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1703,CHEMBL4792,Orexin receptor 2,CHEMBL1588256,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
653,CHEMBL4792,Orexin receptor 2,CHEMBL1468272,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
652,CHEMBL4792,Orexin receptor 2,CHEMBL1468272,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
272,CHEMBL4792,Orexin receptor 2,CHEMBL1721971,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
273,CHEMBL4792,Orexin receptor 2,CHEMBL1721971,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
45,CHEMBL4792,Orexin receptor 2,CHEMBL1386871,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
46,CHEMBL4792,Orexin receptor 2,CHEMBL1386871,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
773,CHEMBL4792,Orexin receptor 2,CHEMBL1583293,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
774,CHEMBL4792,Orexin receptor 2,CHEMBL1583293,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1626,CHEMBL4792,Orexin receptor 2,CHEMBL1479657,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1625,CHEMBL4792,Orexin receptor 2,CHEMBL1479657,624050,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2386,CHEMBL4792,Orexin receptor 2,CHEMBL1422276,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2385,CHEMBL4792,Orexin receptor 2,CHEMBL1422276,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2377,CHEMBL4792,Orexin receptor 2,CHEMBL1559065,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1729,CHEMBL4792,Orexin receptor 2,CHEMBL1438621,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1848,CHEMBL4792,Orexin receptor 2,CHEMBL1511752,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1959,CHEMBL4792,Orexin receptor 2,CHEMBL1493516,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2192,CHEMBL4792,Orexin receptor 2,CHEMBL1405608,624050,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2193,CHEMBL4792,Orexin receptor 2,CHEMBL1405608,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2178,CHEMBL4792,Orexin receptor 2,CHEMBL1379934,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2177,CHEMBL4792,Orexin receptor 2,CHEMBL1379934,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1960,CHEMBL4792,Orexin receptor 2,CHEMBL1493516,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1849,CHEMBL4792,Orexin receptor 2,CHEMBL1511752,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
962,CHEMBL4792,Orexin receptor 2,CHEMBL1478565,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1859,CHEMBL4792,Orexin receptor 2,CHEMBL1720383,624051,Active,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
963,CHEMBL4792,Orexin receptor 2,CHEMBL1478565,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2200,CHEMBL4792,Orexin receptor 2,CHEMBL1327720,624051,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : homogeneous time resolved fluorescence  htrf  based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
2199,CHEMBL4792,Orexin receptor 2,CHEMBL1327720,624050,Inactive,counterscreen assay for antagonists of the orexin 1 receptor  ox1r hcrtr1 : fluorescence based cell based dose response assay for antagonists of the orexin 2 receptor  ox2r hcrtr2 run by assay provider
1015,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3121311,1070710,Active,inhibition of pi3kalpha  1 to 1068 /6xhis tagged p85  1 to 724  unknown origin using dic8 pip2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins
2016,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1911008,626774,Active,antiproliferative activity against human nzov9 cells expressing p110alpha kinase y1021c mutant assessed as incorporation of [3h]thymidine after 5 days
1014,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL4071083,1482747,Active,antiproliferative activity against human skov3 cells harboring pik3ca mutant after 72 hrs by cck 8 assay
1146,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1645110,549732,Inactive,inhibition of human pi3k p110alpha catalytic subunit at 83 3 um by alphascreen assay
900,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL4060108,1482747,Active,antiproliferative activity against human skov3 cells harboring pik3ca mutant after 72 hrs by cck 8 assay
1317,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3585605,1231394,Active,inhibition of cell proliferation of human nzb5 cells containing wild type p110alpha gene incubated for 5 days by [3h]thymidine incorporation assay
1318,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3585605,1231395,Active,inhibition of cell proliferation of human nzov9 cells containing wild type p53 protein and p110alpha y1021c mutant incubated for 5 days by [3h]thymidine incorporation assay
1059,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2057363,673070,Active,inhibition of pi3kalpha in human hl60 cell lysate by kinobead assay
393,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2064481,674825,Active,inhibition of pi3kalpha by high throughput chemoproteomics binding assay
2291,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL4098035,1482747,Active,antiproliferative activity against human skov3 cells harboring pik3ca mutant after 72 hrs by cck 8 assay
1386,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1240545,507072,Active,inhibition of recombinant pi3kalpha by radioactive phosphotransfer assay in presence of 10 um atp
1623,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2059908,673070,Active,inhibition of pi3kalpha in human hl60 cell lysate by kinobead assay
2430,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1241680,507072,Active,inhibition of recombinant pi3kalpha by radioactive phosphotransfer assay in presence of 10 um atp
1624,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2059908,674825,Active,inhibition of pi3kalpha by high throughput chemoproteomics binding assay
1903,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1910995,626774,Active,antiproliferative activity against human nzov9 cells expressing p110alpha kinase y1021c mutant assessed as incorporation of [3h]thymidine after 5 days
1904,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1910995,626775,Active,antiproliferative activity against human nzb5 cells expressing wild type p110alpha assessed as incorporation of [3h]thymidine after 5 days
2062,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL2064489,674825,Active,inhibition of pi3kalpha by high throughput chemoproteomics binding assay
1905,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1910995,626778,Active,inhibition of mouse recombinant pi3k p110alpha expressed in sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging
439,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3585594,1231395,Active,inhibition of cell proliferation of human nzov9 cells containing wild type p53 protein and p110alpha y1021c mutant incubated for 5 days by [3h]thymidine incorporation assay
2293,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL4078233,1447232,Active,inhibition of pi3kalpha mutant in human bt474 cells assessed as decrease in akt phosphorylation at thr308 after 2 hrs
2018,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1911008,626778,Active,inhibition of mouse recombinant pi3k p110alpha expressed in sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging
51,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1946262,643583,Active,inhibition of pi3kalpha
241,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL3121310,1070710,Active,inhibition of pi3kalpha  1 to 1068 /6xhis tagged p85  1 to 724  unknown origin using dic8 pip2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins
1238,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1312643,1198011,Active,inhibition of recombinant pi3kalpha  unknown origin using biotinylated pip2 as substrate
1237,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1312643,663152,Active,inhibition of human recombinant pi3kalpha expressed in baculovirus system using pi 4 5 p2 as substrate after 20 mins
2335,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1645100,549727,Active,inhibition of human p110alpha pi3k fragment by alphascreen assay
2017,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1911008,626775,Active,antiproliferative activity against human nzb5 cells expressing wild type p110alpha assessed as incorporation of [3h]thymidine after 5 days
2393,CHEMBL4005,PI3-kinase p110-alpha subunit,CHEMBL1242030,507072,Active,inhibition of recombinant pi3kalpha by radioactive phosphotransfer assay in presence of 10 um atp
1759,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL3357867,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
1760,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL3357867,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
984,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL2206916,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
2349,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL3121326,1070709,Active,inhibition of pi3kbeta  1 to 1070 /6xhis tagged p85  1 to 724  unknown origin using dic8 pip2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins
2001,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL2418960,768259,Active,inhibition of pi3kbeta  unknown origin using 1alpha phosphotidylinositol by luminescence assay
985,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL2206916,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
62,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL3643349,1502511,Active,inhibition of recombinant pi3kbeta  unknown origin using phosphatidyl inositol/n octyl glucoside as substrate measured after 60 mins by kinaseglo assay
785,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL2087479,685270,Active,inhibition of human pi3kbeta  p110beta/p85alpha by adp accumulation based htrf assay
63,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL3643349,1502515,Active,inhibition of recombinant human myristoylated pi3kbeta catalytic domain expressed in rat1 cells assessed as reduction in akt phosphorylation at ser47 residue after 1 hr by alpha screen surefire assay
2418,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL2170094,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
845,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL1242034,507073,Active,inhibition of recombinant pi3kbeta by radioactive phosphotransfer assay in presence of 10 um atp
2202,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL3649472,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
786,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL2087479,685270,Active,inhibition of human pi3kbeta  p110beta/p85alpha by adp accumulation based htrf assay
2464,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL3646442,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
1257,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL1242758,507073,Active,inhibition of recombinant pi3kbeta by radioactive phosphotransfer assay in presence of 10 um atp
2203,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL3649472,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
2419,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL2170094,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
1272,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL1241587,507073,Active,inhibition of recombinant pi3kbeta by radioactive phosphotransfer assay in presence of 10 um atp
2205,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL1213082,719920,Active,inhibition of pi3kbeta in presence of 10 um atp
2204,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL1213082,496760,Active,inhibition of p110beta
2463,CHEMBL3145,PI3-kinase p110-beta subunit,CHEMBL3646442,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
2198,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL1909655,626776,Active,inhibition of bovine recombinant pi3k p110delta expressed in sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging
1546,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3646559,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
696,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL1911120,626776,Active,inhibition of bovine recombinant pi3k p110delta expressed in sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging
1547,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3646559,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
2208,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3646556,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
234,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL1911123,626776,Active,inhibition of bovine recombinant pi3k p110delta expressed in sf21 insect cells using phosphatidylinositol as substrate after 1 hr by phosphoimaging
2427,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL2170082,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
1245,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3646594,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
1427,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL2381269,746368,Active,inhibition of gst fused human recombinant pi3kdelta expressed in baculovirus infected sf9 cells after 1 hr by scintillation proximity assay in presence of [gamma 33p] atp
369,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL478980,1120065,Active,inhibition of pi3kdelta  unknown origin 
1139,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL2326965,729013,Active,inhibition of pi3k p110delta  unknown origin 
1330,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3121315,1070708,Active,inhibition of pi3kdelta  1 to 1044 /6xhis tagged p85  1 to 724  unknown origin using dic8 pip2 as substrate preincubated for 30 mins followed by substrate addition measured after 45 to 60 mins
1246,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3646594,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
482,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL2206920,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
483,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL2206920,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
2426,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL2170082,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
2207,CHEMBL3130,PI3-kinase p110-delta subunit,CHEMBL3646556,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
1465,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3646593,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
1191,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3357868,1175294,Active,inhibition of human n terminal poly his tagged p110gamma  114 to 1102 aa /p85alpha expressed in sf9 baculovirus system after 20 mins by alphascreen assay
1464,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3646593,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
1207,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3646595,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
1193,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3357868,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
1194,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3357868,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
1017,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL512293,342873,Active,inhibition of pi3kgamma
48,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3643413,1502507,Active,inhibition of pi3kgamma in c57/bl6 mouse bmmc assessed as reduction in adenosine stimulated atk phosphorylation at ser473 residue pretreated for 30 mins followed by adenosine addition measured after 3 minutes
1196,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3955003,1325760,Active,binding affinity to human pi3kgamma  144 to 1102 residues expressed in mammalian expression system by kinomescan assay
316,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL466956,342873,Active,inhibition of pi3kgamma
1279,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3589377,1233495,Active,inhibition of his tagged p110gamma  unknown origin expressed in sf9/baculovirus system using [gamma 33p]atp by scintillation proximity assay
49,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3643413,1502512,Active,inhibition of pi3kgamma  unknown origin using phosphatidyl inositol as substrate measured after 30 mins by alexa fluor647 labelled adp tracer based tr fret assay
1208,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3646595,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
1192,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3357868,1175294,Active,inhibition of human n terminal poly his tagged p110gamma  114 to 1102 aa /p85alpha expressed in sf9 baculovirus system after 20 mins by alphascreen assay
1647,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3915903,1343864,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window 
548,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3646467,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
2382,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3649475,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
886,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3646583,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
885,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3646583,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
2089,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3112861,1068548,Active,inhibition of c terminal ploy his tagged human pi3kgamma expressed in baculovirus infected sf9 cells using pi 4 5 p2 as substrate after 15 mins by htrf assay
540,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3972988,1343863,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window 
1399,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL2088665,683668,Active,inhibition of pi3k p110gamma by fluorescence based immunoassay
541,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3972988,1343864,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window 
1425,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3805337,1343865,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window 
1423,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3805337,1343863,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window 
1449,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3698629,1258232,Active,adp glo kinase assay: some compounds of formula  i described herein were assayed in vitro for their ability to inhibit the lipid kinase activity of pi3ks by using a non radioactive method in details his and gst tagged recombinant proteins  purchased from jenabioscience germany pi3kalpha  pr 335 pi3kbeta  pr 344 pi3kgamma  pr 343 pi3kdelta  pr 345 for each isoform pi3kalpha  beta  gamma and delta were incubated with 10 um of atp with lipid micells containg the appropriate substrate phosphatidylinositol and the phosphatidilserine and different concentrations of the formula  i compounds after 30 minutes of incubation at room temperature the amount of adp produced from atp following the activation of kinase was measured with a luminescent kinase assay adp glo kinase assay  purchased from promega usa  v9101 the luminescent signal positively correlates with the formed adp and therefore with the kinase activity 
1450,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3698629,1258232,Active,adp glo kinase assay: some compounds of formula  i described herein were assayed in vitro for their ability to inhibit the lipid kinase activity of pi3ks by using a non radioactive method in details his and gst tagged recombinant proteins  purchased from jenabioscience germany pi3kalpha  pr 335 pi3kbeta  pr 344 pi3kgamma  pr 343 pi3kdelta  pr 345 for each isoform pi3kalpha  beta  gamma and delta were incubated with 10 um of atp with lipid micells containg the appropriate substrate phosphatidylinositol and the phosphatidilserine and different concentrations of the formula  i compounds after 30 minutes of incubation at room temperature the amount of adp produced from atp following the activation of kinase was measured with a luminescent kinase assay adp glo kinase assay  purchased from promega usa  v9101 the luminescent signal positively correlates with the formed adp and therefore with the kinase activity 
920,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3112866,1068548,Active,inhibition of c terminal ploy his tagged human pi3kgamma expressed in baculovirus infected sf9 cells using pi 4 5 p2 as substrate after 15 mins by htrf assay
2381,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3649475,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
547,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3646467,1258091,Active,alphascreen assay: the pi3k alphascreen assay  perkinelmer waltham mass measures the activity of a panel of four phosphoinositide 3 kinases: pi3kalpha pi3kbeta pi3kgamma and pi3kdelta each of these enzymes phosphorylates the 3' hydroxyl group on phosphatidylinositiol  4 5  bisphosphate  pip2 to produce phosphatidylinositol  3 4 5  trisphosphate  pip3 this phosphorylation activity is measured using a gst tagged pip3 binding protein  echelon biosciences salt lake city utah an anti gst tagged acceptor bead and streptavidin donor bead the interaction of biotinylated pip3 analog  ip4 and the pip3 binding protein brings both acceptor and donor beads together producing upon excitation of the donor beads at 680 nm a singlet oxygen species leading to the luminescent alphascreen signal when pip3 is produced via phosphorylation of pip2 by a pi3k pip3 competes with biotinylated pip3 analog  ip4 for binding to the pip3 binding protein 
199,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3956037,1325760,Active,binding affinity to human pi3kgamma  144 to 1102 residues expressed in mammalian expression system by kinomescan assay
1422,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3805337,1343862,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window 
1424,CHEMBL3267,PI3-kinase p110-gamma subunit,CHEMBL3805337,1343864,Active,time resolved fluorescence resonance energy transfer  tr fret assay: pi3k isoforms were assayed under initial rate conditions in the presence of 25 mm hepes  ph 7 4 and 2xkm atp  100 300 um 10 um pip2 5% glycerol 5 mm mgcl2 50 mm nacl 0 05%  v/v chaps 1 mm dithiothreitol 1%  v/v dmso at the following concentrations for each isoform: pi3k alpha beta delta and gamma at 50 picomolar  pm and pi3kgamma at 2 nanomolar  nm after an assay reaction time of 30 minutes at 25 xb0 c reactions were terminated with a final concentration of 10 mm edta 10 nm labeled pip3 and 35 nm europium labeled grp 1 detector protein before reading tr fret on an envision plate reader  ex: 340 nm em: 615/665 nm 100 us delay and 500 us read window 
1503,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3785872,1291846,Active,agonist activity at ppar delta  unknown origin transfected in hek293 cells at 1 um after 24 hrs by dual luciferase reporter gene assay
1677,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL221580,276054,Active,displacement of fluormone from ppar gamma
1698,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL427080,279990,Active,agonist activity at ppar gamma in mouse 3t3l1 cells assessed as increase in insulin receptor by irba
1502,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3785872,1291845,Inactive,agonist activity at ppar alpha  unknown origin transfected in hek293 cells at 1 um after 24 hrs by dual luciferase reporter gene assay
1829,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760419,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay
1697,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL427080,279989,Active,agonist activity at human ppar delta by fret assay
1831,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3695904,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
1685,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL447538,276054,Active,displacement of fluormone from ppar gamma
1696,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL427080,279988,Active,agonist activity at human ppar alpha by fret assay
1841,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3678136,1258934,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of 5 nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan  ppar green and serial dilutions of the experimental compound beginning at 10  x3bc x39c downwards was added to wells of black 384 well low  volume plates  greiner to a total volume of 18 xl all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium 
1842,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3678136,1258934,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of 5 nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan  ppar green and serial dilutions of the experimental compound beginning at 10  x3bc x39c downwards was added to wells of black 384 well low  volume plates  greiner to a total volume of 18 xl all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium 
336,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760425,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay
383,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL54097,157294,Active,in vitro binding affinity against human ppar gamma  peroxisome proliferator activated gamma receptor 
382,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL54097,157293,Active,in vitro agonist activity tested for transactivation in human ppar gamma gal4 chimeric cos 1 cells
381,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL54097,157292,Active,in vitro binding affinity against human ppar delta  peroxisome proliferator activated delta receptor 
1256,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1089317,473106,Inactive,transactivation of human pparalpha lbd expressed in african green monkey cos7 cells co transfected with fused gal4 dbd at 10 um after 14 hrs by dual glo luciferase reporter gene assay
1830,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3695904,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
1816,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL37495,156625,Active,binding affinity for human ppar delta receptor
1627,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3699390,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
1814,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL37495,156148,Inactive,maximum transcriptional activation of human ppar alpha receptor iainactive
1622,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760270,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay
1740,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL119217,156219,Inactive,in vitro transcription activation on human peroxisome proliferator activated receptor alpha  ppar alpha inactive
1741,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL119217,156235,Inactive,in vitro transcription activation on human peroxisome proliferator activated receptor delta  ppar delta inactive
1742,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL119217,156362,Active,in vitro transcription activation on human peroxisome proliferator activated receptor gamma  ppar gamma 
1750,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL147282,157123,Active,in vitro agonist activity against peroxisome proliferator activated receptor gamma  ppar gamma using alkaline phosphatase activity transactivator assay
1751,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL147282,157271,Active,binding affinity against peroxisome proliferator activated receptor gamma  ppar gamma 
1710,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1778830,597760,Active,agonist activity at human pparalpha lbd expressed in cv1 cells co transfected with gal4 after 40 hrs by luciferase based transactivation assay
354,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL221292,276172,Active,activity at human ppar delta by cell based transactivation assay
1769,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3699382,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
1508,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3785872,1291854,Inactive,agonist activity at ppar delta  unknown origin transfected in hek293 cells at 0 001 to 1000 um after 24 hrs by dr 4 luciferase reporter gene assay
1507,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3785872,1291853,Inactive,agonist activity at ppar delta  unknown origin transfected in hek293 cells at 0 001 to 1000 um after 24 hrs by pgl3 luciferase reporter gene assay
1770,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3699382,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
359,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL477941,382298,Inactive,agonist activity at human pparalpha expressed in hepg2 cells by gal4 transactivation assay relative to gw 9578
1813,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL37495,155978,Active,maximum transcriptional activation of human ppar gamma receptor
1506,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3785872,1291849,Inactive,agonist activity at ppar gamma  unknown origin transfected in hek293 cells at 0 1 to 100 um after 24 hrs by dr 1 luciferase reporter gene assay
1505,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3785872,1291848,Active,agonist activity at ppar delta  unknown origin transfected in hek293 cells after 24 hrs by dual luciferase reporter gene assay
1504,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3785872,1291847,Inactive,agonist activity at ppar gamma  unknown origin transfected in hek293 cells at 1 um after 24 hrs by dual luciferase reporter gene assay
270,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL17805,157283,Active,in vitro transcriptional activation of peroxisome proliferator activated receptor gamma  ppar expressed in cv 1 cells
269,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL17805,157275,Active,in vitro binding to peroxisome proliferator activated receptor gamma  ppar gamma using [3h] brl 49653 as radioligand in scintillation proximity assay  spa 
268,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL17805,156386,Active,inhibition of [125i]sb 236636 binding to human ppar gamma receptor
1628,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3699390,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
266,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL17805,156241,Inactive,in vitro transcriptional activation of peroxisome proliferator activated delta receptor  ppar expressed in cv 1 cells inactive
265,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL17805,156232,Inactive,in vitro transcriptional activation of peroxisome proliferator activated alpha receptor  ppar expressed in cv 1 cells inactive
1815,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL37495,156617,Active,maximum transcriptional activation of human ppar delta receptor
267,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL17805,156385,Active,inhibition of [125i]sb 236636 binding to human ppar gamma receptor
0,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL425116,279989,Active,agonist activity at human ppar delta by fret assay
476,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL52633,157293,Active,in vitro agonist activity tested for transactivation in human ppar gamma gal4 chimeric cos 1 cells
1991,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL416794,156617,Active,maximum transcriptional activation of human ppar delta receptor
2276,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL383646,266372,Active,inhibition of ppar delta
1990,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL416794,156148,Inactive,maximum transcriptional activation of human ppar alpha receptor iainactive
2031,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL2030550,660956,Active,displacement of fluormone pan ppar green from mouse recombinant gst tagged pparbeta/delta lbd at 1 um after 60 mins by tr fret assay
2032,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL2030550,660958,Inactive,antagonist activity at pparalpha in mouse nih3t3 cells coexpressing lexa assessed as decrease in gw7647 induced transcriptional activation at 1 um after 48 hrs by luciferase reporter gene assay relative to control
2033,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL2030550,660960,Active,displacement of fluormone pan ppar green from mouse recombinant gst tagged pparbeta/delta lbd after 60 mins by tr fret assay
1138,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL210613,266372,Active,inhibition of ppar delta
927,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3699429,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
603,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL115463,156219,Inactive,in vitro transcription activation on human peroxisome proliferator activated receptor alpha  ppar alpha inactive
604,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL115463,156234,Active,in vitro transcription activation on human peroxisome proliferator activated receptor delta  ppar delta 
605,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL115463,156362,Active,in vitro transcription activation on human peroxisome proliferator activated receptor gamma  ppar gamma 
2099,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3695762,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
2035,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL2030550,660963,Inactive,displacement of fluormone pan ppar green from ppargamma at 100 to 1000 nm after 60 mins by tr fret assay
899,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL230458,291758,Active,displacement of [3h]rosiglitazone from ppar gamma
2298,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL370152,254642,Active,effective agonist concentration for human ppar gamma gal4 construct in transactivation assay
2092,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1819483,614591,Inactive,modulation of human pparalpha lbd expressed in african green monkey cos7 cells co transfected with gal4 assessed as activation of transactivation activity at 10 um by luciferase assay
2034,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL2030550,660962,Inactive,displacement of fluormone pan ppar green from pparalpha at 100 to 1000 nm after 60 mins by tr fret assay
1079,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL394849,291758,Active,displacement of [3h]rosiglitazone from ppar gamma
928,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3699429,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
2123,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3695814,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
1176,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL215126,270625,Inactive,displacement of [3h]2  4 {2 [3  2 4 difluoro phenyl  1 heptyl ureido] ethyl} phenoxy  2 methyl butyric acid from human pparalpha by spa
1177,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL215126,270633,Inactive,displacement of [3h]2  4 {2 [3  2 4 difluoro phenyl  1 heptyl ureido] ethyl} phenoxy  2 methyl butyric acid from murine pparalpha by spa
1178,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL215126,270634,Inactive,transactivation of murine pparalpha in cv1 cells by luciferase reporter gene assay
477,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL52633,157294,Active,in vitro binding affinity against human ppar gamma  peroxisome proliferator activated gamma receptor 
1199,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL374234,279989,Active,agonist activity at human ppar delta by fret assay
1200,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760416,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay
2157,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL337393,47374,Active,in vitro agonist efficacy against ppar gamma along with 100 nm brl 49653
936,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3753473,1272055,Active,binding affinity to gst tagged human ppar gamma receptor by fret assay
1202,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760399,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay
2158,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL337393,47377,Active,in vitro agonistic activity against ppar gamma along with 100 nm brl 49653
1992,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL416794,156625,Active,binding affinity for human ppar delta receptor
2008,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3695898,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
966,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760410,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay
2009,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3695898,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
127,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL222560,280960,Active,activity at human placenta ppar delta expressed in hek293 cells by ppar gal4 transactivation assay
2124,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3695814,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
1993,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL416794,156945,Active,maximum transcriptional activation of human ppar gamma receptor
1987,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL524829,665203,Active,agonist activity at pparalpha
2098,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3695762,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
715,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL111841,156775,Inactive,binding affinity against peroxisome proliferator activated receptor delta  ppar delta not active
24,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3699405,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
2036,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL2030550,1266292,Active,binding affinity to gst ppar beta/delta lbp  unknown origin after 20 mins by tr fret assay
654,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL373591,279989,Active,agonist activity at human ppar delta by fret assay
759,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760423,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay
2039,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL2030550,1266295,Active,binding affinity to gst ppar beta/delta lbp  unknown origin after 2 hrs by tr fret assay
623,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1956877,648784,Inactive,agonist activity at human pparalpha expressed in cho cells co transfected with pgl3 ppre3 tk luc assessed as transactivation at 20 ug/ml after 24 hrs by firefly luciferase reporter gene assay
50,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL197268,254528,Active,binding affinity for human ppar gamma construct expressed in bacteria with 3[h] rosiglitazone
202,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL83612,156379,Active,tested for transactivation of human ppar gamma gal4 chimera in cv 1 cells
704,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL2204689,718853,Inactive,transactivation of human gal4 fused pparalpha ligand binding domain transfected in hek293 cells after 18 hrs by dual luciferase reporter gene assay
1128,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3695903,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
195,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3699384,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
194,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3699384,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
716,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL111841,157268,Active,binding affinity against peroxisome proliferator activated receptor gamma  ppar gamma 
89,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3393178,1190558,Active,transactivation of gal4 tagged pparalpha ligand binding domain  unknown origin expressed in cos7 cells measured after overnight incubation by luciferase reporter gene assay
23,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3699405,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
2389,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3678138,1258934,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of 5 nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan  ppar green and serial dilutions of the experimental compound beginning at 10  x3bc x39c downwards was added to wells of black 384 well low  volume plates  greiner to a total volume of 18 xl all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium 
201,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL83612,156368,Active,binding affinity was determined by displacement of 20 nm [3h]  thiazolidinedione from 4 nm biotinylated human peroxisome proliferator activated receptor  ppar gamma ligand binding domain
457,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3786533,1291855,Active,agonist activity at human ppar delta by cell based reporter assay
2041,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL2030550,1266297,Active,binding affinity to gst ppar beta/delta lbp  unknown origin after 24 hrs by tr fret assay
456,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3786533,1291848,Active,agonist activity at ppar delta  unknown origin transfected in hek293 cells after 24 hrs by dual luciferase reporter gene assay
1,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL425116,279990,Active,agonist activity at ppar gamma in mouse 3t3l1 cells assessed as increase in insulin receptor by irba
1129,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3695903,1258563,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan ppar green and serial dilutions of the experimental compound beginning at 10  x3bc m downwards was added to wells of black 384 well low volume plates  greiner to a total volume of 18  x3bc l all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium fold change over dmso was calculated using graphpad prism software  la jolla calif by calculating 520 nm/490 nm ratio graphs were plotted as fold change of fret signal for compound treatment over dmso only control 
717,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL111841,162627,Inactive,binding affinity against peroxisome proliferator activated receptor alpha  ppar alpha not active
2388,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3678138,1258934,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of 5 nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan  ppar green and serial dilutions of the experimental compound beginning at 10  x3bc x39c downwards was added to wells of black 384 well low  volume plates  greiner to a total volume of 18 xl all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium 
2040,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL2030550,1266296,Active,binding affinity to gst ppar beta/delta lbp  unknown origin after 3 hrs by tr fret assay
624,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL1760413,591221,Active,displacement of [3h]gw 2433 from human pparalpha by scintillation proximity assay
1986,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL524829,348373,Active,displacement of radiolabeled ligand from human pparalpha by competition binding assay
2373,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3678133,1258934,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of 5 nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan  ppar green and serial dilutions of the experimental compound beginning at 10  x3bc x39c downwards was added to wells of black 384 well low  volume plates  greiner to a total volume of 18 xl all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium 
2374,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL3678133,1258934,Active,lanthascreen competitive binding assay: the assay was performed according to manufacturer protocol a mixture of 5 nm gst pparg lbd 5 nm tb gst antibody 5 nm fluormone pan  ppar green and serial dilutions of the experimental compound beginning at 10  x3bc x39c downwards was added to wells of black 384 well low  volume plates  greiner to a total volume of 18 xl all dilutions were made in tr fret assay buffer c dmso at 2% final concentration was used as a no ligand control experiment was performed in triplicate and incubated for 2 hours in the dark prior to assay read in perkin elmer viewlux ultra hts microplate reader fret signal was measured by excitation at 340 nm and emission at 520 nm for fluorescein and 490 nm for terbium 
2038,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL2030550,1266294,Active,binding affinity to gst ppar beta/delta lbp  unknown origin after 1 hr by tr fret assay
2037,CHEMBL239,Peroxisome proliferator-activated receptor alpha,CHEMBL2030550,1266293,Active,binding affinity to gst ppar beta/delta lbp  unknown origin after 40 mins by tr fret assay
1605,CHEMBL3979,Peroxisome proliferator-activated receptor delta,CHEMBL3094417,1184303,Inactive,activation of human pparbeta ligand binding domain expressed in cos7 cells assessed as residual activity at 10 um by luciferase reporter gene assay
2125,CHEMBL3979,Peroxisome proliferator-activated receptor delta,CHEMBL518038,1183602,Inactive,agonist activity at human ppardelta lbd expressed in cos7 cells at 10 um after 12 hrs by dual glo luciferase assay
607,CHEMBL3979,Peroxisome proliferator-activated receptor delta,CHEMBL1089634,475400,Inactive,agonist activity at human gal4 tagged ppardelta chimeric receptor expressed in hek cells at 30 um by transactivation assay
189,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1259401,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary
177,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743199,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary
339,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL525552,665205,Active,agonist activity at ppargamma
338,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL525552,348374,Active,displacement of radiolabeled ligand from human ppargamma by competition binding assay
178,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1114583,Active,displacement of [3h]brl49653 from homo sapiens  human ppargamma receptor by scintillation proximity assay
180,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224840,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library   cell viability counter screen
183,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224841,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library
182,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224841,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library
184,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224841,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library
185,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224842,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library
186,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224842,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library
377,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL393593,305652,Active,agonist activity at ppargamma in mouse 3t3 l1 cells by irba
192,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1259402,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary
176,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743199,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary
191,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1259402,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary
187,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224842,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library
190,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1259402,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary
188,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1259401,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary
181,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224840,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library   cell viability counter screen
175,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743199,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary
209,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743094,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway
173,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743194,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway   cell viability counter screen
222,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224840,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library   cell viability counter screen
223,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224840,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library   cell viability counter screen
2333,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL1956149,649220,Inactive,agonist activity at n terminal his tagged human ppargamma expressed in escherichia coli bl21 assessed as transactivation activity
224,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224840,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library   cell viability counter screen
225,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224841,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library
226,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224841,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library
227,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224842,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library
228,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224842,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library
229,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1224842,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library
230,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1259401,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary
52,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL221755,277150,Active,agonist potency at ppargamma in cv1 cells by cell based transient transfection assay
768,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL430182,305652,Active,agonist activity at ppargamma in mouse 3t3 l1 cells by irba
231,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1259402,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary
1654,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL1760409,591222,Active,displacement of [3h]gw 2433 from human ppargamma by scintillation proximity assay
232,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1259402,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary
233,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1259402,Inactive,qhts assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library: summary
17,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL239563,305652,Active,agonist activity at ppargamma in mouse 3t3 l1 cells by irba
9,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL393805,305652,Active,agonist activity at ppargamma in mouse 3t3 l1 cells by irba
687,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL3780991,1288254,Active,antagonist activity at ppargamma  unknown origin expressed in hek293a cells after 16 to 18 hrs by luciferase reporter assay
1774,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL241063,305652,Active,agonist activity at ppargamma in mouse 3t3 l1 cells by irba
221,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,1114583,Active,displacement of [3h]brl49653 from homo sapiens  human ppargamma receptor by scintillation proximity assay
220,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743199,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary
219,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743199,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary
172,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743194,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway   cell viability counter screen
171,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743191,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway
170,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743140,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary
169,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743140,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary
168,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743140,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary
167,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743094,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway
166,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743094,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway
165,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743094,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway
208,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743094,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway
174,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,743194,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway   cell viability counter screen
1113,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL1086861,469032,Inactive,agonist activity at ppargamma receptor expressed in hek293 cells co transfected with gal4 at 1 um by transactivation assay
210,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743094,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway
211,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743140,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary
212,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743140,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary
213,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743140,Inactive,qhts assay to identify small molecule agonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary
214,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743191,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway
215,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743191,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway
216,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743194,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway   cell viability counter screen
217,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743194,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway   cell viability counter screen
218,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL82293,743199,Inactive,qhts assay to identify small molecule antagonists of the peroxisome proliferator activated receptor gamma  pparg signaling pathway: summary
116,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL178513,246429,Inactive,agonist activity against human ppargamma in cos 1 cell gal4 assay na not active  less than 20% activation at 10 um 
198,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL233177,299304,Active,displacement of [3h]5  4  3  5 methyl 2 phenyloxazol 4 yl propanoyl benzyl thiazolidine 2 4 dione from human ppargamma after 2 hrs by spa assay
179,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL46403,1224840,Inactive,qhts assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic ppargamma coactivator  pgc from tox21 10k library   cell viability counter screen
1227,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL273035,320687,Active,agonist activity at human ppargamma expressed in cv1 cells by transactivation assay
427,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL360992,246429,Inactive,agonist activity against human ppargamma in cos 1 cell gal4 assay na not active  less than 20% activation at 10 um 
2012,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL3779912,1288254,Active,antagonist activity at ppargamma  unknown origin expressed in hek293a cells after 16 to 18 hrs by luciferase reporter assay
1377,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL3921000,1343332,Active,reporter gene assay: transactivation assay expression vectors were prepared by inserting the ligand binding domain cdna  complementary dna of human pparalpha  amino acid 168 468 and human ppargamma  amino acid 205 505 3 x2032 to and in frame with the yeast gal4 transcription factor dna binding domain and the nuclear localization signal from the t antigen of polyoma virus into the mammalian expression vector psgs  stratagene the resulting expression vectors psggal pparalpha and psggal ppargamma were used in co transfection experiments together with a modified pgl3 promoter plasmid  promega containing five copies of the uas gal4 recognition site 2 5  x3bc g psggal pparalpha or psggal ppargamma were mixed with 25  x3bc g pgl3p 1 xd7 uas and 22 5  x3bc g pbluescript  stratagene in 0 95 ml ice cold pbs containing between 9 12 million u 2 os  human osteosarcoma cells the cell/dna mixture was incubated on ice for 5 minutes and then divided between two 0 4 cm cuvettes and ele
485,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL2030550,660959,Inactive,antagonist activity at ppargamma in mouse nih3t3 cells coexpressing lexa assessed as decrease in gw1929 induced transcriptional activation at 1 um after 48 hrs by luciferase reporter gene assay relative to control
486,CHEMBL235,Peroxisome proliferator-activated receptor gamma,CHEMBL2030550,660963,Inactive,displacement of fluormone pan ppar green from ppargamma at 100 to 1000 nm after 60 mins by tr fret assay
1708,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL564829,422332,Active,inhibition of pdgfr
1666,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL1172957,491930,Active,inhibition pdgfrbeta
2305,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL574059,435505,Active,inhibition of pdgfr
2306,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL574059,435505,Active,inhibition of pdgfr
2307,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL574059,443945,Active,inhibition of human recombinant pdgfr
2308,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL574059,443945,Active,inhibition of human recombinant pdgfr
2162,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL269884,318014,Inactive,inhibition of pdgfrbeta by htrf assay
844,CHEMBL1913,Platelet-derived growth factor receptor beta,CHEMBL205893,263663,Active,inhibitory activity against pdgfrbeta
1501,CHEMBL299,Protein kinase C alpha,CHEMBL502835,397089,Inactive,inhibition of human pkcalpha at 10 umol/l
1606,CHEMBL1824,Receptor protein-tyrosine kinase erbB-2,CHEMBL3234752,1128940,Active,inhibition of erbb2  unknown origin at 1 um by kinomescan assay
1303,CHEMBL3231,Rho-associated protein kinase 1,CHEMBL3218291,1343619,Active,inhibition assay: attention was focused on exploring in turn the sar around the phenyl ring a branching and substitution at the benzylic position urea linkage of 1aa without varying the [4  4 pyridinyl  2 thiazolyl] terminus  fig 4 the [4  4 pyridinyl  2 thiazolyl] group was believed to act as a hinge binding moiety with the nitrogen of the pyridyl h bonding to the back bone nh of the hinge met156 as seen in the crystal complex of rock1 with fasudil  pdb id 2esm  jacobs et al the structure of dimeric rock i reveals the mechanism for ligand selectivity j biol chem 2006 281:260 8 all compounds were systematically screened against rock1 and rock2 ic50 values were systematically determined only for compounds that inhibit 40% of rock1 kinase activities at 50  x3bc m 
1171,CHEMBL3231,Rho-associated protein kinase 1,CHEMBL3426623,1206559,Active,inhibition of human n terminal gst tagged rock1 expressed in insect cells using long s6 kinase peptide as substrate by radiometric assay in presence of [32p]atp
1305,CHEMBL3231,Rho-associated protein kinase 1,CHEMBL3218291,1343620,Active,inhibition assay: attention was focused on exploring in turn the sar around the phenyl ring a branching and substitution at the benzylic position urea linkage of 1aa without varying the [4  4 pyridinyl  2 thiazolyl] terminus  fig 4 the [4  4 pyridinyl  2 thiazolyl] group was believed to act as a hinge binding moiety with the nitrogen of the pyridyl h bonding to the back bone nh of the hinge met156 as seen in the crystal complex of rock1 with fasudil  pdb id 2esm  jacobs et al the structure of dimeric rock i reveals the mechanism for ligand selectivity j biol chem 2006 281:260 8 all compounds were systematically screened against rock1 and rock2 ic50 values were systematically determined only for compounds that inhibit 40% of rock1 kinase activities at 50  x3bc m 
1306,CHEMBL3231,Rho-associated protein kinase 1,CHEMBL3218291,1343620,Active,inhibition assay: attention was focused on exploring in turn the sar around the phenyl ring a branching and substitution at the benzylic position urea linkage of 1aa without varying the [4  4 pyridinyl  2 thiazolyl] terminus  fig 4 the [4  4 pyridinyl  2 thiazolyl] group was believed to act as a hinge binding moiety with the nitrogen of the pyridyl h bonding to the back bone nh of the hinge met156 as seen in the crystal complex of rock1 with fasudil  pdb id 2esm  jacobs et al the structure of dimeric rock i reveals the mechanism for ligand selectivity j biol chem 2006 281:260 8 all compounds were systematically screened against rock1 and rock2 ic50 values were systematically determined only for compounds that inhibit 40% of rock1 kinase activities at 50  x3bc m 
1304,CHEMBL3231,Rho-associated protein kinase 1,CHEMBL3218291,1343620,Active,inhibition assay: attention was focused on exploring in turn the sar around the phenyl ring a branching and substitution at the benzylic position urea linkage of 1aa without varying the [4  4 pyridinyl  2 thiazolyl] terminus  fig 4 the [4  4 pyridinyl  2 thiazolyl] group was believed to act as a hinge binding moiety with the nitrogen of the pyridyl h bonding to the back bone nh of the hinge met156 as seen in the crystal complex of rock1 with fasudil  pdb id 2esm  jacobs et al the structure of dimeric rock i reveals the mechanism for ligand selectivity j biol chem 2006 281:260 8 all compounds were systematically screened against rock1 and rock2 ic50 values were systematically determined only for compounds that inhibit 40% of rock1 kinase activities at 50  x3bc m 
1301,CHEMBL3231,Rho-associated protein kinase 1,CHEMBL3218291,1343619,Active,inhibition assay: attention was focused on exploring in turn the sar around the phenyl ring a branching and substitution at the benzylic position urea linkage of 1aa without varying the [4  4 pyridinyl  2 thiazolyl] terminus  fig 4 the [4  4 pyridinyl  2 thiazolyl] group was believed to act as a hinge binding moiety with the nitrogen of the pyridyl h bonding to the back bone nh of the hinge met156 as seen in the crystal complex of rock1 with fasudil  pdb id 2esm  jacobs et al the structure of dimeric rock i reveals the mechanism for ligand selectivity j biol chem 2006 281:260 8 all compounds were systematically screened against rock1 and rock2 ic50 values were systematically determined only for compounds that inhibit 40% of rock1 kinase activities at 50  x3bc m 
1300,CHEMBL3231,Rho-associated protein kinase 1,CHEMBL3218291,1119753,Active,inhibition of n terminal gst tagged rock1  1 to 535  unknown origin using kkrpqrrsnvf as substrate after 1 hr by z lyte based fret assay
1302,CHEMBL3231,Rho-associated protein kinase 1,CHEMBL3218291,1343619,Active,inhibition assay: attention was focused on exploring in turn the sar around the phenyl ring a branching and substitution at the benzylic position urea linkage of 1aa without varying the [4  4 pyridinyl  2 thiazolyl] terminus  fig 4 the [4  4 pyridinyl  2 thiazolyl] group was believed to act as a hinge binding moiety with the nitrogen of the pyridyl h bonding to the back bone nh of the hinge met156 as seen in the crystal complex of rock1 with fasudil  pdb id 2esm  jacobs et al the structure of dimeric rock i reveals the mechanism for ligand selectivity j biol chem 2006 281:260 8 all compounds were systematically screened against rock1 and rock2 ic50 values were systematically determined only for compounds that inhibit 40% of rock1 kinase activities at 50  x3bc m 
438,CHEMBL2973,Rho-associated protein kinase 2,CHEMBL1922129,631997,Active,inhibition of rock2
1970,CHEMBL2973,Rho-associated protein kinase 2,CHEMBL2023159,660234,Active,inhibition of rock2 after 1 hr by fret based enzyme coupled assay
1972,CHEMBL2973,Rho-associated protein kinase 2,CHEMBL2023159,1344601,Active,fret based enzyme coupled assay: a robust fret based enzyme coupled assay format z lyte xae kinase assay ser/thr 13 peptide kit  invitrogen cat pv3793 was employed in this study to monitor inhibition of rock1  invitrogen cat pv3691 and rock2  invitrogen cat pv3759 enzyme activities compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average ic50 values the assay conditions were optimized to 15  x3bc l of kinase reaction volume with 5 ng of enzyme in 50 mm hepes  ph 7 5 10 mm mgcl2 1 mm egta and 0 01% brij 35 the reaction was incubated 1 hr at room temperature in the presence of 1 5  x3bc m of substrate with 12 5  x3bc m of atp  rock1 assay or 2  x3bc m of substrate with 50  x3bc m of atp  rock2 assay in the presence of various concentrations of the compounds the reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the u
1971,CHEMBL2973,Rho-associated protein kinase 2,CHEMBL2023159,1344600,Active,fret based enzyme coupled assay: a robust fret based enzyme coupled assay format z lyte xae kinase assay ser/thr 13 peptide kit  invitrogen cat pv3793 was employed in this study to monitor inhibition of rock1  invitrogen cat pv3691 and rock2  invitrogen cat pv3759 enzyme activities compounds were tested on three separate days with 8 point dilutions done in duplicate to determine the average ic50 values the assay conditions were optimized to 15  x3bc l of kinase reaction volume with 5 ng of enzyme in 50 mm hepes  ph 7 5 10 mm mgcl2 1 mm egta and 0 01% brij 35 the reaction was incubated 1 hr at room temperature in the presence of 1 5  x3bc m of substrate with 12 5  x3bc m of atp  rock1 assay or 2  x3bc m of substrate with 50  x3bc m of atp  rock2 assay in the presence of various concentrations of the compounds the reaction was then stopped and the ratio of phosphorylated to unphosphorylated peptide substrate was determined by selective cleavage of only the u
1107,CHEMBL4501,Ribosomal protein S6 kinase 1,CHEMBL1081312,507294,Active,inhibition of p70s6k1 in human ln229 cells at 0 04 to 10 um by western blot analysis
1106,CHEMBL4501,Ribosomal protein S6 kinase 1,CHEMBL1081312,507292,Active,inhibition of p70s6k1 in human u87 cells at 0 04 to 10 um by western blot analysis
2242,CHEMBL4501,Ribosomal protein S6 kinase 1,CHEMBL525203,397245,Inactive,inhibition of human s6k1 at 10 umol/l
622,CHEMBL4501,Ribosomal protein S6 kinase 1,CHEMBL31965,1117328,Inactive,human p70s6k1 kinase inhibition screen
1805,CHEMBL4501,Ribosomal protein S6 kinase 1,CHEMBL477772,1117328,Inactive,human p70s6k1 kinase inhibition screen
2104,CHEMBL4282,Serine/threonine-protein kinase AKT,CHEMBL596991,457294,Active,inhibition of pkb in human pc3m cells assessed as gsk3 beta phosphorylation by elisa
651,CHEMBL5145,Serine/threonine-protein kinase B-raf,CHEMBL1778393,597936,Active,inhibition of braf v600e mutant mediated erk phosphorylation in human skmel 28 cells by immunoblotting method
1968,CHEMBL5145,Serine/threonine-protein kinase B-raf,CHEMBL3974325,1344565,Active,inhibition assay: the compounds prepared in examples were tested for inhibitory activities against three subtypes of raf i e raf1 y340d y341d braf normal type and braf v600e using kinase profiling service  invitrogen according to the manufacturer's instructions the levels of the inhibitory activities of the compounds against the enzymes were calculated as % inhibitory activities at various concentrations based on the % inhibitory activities dose response curves were plotted and ic50 values were calculated using graphpad prism software 
1115,CHEMBL5145,Serine/threonine-protein kinase B-raf,CHEMBL3943202,1344565,Active,inhibition assay: the compounds prepared in examples were tested for inhibitory activities against three subtypes of raf i e raf1 y340d y341d braf normal type and braf v600e using kinase profiling service  invitrogen according to the manufacturer's instructions the levels of the inhibitory activities of the compounds against the enzymes were calculated as % inhibitory activities at various concentrations based on the % inhibitory activities dose response curves were plotted and ic50 values were calculated using graphpad prism software 
2026,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL3792742,1293772,Active,inhibition of pim1  unknown origin using bad peptide preincubated for 15 mins followed by atp addition measured after 60 to 100 mins by kinase glo reagent based luminescence assay
2014,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL1336,256650,Inactive,average binding constant for pim1 nanot active at 10 um
271,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL1910912,626549,Active,inhibition of pim1 using bad peptide as substrate preincubated for 15 mins measured after 60 to 100 mins by luminescence assay
358,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL4088576,1481671,Inactive,inhibition of human pim1 using kkrnrtltk as substrate in presence of [gamma 33p] atp
1228,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL3794146,1293772,Active,inhibition of pim1  unknown origin using bad peptide preincubated for 15 mins followed by atp addition measured after 60 to 100 mins by kinase glo reagent based luminescence assay
2015,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL1336,1299356,Inactive,inhibition of pim1  unknown origin 
2339,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL3884319,1336085,Active,inhibition of human recombinant full length his tagged pim1 expressed in baculovirus expression system
2214,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL2387465,749898,Active,inhibition of pim1  unknown origin using fam pimtide as substrate after 90 mins by spectrophotometry in presence of atp
2347,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL2387471,749894,Active,cytotoxicity against mouse ba/f3 cells overexpressing pim1 after 18 hrs by celltitre glo assay
2213,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL2387465,749894,Active,cytotoxicity against mouse ba/f3 cells overexpressing pim1 after 18 hrs by celltitre glo assay
1787,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL496587,410272,Active,inhibition of human recombinant pim1 by atp depletion assay
21,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL535,256650,Inactive,average binding constant for pim1 nanot active at 10 um
2337,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL494355,418377,Active,inhibition of pim1 in presence of 1 um atp
2348,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL2387471,749898,Active,inhibition of pim1  unknown origin using fam pimtide as substrate after 90 mins by spectrophotometry in presence of atp
2076,CHEMBL2147,Serine/threonine-protein kinase PIM1,CHEMBL1910907,626549,Active,inhibition of pim1 using bad peptide as substrate preincubated for 15 mins measured after 60 to 100 mins by luminescence assay
1734,CHEMBL4523,Serine/threonine-protein kinase PIM2,CHEMBL426658,505,Active,compound screen assay human pim2
1827,CHEMBL4523,Serine/threonine-protein kinase PIM2,CHEMBL939,256570,Inactive,average binding constant for pim2 nanot active at 10 um
424,CHEMBL5407,Serine/threonine-protein kinase PIM3,CHEMBL2048870,670927,Active,inhibition of human pim3 using fitc  ahx rsrhssypagt cooh as substrate after 90 mins by mobility shift assay in presence of 5 mm atp
423,CHEMBL5407,Serine/threonine-protein kinase PIM3,CHEMBL2048870,670924,Active,inhibition of human pim3 using fitc  ahx rsrhssypagt cooh as substrate after 90 mins by mobility shift assay in presence of 50 um atp
2126,CHEMBL5407,Serine/threonine-protein kinase PIM3,CHEMBL1910904,626551,Active,inhibition of pim3 using bad peptide as substrate preincubated for 15 mins measured after 60 to 100 mins by luminescence assay
735,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3415555,1199490,Active,binding affinity to wild type b raf  unknown origin 
1967,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL578391,446544,Active,antiproliferative activity against human wm266 4 cells expressing b raf v600e mutant
1201,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3354842,1174653,Active,inhibition of human gst tagged full length b raf v600e mutant  unknown origin using his6 tagged full length human mek1  k97r substrate and [33p] gamma atp incubated for 120 mins by by filter binding method
769,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3689924,1345096,Active,kinase assay: the final concentration of dmso is 5% 10  x3bc l of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 24 h at rt under with shaking the kinase reaction is started by the addition of 20  x3bc l atp solution [final concentration: 250  x3bc m atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  p2850 dilution recommended by the manufacturer 0 1 mm egta] and 10  x3bc l mek1 solution [containing 50 ng biotinylated mek1  prepared from purified mek1 according to standard procedure e g with ez link sulpho nhs lc biotin reagent pierce  21335 and carried out for 60 min at rt with constant shaking 
2221,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3697816,1345096,Active,kinase assay: the final concentration of dmso is 5% 10  x3bc l of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 24 h at rt under with shaking the kinase reaction is started by the addition of 20  x3bc l atp solution [final concentration: 250  x3bc m atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  p2850 dilution recommended by the manufacturer 0 1 mm egta] and 10  x3bc l mek1 solution [containing 50 ng biotinylated mek1  prepared from purified mek1 according to standard procedure e g with ez link sulpho nhs lc biotin reagent pierce  21335 and carried out for 60 min at rt with constant shaking 
694,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3641070,1345096,Active,kinase assay: the final concentration of dmso is 5% 10  x3bc l of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 24 h at rt under with shaking the kinase reaction is started by the addition of 20  x3bc l atp solution [final concentration: 250  x3bc m atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  p2850 dilution recommended by the manufacturer 0 1 mm egta] and 10  x3bc l mek1 solution [containing 50 ng biotinylated mek1  prepared from purified mek1 according to standard procedure e g with ez link sulpho nhs lc biotin reagent pierce  21335 and carried out for 60 min at rt with constant shaking 
733,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3415555,1199487,Active,inhibition of b raf v600e mutant  unknown origin assessed as inhibition of phosphorylation of peptide substrate
193,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3959719,1343927,Active,b raf  v600e kinase assay: in a dilution series 10 ul/well of test substance solution are placed in a multiwell plate the dilution series is selected so that generally a range of concentrations of 2 um to 0 119 nm or 0 017 nm is covered if necessary the initial concentration of 2 um is changed to 50 um 10 um or 0 4 um or 0 2857 um and further dilution is carried out accordingly the final concentration of dmso is 5% 10 ul/well of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase  e g from upstate in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 1 h at rt under with shaking the kinase reaction is started by the addition of 20 ul/well atp solution [final concentration: 250 um atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  
866,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3956709,1343927,Active,b raf  v600e kinase assay: in a dilution series 10 ul/well of test substance solution are placed in a multiwell plate the dilution series is selected so that generally a range of concentrations of 2 um to 0 119 nm or 0 017 nm is covered if necessary the initial concentration of 2 um is changed to 50 um 10 um or 0 4 um or 0 2857 um and further dilution is carried out accordingly the final concentration of dmso is 5% 10 ul/well of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase  e g from upstate in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 1 h at rt under with shaking the kinase reaction is started by the addition of 20 ul/well atp solution [final concentration: 250 um atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  
1403,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL257986,332005,Active,inhibition of b raf kinase
281,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL496477,362268,Active,inhibition of human recombinant b raf by fluorescence anisotropy
909,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3694052,1345096,Active,kinase assay: the final concentration of dmso is 5% 10  x3bc l of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 24 h at rt under with shaking the kinase reaction is started by the addition of 20  x3bc l atp solution [final concentration: 250  x3bc m atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  p2850 dilution recommended by the manufacturer 0 1 mm egta] and 10  x3bc l mek1 solution [containing 50 ng biotinylated mek1  prepared from purified mek1 according to standard procedure e g with ez link sulpho nhs lc biotin reagent pierce  21335 and carried out for 60 min at rt with constant shaking 
1775,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3643295,1345096,Active,kinase assay: the final concentration of dmso is 5% 10  x3bc l of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 24 h at rt under with shaking the kinase reaction is started by the addition of 20  x3bc l atp solution [final concentration: 250  x3bc m atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  p2850 dilution recommended by the manufacturer 0 1 mm egta] and 10  x3bc l mek1 solution [containing 50 ng biotinylated mek1  prepared from purified mek1 according to standard procedure e g with ez link sulpho nhs lc biotin reagent pierce  21335 and carried out for 60 min at rt with constant shaking 
734,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3415555,1199489,Active,binding affinity to b raf v600e mutant  unknown origin 
544,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3814097,1306021,Active,inhibition of full length his6 tagged braf v600e mutant  2 to 766 residues  unknown origin expressed in baculovirus system by b raf accelerated mek atpase assay
932,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3641185,1345096,Active,kinase assay: the final concentration of dmso is 5% 10  x3bc l of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 24 h at rt under with shaking the kinase reaction is started by the addition of 20  x3bc l atp solution [final concentration: 250  x3bc m atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  p2850 dilution recommended by the manufacturer 0 1 mm egta] and 10  x3bc l mek1 solution [containing 50 ng biotinylated mek1  prepared from purified mek1 according to standard procedure e g with ez link sulpho nhs lc biotin reagent pierce  21335 and carried out for 60 min at rt with constant shaking 
1966,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL578391,446543,Active,antiproliferative activity against human a375 cells expressing b raf v600e mutant
736,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3415555,1199491,Active,inhibition of b raf v600e mutant in human a375 cells assessed as phosphorylation of erk
738,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3415555,1199493,Inactive,inhibition of cell proliferation in human sw620 cells expressing wild type b raf after 96 hrs by mtt assay
1883,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL1934641,639213,Active,inhibition of b raf in human a375 cells assessed as inhibition of phosphorylation of mek1/2 by meso scale assay
1882,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL1934641,639211,Active,inhibition of b raf v600e mutant preincubated for 15 mins before atp addition measured after 60 mins by scintillation counting
453,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3641111,1345096,Active,kinase assay: the final concentration of dmso is 5% 10  x3bc l of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 24 h at rt under with shaking the kinase reaction is started by the addition of 20  x3bc l atp solution [final concentration: 250  x3bc m atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  p2850 dilution recommended by the manufacturer 0 1 mm egta] and 10  x3bc l mek1 solution [containing 50 ng biotinylated mek1  prepared from purified mek1 according to standard procedure e g with ez link sulpho nhs lc biotin reagent pierce  21335 and carried out for 60 min at rt with constant shaking 
751,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL1080269,469746,Active,inhibition of human recombinant b raf expressed in sf9 cells
675,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3968087,1344371,Active,inhibition assay: [experimental method]: use adp glo x2122 assay kit from promega to evaluate the inhibitory activity of compounds at b raf [instrument]: perkinelmer's envision plate reader [material]: optiplate 384 well plate  perkinelmer kinase buffer  50 mm hepes ph7 5 1 mm egta 2 mm dtt 10 mm mg2+ 0 05% bsa b raf kinase  millipore catalogue  14 530 k gst mek1 substrate  carna catalogue  07 141 10 super pure atp  promega adp glo x2122 assay kit  promega catalogue  v9102 dmso  sigma catalogue  34869 purified water  millipore type: milli q [study conditions]: mix b raf kinase  final concentration: 5 nm and compound  dmso final concentration: 0 25% and preincubate at 30 xb0 c for 20 min then add atp  final concentration: 6  x3bc m and reaction substrate  final concentration: 30 nm react for 2 hrs at 30 xb0 c after reaction add adp glo x2122 reagent react for 40 min at room temperature then add adp glo x2122 detecting agent react for 
1144,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3814010,1306021,Active,inhibition of full length his6 tagged braf v600e mutant  2 to 766 residues  unknown origin expressed in baculovirus system by b raf accelerated mek atpase assay
1752,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3901325,1343927,Active,b raf  v600e kinase assay: in a dilution series 10 ul/well of test substance solution are placed in a multiwell plate the dilution series is selected so that generally a range of concentrations of 2 um to 0 119 nm or 0 017 nm is covered if necessary the initial concentration of 2 um is changed to 50 um 10 um or 0 4 um or 0 2857 um and further dilution is carried out accordingly the final concentration of dmso is 5% 10 ul/well of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase  e g from upstate in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 1 h at rt under with shaking the kinase reaction is started by the addition of 20 ul/well atp solution [final concentration: 250 um atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  
737,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3415555,1199492,Active,inhibition of cell proliferation in human a375 cells expressing b raf v600e mutant after 96 hrs by mtt assay
902,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL1213924,497610,Active,inhibition of human recombinant full length gst tagged b raf by radiometric kinase assay
1965,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL578391,446542,Active,inhibition of b raf
1511,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3641226,1345096,Active,kinase assay: the final concentration of dmso is 5% 10  x3bc l of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 24 h at rt under with shaking the kinase reaction is started by the addition of 20  x3bc l atp solution [final concentration: 250  x3bc m atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  p2850 dilution recommended by the manufacturer 0 1 mm egta] and 10  x3bc l mek1 solution [containing 50 ng biotinylated mek1  prepared from purified mek1 according to standard procedure e g with ez link sulpho nhs lc biotin reagent pierce  21335 and carried out for 60 min at rt with constant shaking 
275,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3641076,1345096,Active,kinase assay: the final concentration of dmso is 5% 10  x3bc l of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 24 h at rt under with shaking the kinase reaction is started by the addition of 20  x3bc l atp solution [final concentration: 250  x3bc m atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  p2850 dilution recommended by the manufacturer 0 1 mm egta] and 10  x3bc l mek1 solution [containing 50 ng biotinylated mek1  prepared from purified mek1 according to standard procedure e g with ez link sulpho nhs lc biotin reagent pierce  21335 and carried out for 60 min at rt with constant shaking 
740,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3415555,1199497,Active,inhibition of phosphorylation of erk level in human sw620 cells expressing wild type b raf at 3 microm after 48 hrs by immunoblotting analysis
739,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3415555,1199496,Active,inhibition of phosphorylation of mek level in human sw620 cells expressing wild type b raf at 3 microm after 48 hrs by immunoblotting analysis
2048,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3694213,1345096,Active,kinase assay: the final concentration of dmso is 5% 10  x3bc l of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 24 h at rt under with shaking the kinase reaction is started by the addition of 20  x3bc l atp solution [final concentration: 250  x3bc m atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  p2850 dilution recommended by the manufacturer 0 1 mm egta] and 10  x3bc l mek1 solution [containing 50 ng biotinylated mek1  prepared from purified mek1 according to standard procedure e g with ez link sulpho nhs lc biotin reagent pierce  21335 and carried out for 60 min at rt with constant shaking 
2093,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3641103,1345096,Active,kinase assay: the final concentration of dmso is 5% 10  x3bc l of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 24 h at rt under with shaking the kinase reaction is started by the addition of 20  x3bc l atp solution [final concentration: 250  x3bc m atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  p2850 dilution recommended by the manufacturer 0 1 mm egta] and 10  x3bc l mek1 solution [containing 50 ng biotinylated mek1  prepared from purified mek1 according to standard procedure e g with ez link sulpho nhs lc biotin reagent pierce  21335 and carried out for 60 min at rt with constant shaking 
288,CHEMBL1906,Serine/threonine-protein kinase RAF,CHEMBL3694043,1345096,Active,kinase assay: the final concentration of dmso is 5% 10  x3bc l of the b raf  v600e  kinase solution are pipetted in  containing 0 5 ng b raf  v600e  kinase in 20 mm tris hcl ph 7 5 0 1 mm edta 0 1 mm egta 0 286 mm sodium orthovanadate 10% glycerol 1 mg/ml bovine serum albumin 1 mm dithiothreitol and the mixture is incubated for 24 h at rt under with shaking the kinase reaction is started by the addition of 20  x3bc l atp solution [final concentration: 250  x3bc m atp 30 mm tris hcl ph 7 5 0 02% brij 0 2 mm sodium orthovanadate 10 mm magnesium acetate 0 1 mm egta phosphatase cocktail  sigma  p2850 dilution recommended by the manufacturer 0 1 mm egta] and 10  x3bc l mek1 solution [containing 50 ng biotinylated mek1  prepared from purified mek1 according to standard procedure e g with ez link sulpho nhs lc biotin reagent pierce  21335 and carried out for 60 min at rt with constant shaking 
2466,CHEMBL2842,Serine/threonine-protein kinase mTOR,CHEMBL3930435,1343816,Active,"biochemical assay: pi3ka_fl: genes encoding for full length p110alpha and p85alpha subunits of pi3kalpha complex were subcloned from existing constructs into pfastbac dual vector  life technologies carlsbad calif using standard cloning procedures gene encoding p110alpha subunit was subcloned into polyhedrine promoter while gene encoding p85alpha subunit was subcloned into p10 promoter additionally sequence encoding for histidine tag and tobacco etch virus  ""tev"" cleavage site preceded p110alpha orf  open reading frame the biochemical assays of kinase activity of full length pi3kalpha  full length p110alpha/p85a or truncated pi3kalpha  p110alpha/ish2 p85a were conducted using a fluorescence polarization format similar to the procedure of yuan j et al  2011 pf 04691502 a potent and selective oral inhibitor of pi3k and mtor kinases with antitumor activity mol cancer ther 10 2189 2199 the enzymatic reactions were conducted in 50 ul volumes in 96 well plates "
2465,CHEMBL2842,Serine/threonine-protein kinase mTOR,CHEMBL3930435,1343816,Active,"biochemical assay: pi3ka_fl: genes encoding for full length p110alpha and p85alpha subunits of pi3kalpha complex were subcloned from existing constructs into pfastbac dual vector  life technologies carlsbad calif using standard cloning procedures gene encoding p110alpha subunit was subcloned into polyhedrine promoter while gene encoding p85alpha subunit was subcloned into p10 promoter additionally sequence encoding for histidine tag and tobacco etch virus  ""tev"" cleavage site preceded p110alpha orf  open reading frame the biochemical assays of kinase activity of full length pi3kalpha  full length p110alpha/p85a or truncated pi3kalpha  p110alpha/ish2 p85a were conducted using a fluorescence polarization format similar to the procedure of yuan j et al  2011 pf 04691502 a potent and selective oral inhibitor of pi3k and mtor kinases with antitumor activity mol cancer ther 10 2189 2199 the enzymatic reactions were conducted in 50 ul volumes in 96 well plates "
823,CHEMBL2842,Serine/threonine-protein kinase mTOR,CHEMBL1765604,591843,Active,inhibition of mtor in p53 deficient mef assessed as phosphorylation of s6k1 at thr389 by immunoblotting
933,CHEMBL2842,Serine/threonine-protein kinase mTOR,CHEMBL1242034,507076,Active,inhibition of recombinant mtor by radioactive phosphotransfer assay in presence of 10 um atp
767,CHEMBL2842,Serine/threonine-protein kinase mTOR,CHEMBL1242198,507076,Active,inhibition of recombinant mtor by radioactive phosphotransfer assay in presence of 10 um atp
1634,CHEMBL2842,Serine/threonine-protein kinase mTOR,CHEMBL1957857,657210,Active,inhibition of mtor
824,CHEMBL2842,Serine/threonine-protein kinase mTOR,CHEMBL1765604,591844,Active,inhibition of human mtor complex 1 after 30 mins by fret assay
649,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL219916,567,Inactive,primary hts assay for 5 hydroxytryptamine  serotonin receptor subtype 1a  5ht1a agonists
2164,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL3121416,1072132,Active,displacement of [3h] 8 oh dpat from 5ht1a receptor in rat hippocampus homogenates after 15 mins by scintillation counting
1352,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL515783,416168,Active,inhibition of rat hippocampus 5ht1a receptor by competitive binding assay
1790,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL518752,416168,Active,inhibition of rat hippocampus 5ht1a receptor by competitive binding assay
274,CHEMBL214,Serotonin 1a (5-HT1a) receptor,CHEMBL239897,309463,Active,displacement of [3h]8 oh dpat from 5ht1a in rat hippocampal membranes
2060,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL211980,269244,Active,binding affinity to human 5ht2a receptor
206,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL500,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a 
542,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL3770174,1280456,Inactive,agonist activity at recombinant human 5ht2a receptor expressed in flp in 293 cells assessed as calcium flux by flipr assay
594,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL234006,292746,Active,displacement of [3h]ketanserin from 5ht2a receptor expressed in hek293 cells
1792,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL388882,292770,Active,displacement of [3h]ketanserin from human 5ht2a receptor expressed in hek293 cells
1793,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL388882,292775,Inactive,agonist activity at human 5ht2a receptor expressed in hek293 cells by measuring intracellular calcium mobilization upto 10 um
543,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL3770174,1280456,Inactive,agonist activity at recombinant human 5ht2a receptor expressed in flp in 293 cells assessed as calcium flux by flipr assay
1267,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL490632,415447,Active,displacement of [3h]mdl from rat 5ht2a receptor expressed in gf62 cells by liquid scintillation analyser
2160,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL2022180,658524,Inactive,agonist activity at human 5ht2a receptor expressed in hek293 cells assessed as calcium flux measured every sec for 3 mins by flipr assay
752,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL517712,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a 
2105,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL210405,457689,Active,displacement of [3h]ketanserin from 5ht2a receptor in wistar rat cortex homogenate
2013,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL492917,418828,Inactive,agonist activity at human 5ht2a receptor expressed in hek293 cells assessed as calcium flux by flipr assay
1810,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL211719,269244,Active,binding affinity to human 5ht2a receptor
595,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL234006,292752,Inactive,agonist activity at 5ht2a receptor expressed in hek293 cells assessed as intracellular calcium mobilisation up to 10 um
805,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL276778,343052,Active,antagonist activity at serotonin 5ht2a receptor assessed as effect on 5ht induced isometric contractile force in isolated rings of pig coronary artery
1997,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL240773,1153303,Active,displacement of [3h] ketanserin from pig 5ht2 receptor by competitive binding assay
1184,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL3287394,1153303,Active,displacement of [3h] ketanserin from pig 5ht2 receptor by competitive binding assay
1188,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL492698,418828,Inactive,agonist activity at human 5ht2a receptor expressed in hek293 cells assessed as calcium flux by flipr assay
2367,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL475021,418828,Inactive,agonist activity at human 5ht2a receptor expressed in hek293 cells assessed as calcium flux by flipr assay
247,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL214397,269244,Active,binding affinity to human 5ht2a receptor
379,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL3287391,1153303,Active,displacement of [3h] ketanserin from pig 5ht2 receptor by competitive binding assay
1958,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL496,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a 
1957,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL3287392,1153303,Active,displacement of [3h] ketanserin from pig 5ht2 receptor by competitive binding assay
203,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL2022190,658524,Inactive,agonist activity at human 5ht2a receptor expressed in hek293 cells assessed as calcium flux measured every sec for 3 mins by flipr assay
2362,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL223584,280444,Active,activity at human 5ht2a expressed in hek293e cells assessed as elevation of intracellular calcium by 384 flipr assay relative to serotonin
367,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL46516,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a 
455,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL1323615,624169,Inactive,luminescence based cell based primary high throughput screening assay to identify agonists of the mouse 5 hydroxytryptamine  serotonin receptor 2a  htr2a 
1646,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL210059,269244,Active,binding affinity to human 5ht2a receptor
723,CHEMBL224,Serotonin 2a (5-HT2a) receptor,CHEMBL212686,269244,Active,binding affinity to human 5ht2a receptor
2387,CHEMBL1833,Serotonin 2b (5-HT2b) receptor,CHEMBL475384,418829,Inactive,agonist activity at human 5ht2b receptor expressed in hek293 cells assessed as calcium flux by flipr assay
91,CHEMBL1833,Serotonin 2b (5-HT2b) receptor,CHEMBL360479,312494,Active,agonist activity at human 5ht2b receptor expressed in hek293 cells assessed as intracellular ip3 accumulation
1221,CHEMBL1833,Serotonin 2b (5-HT2b) receptor,CHEMBL492698,418829,Inactive,agonist activity at human 5ht2b receptor expressed in hek293 cells assessed as calcium flux by flipr assay
360,CHEMBL1833,Serotonin 2b (5-HT2b) receptor,CHEMBL211466,269245,Active,binding affinity to human 5ht2b receptor
2336,CHEMBL225,Serotonin 2c (5-HT2c) receptor,CHEMBL391984,308686,Active,displacement of [3h]mesulergine human cloned serotonin 5ht2c receptor
1791,CHEMBL225,Serotonin 2c (5-HT2c) receptor,CHEMBL183460,305571,Active,displacement of [3h]mesulergine from human cloned 5ht2c receptor expressed in hek293 cells
1291,CHEMBL3371,Serotonin 6 (5-HT6) receptor,CHEMBL2179217,708172,Active,antagonist activity at human recombinant 5ht6 receptor expressed in cho cells assessed as inhibition of 5ht induced luciferase activity after 4 hrs by reporter gene assay
1649,CHEMBL3155,Serotonin 7 (5-HT7) receptor,CHEMBL213987,269250,Active,binding affinity to human 5ht7 receptor
910,CHEMBL228,Serotonin transporter,CHEMBL238520,305568,Active,inhibition of [3h]5 ht uptake at sert in rat cortical synaptosomes
1214,CHEMBL228,Serotonin transporter,CHEMBL3704753,1259104,Active,radioligand binding assay: the monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising formula  i are reported herein the compounds were evaluated using well established radioligand binding assays protocols  galli a et al j exp biol 1995 198 2197 2212 giros b et al trends pharmcol sci 1993 14 43 49 gu h et al j biol chem 1994 269 10 7124 7130 shearman l p et al am j physiol 1998 275 6 pt 1 c1621 1629 wolf w a et al j biol chem 1992 267 29 20820 20825 the human recombinant transporter proteins dopamine  dat norepinephrine  net and serotonin  sert were selected for the in vitro assays the radioligand binding assays were carried out at 11 different test concentrations 0 1 nm to 1  x3bc m 
2378,CHEMBL228,Serotonin transporter,CHEMBL2064645,1443748,Inactive,enhancing of [125i]rti 55 binding to recombinant human sert expressed in hek293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
2379,CHEMBL228,Serotonin transporter,CHEMBL2064645,1443749,Inactive,enhancing of [3h]mazindol binding to recombinant human sert expressed in hek293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
1713,CHEMBL228,Serotonin transporter,CHEMBL814,1346955,Active,rat sert  monoamine transporter subfamily 
1712,CHEMBL228,Serotonin transporter,CHEMBL814,1346943,Active,human sert  monoamine transporter subfamily 
718,CHEMBL228,Serotonin transporter,CHEMBL668,1346943,Active,human sert  monoamine transporter subfamily 
2477,CHEMBL228,Serotonin transporter,CHEMBL26907,313115,Active,displacement of [3h]5 ht from rat sert
2478,CHEMBL228,Serotonin transporter,CHEMBL26907,313115,Active,displacement of [3h]5 ht from rat sert
5,CHEMBL228,Serotonin transporter,CHEMBL1631532,541184,Active,inhibition of [3h]5 ht uptake at sert in rat cortical synaptosomes
1298,CHEMBL228,Serotonin transporter,CHEMBL3916231,1324591,Active,displacement of [3h]citalopram from sert in sprague dawley rat brain stem membranes incubated for 60 mins by radioligand binding assay
1314,CHEMBL228,Serotonin transporter,CHEMBL358967,471665,Active,inhibition of [3h]5 ht uptake at sert in rat brain synaptosome
454,CHEMBL228,Serotonin transporter,CHEMBL243204,296171,Active,displacement of [125i]rti55 from human sert expressed in cos1 cell membrane
1496,CHEMBL228,Serotonin transporter,CHEMBL39,386321,Active,effect on 2  aminoethyl methanethiosulphonate hydrobromide induced inactivation of rat sert w828c mutant assessed as increase in rate constant for inactivation
1489,CHEMBL228,Serotonin transporter,CHEMBL39,386310,Active,inhibition of 2  aminoethyl methanethiosulphonate hydrobromide induced inactivation of rat sert s277 mutant assessed as drug level causing half maximal protection from inactivation
1497,CHEMBL228,Serotonin transporter,CHEMBL39,386322,Active,effect on 2  aminoethyl methanethiosulphonate hydrobromide induced inactivation of rat sert y107c mutant assessed as increase in rate constant for inactivation
2069,CHEMBL228,Serotonin transporter,CHEMBL1672355,570373,Inactive,displacement of [3h]citalopram from sert in sprague dawley rat brain membranes at 10 um
1080,CHEMBL228,Serotonin transporter,CHEMBL3407785,1443748,Inactive,enhancing of [125i]rti 55 binding to recombinant human sert expressed in hek293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
1509,CHEMBL228,Serotonin transporter,CHEMBL4074774,1472454,Active,displacement of [3h]citalopram from sprague dawley rat brain sert after 60 mins by liquid scintillation counting method
1510,CHEMBL228,Serotonin transporter,CHEMBL4074774,1472454,Active,displacement of [3h]citalopram from sprague dawley rat brain sert after 60 mins by liquid scintillation counting method
960,CHEMBL228,Serotonin transporter,CHEMBL559490,431883,Active,inhibition of [3h]hydroxytryptamine creatinine sulfate uptake at human sert expressed in human jar cells
1491,CHEMBL228,Serotonin transporter,CHEMBL39,386316,Active,effect on 2  aminoethyl methanethiosulphonate hydrobromide induced inactivation of rat sert s277c mutant assessed as increase in rate constant for inactivation
1081,CHEMBL228,Serotonin transporter,CHEMBL3407785,1443749,Inactive,enhancing of [3h]mazindol binding to recombinant human sert expressed in hek293 cell membranes preincubated for 10 mins followed by radioligand addition measured after 90 mins by micro beta scintillation counting analysis
1490,CHEMBL228,Serotonin transporter,CHEMBL39,386313,Active,effect on 2  aminoethyl methanethiosulphonate hydrobromide induced inactivation of rat sert g273c mutant assessed as increase in rate constant for inactivation
582,CHEMBL228,Serotonin transporter,CHEMBL1632210,541184,Active,inhibition of [3h]5 ht uptake at sert in rat cortical synaptosomes
1211,CHEMBL228,Serotonin transporter,CHEMBL3704753,1259103,Active,radioligand binding assay: the monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising formula  i are reported herein the compounds were evaluated using well established radioligand binding assays protocols  galli a et al j exp biol 1995 198 2197 2212 giros b et al trends pharmcol sci 1993 14 43 49 gu h et al j biol chem 1994 269 10 7124 7130 shearman l p et al am j physiol 1998 275 6 pt 1 c1621 1629 wolf w a et al j biol chem 1992 267 29 20820 20825 the human recombinant transporter proteins dopamine  dat norepinephrine  net and serotonin  sert were selected for the in vitro assays the radioligand binding assays were carried out at 11 different test concentrations 0 1 nm to 1  x3bc m 
380,CHEMBL228,Serotonin transporter,CHEMBL199103,1472454,Active,displacement of [3h]citalopram from sprague dawley rat brain sert after 60 mins by liquid scintillation counting method
1495,CHEMBL228,Serotonin transporter,CHEMBL39,386320,Active,effect on 2  aminoethyl methanethiosulphonate hydrobromide induced inactivation of rat sert t276c mutant assessed as increase in rate constant for inactivation
1498,CHEMBL228,Serotonin transporter,CHEMBL39,386323,Active,effect on 2  aminoethyl methanethiosulphonate hydrobromide induced inactivation of rat sert s404c mutant assessed as increase in rate constant for inactivation
1492,CHEMBL228,Serotonin transporter,CHEMBL39,386317,Active,effect on 2  aminoethyl methanethiosulphonate hydrobromide induced inactivation of rat sert v281c mutant assessed as increase in rate constant for inactivation
388,CHEMBL228,Serotonin transporter,CHEMBL248825,309729,Active,displacement of [125i]rti55 from human sert transfected in cos1 cells
1212,CHEMBL228,Serotonin transporter,CHEMBL3704753,1259104,Active,radioligand binding assay: the monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising formula  i are reported herein the compounds were evaluated using well established radioligand binding assays protocols  galli a et al j exp biol 1995 198 2197 2212 giros b et al trends pharmcol sci 1993 14 43 49 gu h et al j biol chem 1994 269 10 7124 7130 shearman l p et al am j physiol 1998 275 6 pt 1 c1621 1629 wolf w a et al j biol chem 1992 267 29 20820 20825 the human recombinant transporter proteins dopamine  dat norepinephrine  net and serotonin  sert were selected for the in vitro assays the radioligand binding assays were carried out at 11 different test concentrations 0 1 nm to 1  x3bc m 
1213,CHEMBL228,Serotonin transporter,CHEMBL3704753,1259104,Active,radioligand binding assay: the monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising formula  i are reported herein the compounds were evaluated using well established radioligand binding assays protocols  galli a et al j exp biol 1995 198 2197 2212 giros b et al trends pharmcol sci 1993 14 43 49 gu h et al j biol chem 1994 269 10 7124 7130 shearman l p et al am j physiol 1998 275 6 pt 1 c1621 1629 wolf w a et al j biol chem 1992 267 29 20820 20825 the human recombinant transporter proteins dopamine  dat norepinephrine  net and serotonin  sert were selected for the in vitro assays the radioligand binding assays were carried out at 11 different test concentrations 0 1 nm to 1  x3bc m 
1493,CHEMBL228,Serotonin transporter,CHEMBL39,386318,Inactive,effect on 2  aminoethyl methanethiosulphonate hydrobromide induced inactivation of rat sert t284c mutant assessed as increase in rate constant for inactivation
1494,CHEMBL228,Serotonin transporter,CHEMBL39,386319,Active,effect on 2  aminoethyl methanethiosulphonate hydrobromide induced inactivation of rat sert k272c mutant assessed as increase in rate constant for inactivation
2215,CHEMBL4979,Sodium/glucose cotransporter 1,CHEMBL1093013,475685,Active,inhibition of human sglt1 expressed in chok1 cells assessed as inhibition of glucose uptake
714,CHEMBL4979,Sodium/glucose cotransporter 1,CHEMBL2172380,703959,Active,inhibition of human sglt1 expressed in cho cells assessed as inhibition of sodium dependent [14c]methyl alpha d glucopyranoside uptake after 45 mins
1667,CHEMBL3884,Sodium/glucose cotransporter 2,CHEMBL1807541,609738,Active,inhibition of human sglt2 expressed in african green monkey cos7 cells assessed as inhibition of [14c] methyl alpha d glucopyranoside uptake after 2 hrs by scintillation counting in presence of 25 % human plasma
1069,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1969371,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3
1068,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1969371,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3
1067,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1969371,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3
1066,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1969371,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3
2003,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL2004782,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3
2004,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL2004782,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3
517,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1968913,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3
2006,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL2004782,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3
520,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1968913,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3
519,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1968913,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3
2005,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL2004782,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3
518,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1968913,540368,Inactive,late stage fluorescence based dose response cell based counterscreen assay to identify agonists of the sphingosine 1 phosphate receptor 3  s1p3 : sphingosine 1 phosphate receptor 1  s1p1 agonist assay set 3
2007,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL2004782,1054299,Active,agonist activity at s1p1 receptor  unknown origin 
521,CHEMBL4333,Sphingosine 1-phosphate receptor Edg-1,CHEMBL1968913,1054299,Active,agonist activity at s1p1 receptor  unknown origin 
922,CHEMBL3892,Sphingosine 1-phosphate receptor Edg-3,CHEMBL3701844,1258148,Active,receptor binding assay: receptor binding assay: membranes were prepared from cho cells expressing s1p1 or s1p3 for use in ligand and 355 gtpgammas binding studies cells were suspended in 50 mm tris ph 7 4 2 mm edta 250 mm sucrose  buffer a and 1x complete protease inhibitor cocktail  roche and disrupted at 4 c by n2 decompression using a cell disruption bomb  parr instrument following centrifugation at 1000 rpm for 10 min at 4 c the supernatant was suspended in buffer a and centrifuged again at 19000 rpm for 60 min at 4 c the pellet was then suspended in 10 mm hepes ph 7 4 1 mm edta 250 mm sucrose  buffer b and 1x complete edta free protease inhibitor cocktail and homogenized using a potter membranes were flash frozen in liquid n2 and stored at   80 c [33p]sphingosine 1 phosphate  3000 ci/mmol american radiolabeled chemicals inc was added to test compounds in dmso membranes and wga spa beads  ge healthcare were added to give a final volume of 100 ul in 96 well
1549,CHEMBL3892,Sphingosine 1-phosphate receptor Edg-3,CHEMBL46874,485,Inactive,primary hts assay for s1p3 antagonists
1850,CHEMBL3892,Sphingosine 1-phosphate receptor Edg-3,CHEMBL518292,485,Inactive,primary hts assay for s1p3 antagonists
529,CHEMBL3892,Sphingosine 1-phosphate receptor Edg-3,CHEMBL3699118,1258344,Active,in vitro assay: receptor binding assay: membranes were prepared from cho cells expressing s1p1 or s1p3 for use in ligand and 35s gtpgammas binding studies cells were suspended in 50 mm tris ph 7 4 2 mm edta 250 mm sucrose  buffer a and 1x complete protease inhibitor cocktail  roche and disrupted at 4 c by nitrogen decompression using a cell disruption bomb  parr instrument following centrifugation at 1000 rpm for 10 min at 4 c the supernatant was suspended in buffer a and centrifuged again at 19000 rpm for 60 min at 4 c the pellet was then suspended in 10 mm hepes ph 7 4 1 mm edta 250 mm sucrose  buffer b and 1x complete edta free protease inhibitor cocktail and homogenized using a potter membranes were flash frozen in liquid nitrogen and stored at  80 c [33p]sphingosine 1 phosphate  3000 ci/mmol american radiolabeled chemicals inc was added to test compounds in dmso membranes and wga spa beads  ge healthcare were added to give a final volume of 100 ul in 96 we
528,CHEMBL3892,Sphingosine 1-phosphate receptor Edg-3,CHEMBL3699118,1258344,Active,in vitro assay: receptor binding assay: membranes were prepared from cho cells expressing s1p1 or s1p3 for use in ligand and 35s gtpgammas binding studies cells were suspended in 50 mm tris ph 7 4 2 mm edta 250 mm sucrose  buffer a and 1x complete protease inhibitor cocktail  roche and disrupted at 4 c by nitrogen decompression using a cell disruption bomb  parr instrument following centrifugation at 1000 rpm for 10 min at 4 c the supernatant was suspended in buffer a and centrifuged again at 19000 rpm for 60 min at 4 c the pellet was then suspended in 10 mm hepes ph 7 4 1 mm edta 250 mm sucrose  buffer b and 1x complete edta free protease inhibitor cocktail and homogenized using a potter membranes were flash frozen in liquid nitrogen and stored at  80 c [33p]sphingosine 1 phosphate  3000 ci/mmol american radiolabeled chemicals inc was added to test compounds in dmso membranes and wga spa beads  ge healthcare were added to give a final volume of 100 ul in 96 we
921,CHEMBL3892,Sphingosine 1-phosphate receptor Edg-3,CHEMBL3701844,1258148,Active,receptor binding assay: receptor binding assay: membranes were prepared from cho cells expressing s1p1 or s1p3 for use in ligand and 355 gtpgammas binding studies cells were suspended in 50 mm tris ph 7 4 2 mm edta 250 mm sucrose  buffer a and 1x complete protease inhibitor cocktail  roche and disrupted at 4 c by n2 decompression using a cell disruption bomb  parr instrument following centrifugation at 1000 rpm for 10 min at 4 c the supernatant was suspended in buffer a and centrifuged again at 19000 rpm for 60 min at 4 c the pellet was then suspended in 10 mm hepes ph 7 4 1 mm edta 250 mm sucrose  buffer b and 1x complete edta free protease inhibitor cocktail and homogenized using a potter membranes were flash frozen in liquid n2 and stored at   80 c [33p]sphingosine 1 phosphate  3000 ci/mmol american radiolabeled chemicals inc was added to test compounds in dmso membranes and wga spa beads  ge healthcare were added to give a final volume of 100 ul in 96 well
2364,CHEMBL1936,Stem cell growth factor receptor,CHEMBL3687210,1258606,Active,inhibition assay: a recombinant retrovirus was created from expression plasmid flag eml4 alkv1/pmx irescd8 in which cdna for emla alk fusion protein v1 was integrated and injected into mouse lymphoid cell line ba/f3 cells using a magnetic bead reagent for cell separation and a purification column  anti cd8 monoclonal antibody immobilized on magnetic beads and a minimacs purification column both are products of miltedyi biotec inc cell surface cd8 expressing cells were purified to establish eml4 alk fusion protein v1 expressing ba/f3 cells from the cells eml4 alk fusion protein v1 was purified and subjected to kinase activity evaluation eml4 alk fusion protein v1 was investigated for its phosphorylation activity toward a peptide substrate by using a kinase activity detection kit  htrf kinease tk cisbio inc test compounds were each added to a reaction solution containing the enzyme protein to give 8 final concentrations from 1000 nm to 0 3 nm followed by addition of atp 
357,CHEMBL1936,Stem cell growth factor receptor,CHEMBL184227,241904,Active,inhibition of pdgfr beta/c kit chimeric receptor autophosphorylation in cho cells
1234,CHEMBL1936,Stem cell growth factor receptor,CHEMBL3687205,1258606,Active,inhibition assay: a recombinant retrovirus was created from expression plasmid flag eml4 alkv1/pmx irescd8 in which cdna for emla alk fusion protein v1 was integrated and injected into mouse lymphoid cell line ba/f3 cells using a magnetic bead reagent for cell separation and a purification column  anti cd8 monoclonal antibody immobilized on magnetic beads and a minimacs purification column both are products of miltedyi biotec inc cell surface cd8 expressing cells were purified to establish eml4 alk fusion protein v1 expressing ba/f3 cells from the cells eml4 alk fusion protein v1 was purified and subjected to kinase activity evaluation eml4 alk fusion protein v1 was investigated for its phosphorylation activity toward a peptide substrate by using a kinase activity detection kit  htrf kinease tk cisbio inc test compounds were each added to a reaction solution containing the enzyme protein to give 8 final concentrations from 1000 nm to 0 3 nm followed by addition of atp 
1233,CHEMBL1936,Stem cell growth factor receptor,CHEMBL3687205,1258606,Active,inhibition assay: a recombinant retrovirus was created from expression plasmid flag eml4 alkv1/pmx irescd8 in which cdna for emla alk fusion protein v1 was integrated and injected into mouse lymphoid cell line ba/f3 cells using a magnetic bead reagent for cell separation and a purification column  anti cd8 monoclonal antibody immobilized on magnetic beads and a minimacs purification column both are products of miltedyi biotec inc cell surface cd8 expressing cells were purified to establish eml4 alk fusion protein v1 expressing ba/f3 cells from the cells eml4 alk fusion protein v1 was purified and subjected to kinase activity evaluation eml4 alk fusion protein v1 was investigated for its phosphorylation activity toward a peptide substrate by using a kinase activity detection kit  htrf kinease tk cisbio inc test compounds were each added to a reaction solution containing the enzyme protein to give 8 final concentrations from 1000 nm to 0 3 nm followed by addition of atp 
2363,CHEMBL1936,Stem cell growth factor receptor,CHEMBL3687210,1258606,Active,inhibition assay: a recombinant retrovirus was created from expression plasmid flag eml4 alkv1/pmx irescd8 in which cdna for emla alk fusion protein v1 was integrated and injected into mouse lymphoid cell line ba/f3 cells using a magnetic bead reagent for cell separation and a purification column  anti cd8 monoclonal antibody immobilized on magnetic beads and a minimacs purification column both are products of miltedyi biotec inc cell surface cd8 expressing cells were purified to establish eml4 alk fusion protein v1 expressing ba/f3 cells from the cells eml4 alk fusion protein v1 was purified and subjected to kinase activity evaluation eml4 alk fusion protein v1 was investigated for its phosphorylation activity toward a peptide substrate by using a kinase activity detection kit  htrf kinease tk cisbio inc test compounds were each added to a reaction solution containing the enzyme protein to give 8 final concentrations from 1000 nm to 0 3 nm followed by addition of atp 
1488,CHEMBL204,Thrombin,CHEMBL570639,444383,Active,anticoagulant activity in human plasma assessed as concentration required to double the prothrombin based clotting time after 30 seconds
626,CHEMBL204,Thrombin,CHEMBL455916,361999,Active,anticoagulant activity in human plasma assessed as concentration required to double prothrombin time
434,CHEMBL204,Thrombin,CHEMBL3970347,1323704,Active,anticoagulant activity in rabbit plasma assessed as increase in prothrombin time
69,CHEMBL204,Thrombin,CHEMBL1221581,501320,Active,anticoagulant activity in plasma assessed as concentration required to double prothrombin time
1632,CHEMBL204,Thrombin,CHEMBL385198,270180,Active,anticoagulant activity in human plasma measured as prothrombin time
1633,CHEMBL204,Thrombin,CHEMBL385198,270180,Active,anticoagulant activity in human plasma measured as prothrombin time
760,CHEMBL204,Thrombin,CHEMBL401235,300711,Active,anticoagulant potency in human plasma assessed as concentration required to double prothrombin time
2010,CHEMBL204,Thrombin,CHEMBL260360,322197,Active,anticoagulant potency in human plasma assessed as concentration required to double prothrombin time
433,CHEMBL204,Thrombin,CHEMBL3970347,1323703,Active,anticoagulant activity in healthy human plasma assessed as increase in prothrombin time
1718,CHEMBL204,Thrombin,CHEMBL1271162,527398,Active,anticoagulant activity in human platelet assessed as concentration required to double activated partial prothrombin time
1190,CHEMBL204,Thrombin,CHEMBL251762,310310,Active,anticoagulant potency in human plasma assessed as concentration required to double prothrombin time
545,CHEMBL204,Thrombin,CHEMBL466965,361581,Active,anticoagulant activity in human plasma assessed as concentration required to double prothrombin based clotting time
898,CHEMBL204,Thrombin,CHEMBL237286,300711,Active,anticoagulant potency in human plasma assessed as concentration required to double prothrombin time
1856,CHEMBL204,Thrombin,CHEMBL604954,459567,Active,anticoagulant potency in human plasma assessed as concentration required to double the prothrombin time
1804,CHEMBL204,Thrombin,CHEMBL516922,367980,Active,anticoagulant activity in human plasma assessed as concentration required to double prothrombin time
1384,CHEMBL204,Thrombin,CHEMBL503078,362261,Active,anticoagulant activity in rat plasma assessed as concentration required to double prothrombin time
2283,CHEMBL204,Thrombin,CHEMBL260354,331786,Active,anticoagulant activity in human plasma assessed as concentration required to double prothrombin time
1108,CHEMBL204,Thrombin,CHEMBL163218,163724,Active,concentration required to inhibit the activation of human prothrombin in a preformed complex of factor xa factor iia and phospholipid in vitro
1308,CHEMBL204,Thrombin,CHEMBL1681798,633522,Active,anticoagulant activity in human plasma assessed as concentration required to double prothrombin time after 1 min using micro coagulometer
1331,CHEMBL204,Thrombin,CHEMBL473243,367980,Active,anticoagulant activity in human plasma assessed as concentration required to double prothrombin time
1307,CHEMBL204,Thrombin,CHEMBL1681798,579607,Active,anticoagulant activity in human plasma assessed as concentration required to double prothrombin time
546,CHEMBL204,Thrombin,CHEMBL466965,444383,Active,anticoagulant activity in human plasma assessed as concentration required to double the prothrombin based clotting time after 30 seconds
1913,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,271012,Active,inhibition of bcr abl fusion protein
1912,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,255819,Active,inhibitory concentration against abl transformed rat fibroblast cells
1914,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,271012,Active,inhibition of bcr abl fusion protein
1908,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,240522,Active,inhibition of v abl tyrosine kinase
2470,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL515432,414722,Active,inhibition of c abl t315i mutant by liquid scintillation counting
1909,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,254706,Active,inhibitory concentration against v abl tyrosine kinase
2469,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL515432,414721,Active,inhibition of wild type c abl by liquid scintillation counting
1921,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624981,Active,binding constant for abl1 f317l  non phosphorylated kinase domain
1892,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,496995,Active,antiproliferative activity against mouse ba/f3 cells expressing bcr abl y253h mutant
1907,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,32559,Active,inhibition of abl kinase
1893,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,496996,Active,antiproliferative activity against mouse ba/f3 cells expressing bcr abl e255k mutant
1900,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,497004,Active,inhibition of bcr abl e255v mutant
1919,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624979,Active,binding constant for abl1 f317i  non phosphorylated kinase domain
1918,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624978,Active,binding constant for abl1 e255k  phosphorylated kinase domain
1901,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,497006,Active,inhibition of bcr abl m351t mutant
1899,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,497002,Active,inhibition of c abl
1898,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,497001,Active,inhibition of bcr abl t315i mutant autophosphorylation in mouse ba/f3 cells
1920,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624980,Active,binding constant for abl1 f317i  phosphorylated kinase domain
1906,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,32559,Active,inhibition of abl kinase
1917,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,507680,Active,inhibition of abl t315i mutant
1902,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,497198,Active,inhibition of bcr abl t315i mutant
1916,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,507429,Active,inhibition of abl1
1896,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,496999,Active,antiproliferative activity against mouse ba/f3 cells expressing bcr abl f317l mutant
1895,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,496998,Active,antiproliferative activity against mouse ba/f3 cells expressing bcr abl t315i mutant
1915,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,463625,Active,inhibition of wild type abl
1894,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,496997,Active,antiproliferative activity against mouse ba/f3 cells expressing bcr abl e255v mutant
1897,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,497000,Active,antiproliferative activity against mouse ba/f3 cells expressing bcr abl m351t mutant
1922,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624982,Active,binding constant for abl1 f317l  phosphorylated kinase domain
1938,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386050,Active,inhibition of wild type bcr abl1  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of cell proliferation after 48 hrs by britelight luciferase assay
1890,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,496993,Active,antiproliferative activity against mouse ba/f3 cells expressing bcr abl g250e mutant
1930,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624990,Active,binding constant for abl1 y253f  phosphorylated kinase domain
1931,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624991,Active,binding constant for abl1 non phosphorylated kinase domain
1944,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386085,Active,inhibition of bcr abl1 q252h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1943,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386085,Active,inhibition of bcr abl1 q252h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1942,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386084,Active,inhibition of bcr abl1 g250h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1932,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624992,Active,binding constant for abl1 phosphorylated kinase domain
1933,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1283290,Active,cytotoxicity against mouse ba/f3 cells expressing bcr abl t315i mutant after 72 hrs by mtt assay
1934,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1299348,Active,inhibition of abl  unknown origin 
1935,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1301434,Active,inhibition of human abl using eaiyaapfakkk as substrate after 40 mins by scintillation counting analysis in presence of [gamma 33p atp]
1936,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1345606,Active,human abl proto oncogene 1 non receptor tyrosine kinase  abl family 
113,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL355322,228813,Active,concentration required for inhibition of v abl receptor by tyrosine kinase enzyme assay
112,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL355322,228813,Active,concentration required for inhibition of v abl receptor by tyrosine kinase enzyme assay
1937,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386050,Active,inhibition of wild type bcr abl1  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of cell proliferation after 48 hrs by britelight luciferase assay
1911,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,255763,Active,inhibitory activity against abl kinase
1941,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386084,Active,inhibition of bcr abl1 g250h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1940,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386051,Active,inhibition of bcr abl1 t315i mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of cell proliferation after 48 hrs by britelight luciferase assay
1939,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386051,Active,inhibition of bcr abl1 t315i mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of cell proliferation after 48 hrs by britelight luciferase assay
1945,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386086,Active,inhibition of bcr abl1 y253h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1891,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,496994,Active,antiproliferative activity against mouse ba/f3 cells expressing bcr abl q252h mutant
1946,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386086,Active,inhibition of bcr abl1 y253h mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1947,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386087,Active,inhibition of bcr abl1 e255k mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1889,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,496992,Active,antiproliferative activity against mouse ba/f3 cells expressing wild type bcr abl
1888,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL459850,383084,Active,inhibition of bcr abl by cellular assay
1956,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386091,Active,inhibition of bcr abl1 e459k mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1955,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386091,Active,inhibition of bcr abl1 e459k mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1954,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386090,Active,inhibition of bcr abl1 f359v mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1923,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624983,Active,binding constant for abl1 h396p  non phosphorylated kinase domain
1924,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624984,Active,binding constant for abl1 h396p  phosphorylated kinase domain
1953,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386090,Active,inhibition of bcr abl1 f359v mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1925,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624985,Active,binding constant for abl1 m351t  phosphorylated kinase domain
1926,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624986,Active,binding constant for abl1 q252h  non phosphorylated kinase domain
1952,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386089,Active,inhibition of bcr abl1 e355g mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1927,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624987,Active,binding constant for abl1 q252h  phosphorylated kinase domain
1951,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386089,Active,inhibition of bcr abl1 e355g mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1950,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386088,Active,inhibition of bcr abl1 e255v mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1949,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386088,Active,inhibition of bcr abl1 e255v mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1948,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,1386087,Active,inhibition of bcr abl1 e255k mutant  unknown origin expressed in mouse ba/f3 cells assessed as inhibition of bcr abl1 mediated cell proliferation after 48 hrs by britelight luciferase assay
1928,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624988,Active,binding constant for abl1 t315i  non phosphorylated kinase domain
1929,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,624989,Active,binding constant for abl1 t315i  phosphorylated kinase domain
1910,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL288441,255763,Active,inhibitory activity against abl kinase
1583,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,629262,Active,inhibition of abl1
797,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL559826,491289,Active,antiproliferative activity against mouse ba/f3 cells expressing abl t315i mutant after 3 days by mts assay
612,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL91829,256669,Inactive,average binding constant for abl1 m351t nanot active at 10 um
611,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL91829,256668,Inactive,average binding constant for abl1 h396p nanot active at 10 um
610,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL91829,256667,Inactive,average binding constant for abl1 e255k nanot active at 10 um
609,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL91829,256666,Inactive,average binding constant for abl1 q252h nanot active at 10 um
608,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL91829,256665,Inactive,average binding constant for abl1 nanot active at 10 um
1576,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624986,Active,binding constant for abl1 q252h  non phosphorylated kinase domain
1577,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624987,Active,binding constant for abl1 q252h  phosphorylated kinase domain
1578,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624988,Active,binding constant for abl1 t315i  non phosphorylated kinase domain
1579,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624989,Active,binding constant for abl1 t315i  phosphorylated kinase domain
1580,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624990,Active,binding constant for abl1 y253f  phosphorylated kinase domain
1581,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624991,Active,binding constant for abl1 non phosphorylated kinase domain
1582,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624992,Active,binding constant for abl1 phosphorylated kinase domain
1584,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1069558,Active,inhibition of abl  unknown origin after 30 mins
1585,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1236888,Active,inhibition of bcr abl1  unknown origin assessed as atp remaining by kinase glo luminescent kinase assay
1555,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256667,Active,average binding constant for abl1 e255k nanot active at 10 um
796,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL559826,491288,Active,antiproliferative activity against mouse ba/f3 cells expressing wild type abl after 3 days by mts assay
1586,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1236888,Active,inhibition of bcr abl1  unknown origin assessed as atp remaining by kinase glo luminescent kinase assay
795,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL559826,491287,Active,inhibition of human abl t315i mutant after 2 hrs by tr fret assay
1587,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1300795,Active,inhibition of abl  unknown origin by mobility shift assay
1588,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1308928,Active,inhibition of abl  unknown origin incubated for 1 hr by spectrophotometric analysis
1589,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1350953,Active,inhibition of abl1  unknown origin 
613,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL91829,256670,Inactive,average binding constant for abl1 t315i nanot active at 10 um
614,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL91829,256671,Inactive,average binding constant for abl1 y253f nanot active at 10 um
1575,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624985,Active,binding constant for abl1 m351t  phosphorylated kinase domain
1574,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624984,Active,binding constant for abl1 h396p  phosphorylated kinase domain
1556,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256668,Active,average binding constant for abl1 h396p nanot active at 10 um
1557,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256669,Active,average binding constant for abl1 m351t nanot active at 10 um
1558,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256670,Active,average binding constant for abl1 t315i nanot active at 10 um
1559,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256671,Active,average binding constant for abl1 y253f nanot active at 10 um
1560,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,350250,Active,inhibition of abl1
1553,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256665,Active,average binding constant for abl1 nanot active at 10 um
1561,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435146,Active,binding constant for abl1 h396p kinase domain
1552,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,240823,Active,inhibition of c abl tyrosine kinase activity
1562,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435514,Active,binding constant for abl1 m351t kinase domain
1563,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435515,Active,binding constant for abl1 q252h kinase domain
794,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL559826,491287,Active,inhibition of human abl t315i mutant after 2 hrs by tr fret assay
1564,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435644,Active,binding constant for abl1 e255k kinase domain
1566,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435776,Active,binding constant for abl1 y253f kinase domain
1551,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,228824,Active,inhibition of abl tyrosine kinase
1550,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,228824,Active,inhibition of abl tyrosine kinase
1567,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435897,Active,binding constant for abl1 t315i kinase domain
1568,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624978,Active,binding constant for abl1 e255k  phosphorylated kinase domain
1569,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624979,Active,binding constant for abl1 f317i  non phosphorylated kinase domain
1570,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624980,Active,binding constant for abl1 f317i  phosphorylated kinase domain
1571,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624981,Active,binding constant for abl1 f317l  non phosphorylated kinase domain
1572,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624982,Active,binding constant for abl1 f317l  phosphorylated kinase domain
1573,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,624983,Active,binding constant for abl1 h396p  non phosphorylated kinase domain
1565,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,435775,Active,binding constant for abl1 kinase domain
1590,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1394735,Active,inhibition of recombinant human abl expressed in insect cells using ulight tk peptide as substrate after 60 mins by lance method
1554,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,256666,Active,average binding constant for abl1 q252h nanot active at 10 um
790,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL559826,421459,Active,antiproliferative activity against mouse ba/f3 cells expressing wild type bcr abl after 3 days by mts assay
1598,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL496,588664,Inactive,trfret based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the ras and rab interactor 1 protein  rin1 and the c abl oncogene 1 non receptor tyrosine kinase  abl 
1599,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL496,588664,Inactive,trfret based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the ras and rab interactor 1 protein  rin1 and the c abl oncogene 1 non receptor tyrosine kinase  abl 
793,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL559826,491286,Active,inhibition of wild type human abl after 1 hr by tr fret assay
1591,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL388978,1481070,Active,inhibition of human abl1 using eaiyaapfakkk as substrate in presence of [gamma 32p]atp
792,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL559826,421479,Active,antiproliferative activity against mouse ba/f3 cells expressing bcr abl t315i mutant after 3 days by mts assay
791,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL559826,421478,Active,inhibition of human abl t315i mutant by tr fret assay
789,CHEMBL1862,Tyrosine-protein kinase ABL,CHEMBL559826,421457,Active,inhibition of wild type human abl kinase by tr fret assay
1820,CHEMBL5251,Tyrosine-protein kinase BTK,CHEMBL428690,256561,Inactive,average binding constant for btk nanot active at 10 um
2129,CHEMBL5251,Tyrosine-protein kinase BTK,CHEMBL1725279,256561,Inactive,average binding constant for btk nanot active at 10 um
437,CHEMBL2959,Tyrosine-protein kinase ITK/TSK,CHEMBL1421,329195,Active,inhibition of itk f435t mutant
436,CHEMBL2959,Tyrosine-protein kinase ITK/TSK,CHEMBL1421,329187,Inactive,inhibition of recombinant itk
435,CHEMBL2959,Tyrosine-protein kinase ITK/TSK,CHEMBL1421,329183,Inactive,binding affinity to itk from human k562 cells extract by lc msms
2155,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3601227,1239422,Active,antiproliferative activity against mouse ba/f3 cells expressing tel jak1 after 72 hrs by cell titer glo assay
1655,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3314283,1179884,Active,inhibition of jak1  unknown origin by radiometric assay
1690,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3116050,1067897,Active,cytotoxicity against mouse ba/f3 cells expressing tel jak1 after 72 hrs by mts assay
1004,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675688,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
650,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3645550,1257634,Active,in vitro kinase enzyme assay: in vitro kinase enzyme assay using jak3 jak2 jak1 and tyk2 
1789,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3601118,1239422,Active,antiproliferative activity against mouse ba/f3 cells expressing tel jak1 after 72 hrs by cell titer glo assay
1691,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3116050,1067944,Active,inhibition of jak1  unknown origin 
1003,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675688,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
2096,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3622829,1251066,Active,inhibition of jak1  unknown origin using 87 um of atp and tyr6 peptide by z' lyte kinase assay
1393,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675685,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
1689,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3116050,1067895,Active,inhibition of jak1 in mouse ba/f3 cells expressing tel jak1 assessed as inhibition of stat5 phosphorylation by western blotting analysis
1183,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3622828,1251066,Active,inhibition of jak1  unknown origin using 87 um of atp and tyr6 peptide by z' lyte kinase assay
1143,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675695,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
1394,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675685,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
1142,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL3675695,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
2220,CHEMBL2835,Tyrosine-protein kinase JAK1,CHEMBL553,256646,Inactive,average binding constant for jak1  kin dom 1 nanot active at 10 um
2094,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675692,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
1839,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3647897,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1838,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3647897,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1837,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3647897,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2030,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL2322139,727997,Active,inhibition of jak2  unknown origin after 2 5 hrs by time resolved fluorescence resonance energy transfer assay in presence of 100 um atp
502,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675695,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
304,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4113009,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
1828,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3601243,1239423,Active,antiproliferative activity against mouse ba/f3 cells expressing tel jak2 after 72 hrs by cell titer glo assay
484,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3601229,1239423,Active,antiproliferative activity against mouse ba/f3 cells expressing tel jak2 after 72 hrs by cell titer glo assay
1988,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3601861,1239423,Active,antiproliferative activity against mouse ba/f3 cells expressing tel jak2 after 72 hrs by cell titer glo assay
1217,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675693,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
1216,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675693,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
2011,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3746743,1267667,Active,inhibition of n terminal gst fused recombinant jak2  831 to 1132 residues  unknown origin expressed in insect cells using 5fam geeplywsfpakkk nh2 as substrate by microfluidic capillary electrophoresis method
1109,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3651040,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w
1093,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3907227,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2095,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675692,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
501,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675695,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
503,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3651026,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w
1395,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3601238,1239423,Active,antiproliferative activity against mouse ba/f3 cells expressing tel jak2 after 72 hrs by cell titer glo assay
1061,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL2010872,653737,Active,inhibition of jak2 at 1 um
1396,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3647910,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1397,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3647910,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1398,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3647910,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1411,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3927316,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1374,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3814195,1306231,Active,inhibition of jak2  unknown origin using tyrosine 6 peptide as substrate by z' lyte assay
2229,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3645545,1257634,Active,in vitro kinase enzyme assay: in vitro kinase enzyme assay using jak3 jak2 jak1 and tyk2 
2230,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3645545,1257635,Active,in vitro kinase enzyme assay: in vitro kinase enzyme assay using jak3 jak2 jak1 and tyk2 
2254,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4101725,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
2255,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4101725,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
2256,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4101725,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
2257,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4101725,1468044,Active,inhibition of recombinant human jak2 using fitc kggeeeeyfelvkk as substrate in presence of 1 mm atp by mobility shift assay
2102,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3699496,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2258,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4101725,1468047,Active,inhibition of jak2 in cd34+ human whole blood assessed as reduction in eop induced stat5 phosphorylation preincubated for 45 mins followed by eop addition measured after 15 mins by flow cytometric analysis
2143,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL10,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um
416,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3779913,1287924,Active,inhibition of jak2  unknown origin 
417,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3779913,1287932,Active,inhibition of jak2 in human cd34+ cells assessed as inhibition of epo mediated cell proliferation
1038,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4115248,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
602,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL2325897,726697,Active,inhibition of jak2  unknown origin  mediated phosphorylation of biotin kaietdkeyytvkd incubated for 10 mins prior to substrate addition measured after 30 mins by scintillation counting analysis in presence of [gamma 33p]atp
1294,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675691,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
1293,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675691,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
1523,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675688,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
448,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4113802,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
865,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3651050,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w
1250,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3114785,1070027,Active,inhibition of jak2  unknown origin 
929,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3601708,1239423,Active,antiproliferative activity against mouse ba/f3 cells expressing tel jak2 after 72 hrs by cell titer glo assay
1522,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675688,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
328,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3601237,1239423,Active,antiproliferative activity against mouse ba/f3 cells expressing tel jak2 after 72 hrs by cell titer glo assay
1811,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675697,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
1812,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675697,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
1607,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4109366,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
284,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3648430,1257634,Active,in vitro kinase enzyme assay: in vitro kinase enzyme assay using jak3 jak2 jak1 and tyk2 
77,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL91829,256645,Inactive,average binding constant for jak2  kin dom 2 nanot active at 10 um
54,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3639498,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w
2371,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3943946,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
825,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3651001,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w
96,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675700,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
1786,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3746463,1267685,Inactive,inhibition of jak2 in human hel 92 1 7 cells assessed as reduction in stat5 phosphorylation after 2 hrs by western blot analysis
1608,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL4109366,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
1684,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3699482,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
97,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3675700,1257898,Active,inhibition assay: to determine the inhibition constants  ki of examples 1 240 compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing 1 5 nm jak1 0 2 nm purified jak2 or 1 nm purified tyk2 enzyme 100 mm hepes ph7 2 0 015% brij 35 1 5  x3bc m peptide substrate 25  x3bc m atp 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm ki values were then determined using the morrison tight binding model morrison j f biochim biophys acta 185:269 296  1969 william j w and morrison j f meth enzymol 63:437 467  1979 
1809,CHEMBL2971,Tyrosine-protein kinase JAK2,CHEMBL3702969,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
516,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3899281,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
515,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3899281,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
761,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3940421,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
757,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702998,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
756,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702998,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
755,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702998,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1048,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3946179,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1049,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3946179,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
754,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702998,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1123,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699460,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1040,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917864,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
513,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3899281,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
512,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3899281,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
2116,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4115665,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
2115,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4115665,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
1140,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647847,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1056,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3964801,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1057,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3964801,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
511,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3899281,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
514,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3899281,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
762,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3940421,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2130,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3937827,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2131,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3937827,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
533,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343589,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
532,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703028,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3658869,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
531,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703028,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
783,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900631,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2153,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3913483,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2152,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3913483,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2151,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3974692,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2150,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3974692,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1032,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703095,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1033,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703095,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
3,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3658869,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
782,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900631,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
781,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900631,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1141,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647847,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1039,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917864,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
2132,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3937827,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
772,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL201307,259744,Active,inhibitory activity against jak3
763,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3940421,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
39,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3915738,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1063,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3940644,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1064,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3940644,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1065,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3940644,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1098,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3938660,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1099,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3938660,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1100,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3938660,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1101,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3938660,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1102,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3938660,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1103,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3938660,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2058,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3984406,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2057,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3984406,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2055,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647756,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
10,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647840,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2054,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647756,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
487,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3954699,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
196,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647895,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
197,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647895,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
490,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3954699,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
697,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699512,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
489,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3954699,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1120,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699460,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1121,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699460,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1122,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699460,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
698,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699512,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
11,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647840,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
670,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647758,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
669,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647758,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
38,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3915738,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2101,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647813,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2100,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647813,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
534,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
36,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655082,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
35,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655082,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
657,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3897648,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2085,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3903941,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2084,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3903941,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2083,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3903941,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2082,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3903941,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2081,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3903941,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2080,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3901746,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2079,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3901746,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2078,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917134,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
658,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3897648,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2077,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917134,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
659,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3897648,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
667,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647733,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
668,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647733,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
4,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3658869,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
488,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3954699,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
37,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655082,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
2184,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3902428,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
156,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655099,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
2354,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942459,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2355,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942459,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
882,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647770,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
887,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3950892,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
888,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3950892,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
889,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647859,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
890,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647859,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
94,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647833,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
93,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647833,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
881,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647770,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1147,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4113261,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
2296,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112986,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2295,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112986,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2294,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112986,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2360,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3959420,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2361,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3959420,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
109,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
619,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3894688,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
601,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3967830,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
600,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3967830,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2297,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112986,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2353,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942459,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
875,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917860,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
874,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917860,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
848,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3892314,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
835,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647817,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
849,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3892314,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
851,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647920,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
852,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647920,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
862,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655090,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
834,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647817,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
102,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343589,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
863,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655090,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
103,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
104,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
105,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
106,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
833,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3984319,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
832,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3984319,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2350,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647766,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
864,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655090,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
2351,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647766,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
107,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
108,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
873,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3917860,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
914,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4110635,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2282,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3985677,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2281,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3985677,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
915,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4110635,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
135,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647925,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
136,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647925,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
137,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647925,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
138,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647925,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
559,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647911,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
802,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3958691,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2394,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647906,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2395,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647906,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2401,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3932570,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2402,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3932570,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
788,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702884,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
558,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647911,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
539,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
538,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
537,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
536,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
535,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3968423,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2186,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3902428,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2185,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3902428,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
154,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655099,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
155,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655099,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
803,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3958691,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
787,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702884,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
560,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647911,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2227,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3922122,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
925,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3899762,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
926,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3899762,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
620,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3894688,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
110,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
111,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3934627,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2260,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3894591,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
2259,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3894591,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
2368,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3896766,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2369,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3896766,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2370,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3896766,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
117,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703016,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
118,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703016,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2244,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647913,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2243,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647913,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
125,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647734,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
126,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647734,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2234,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3979961,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
2233,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3979961,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
629,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702883,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
630,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702883,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2228,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3922122,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
561,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647911,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1148,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4113261,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
682,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3983256,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1784,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655088,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
1778,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699499,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1777,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699499,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1776,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699499,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1768,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702941,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1767,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702941,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1329,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1249,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3986588,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1345,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3933397,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1854,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699517,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1248,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3986588,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
681,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3983256,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1244,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3911942,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1243,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3911942,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1779,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699499,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1855,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699517,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1239,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3915926,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
329,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3981144,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
330,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3981144,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
331,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647928,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1346,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3933397,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1347,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3933397,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1350,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3980369,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
332,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647928,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1758,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3916637,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1757,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3916637,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1756,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647737,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1755,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647737,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1351,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3980369,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1240,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3915926,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1780,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655088,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
1781,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655088,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
1782,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655088,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
1846,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699557,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1323,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343589,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1847,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699557,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1320,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3932031,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1319,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3932031,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1844,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699557,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1325,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1834,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699468,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1833,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699468,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1535,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3918506,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1536,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3918506,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1541,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703065,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1542,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703065,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1311,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3639465,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1310,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3639465,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1543,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703065,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1544,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703065,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1326,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1327,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1799,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647809,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1798,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647809,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1785,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655088,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
1328,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
362,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3892562,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1783,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3655088,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
425,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3983502,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
426,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3983502,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
430,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699537,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
431,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699537,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1375,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3974801,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1324,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3942424,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1376,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3974801,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1749,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702976,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1174,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4109793,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
1173,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4109793,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
1639,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3920777,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1640,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3920777,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1170,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703084,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1169,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703084,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1643,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3951947,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1164,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702965,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1644,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3951947,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1668,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699519,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1163,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702965,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1669,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699519,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1871,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900033,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1670,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699519,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1701,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699459,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1700,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699459,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1459,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3924451,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1157,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3908409,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1156,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3908409,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1458,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL568789,446098,Active,inhibition of jak3 using 5 mm atp as a substrate
1414,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900020,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
1415,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900020,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
349,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3913397,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
350,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3913397,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
351,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3913397,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
361,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3892562,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1671,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699519,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1714,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112922,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1877,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3935161,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1999,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3971083,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1748,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3702976,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1872,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3900033,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1873,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3914541,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1874,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3914541,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1601,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647775,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1739,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3946758,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1738,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3946758,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1737,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3946758,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1602,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647775,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
291,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3658865,1258881,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
290,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3658865,1258880,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
289,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3658865,1258879,Active,enzyme assay: test article and assay controls were added to a 384 well plate reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 1 mm atp and 1  x3bc m peptide substrate the jak1 and tyk2 assays contained 1  x3bc m of the irstide peptide  5famkksrgdymtmqid and the jak2 and jak3 assays contained 1  x3bc m of the jaktide peptide  fitc kggeeeeyfelvkk the assays were initiated by the addition of 20 nm jak1 1 nm jak2 1 nm jak3 or 1 nm tyk2 enzyme and were incubated at room temperature for three hours for jak1 60 minutes for jak2 75 minutes for jak3 or 135 minutes for tyk2 enzyme concentrations and incubation times were optimized for each new enzyme preps and were modified slightly over time to ensure 20% 30% phosphorylation the assays were stopped with a final concentration of 10 mm edta 0 1% coating reagent and 100 mm hepes ph7 4 
1728,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647742,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1210,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3951874,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1209,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3951874,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1727,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3647742,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1726,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3980959,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1998,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3971083,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1180,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699506,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1715,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112922,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1716,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL4112922,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1383,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703098,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1876,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3935161,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1179,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699506,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1382,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3703098,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1725,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3980959,1344297,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1460,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3924451,1344298,Active,jak enzyme assay: the activity of the isolated recombinant jak1 and jak2 kinase domain was measured by monitoring phosphorylation of a peptide derived from jak3  val ala leu val asp gly tyr phe arg leu thr thr fluorescently labeled on the n terminus with 5 carboxyfluorescein using the caliper labchip xae technology  caliper life sciences hopkinton mass to determine inhibition constants  ki compounds were diluted serially in dmso and added to 50  x3bc l kinase reactions containing purified enzyme  1 5 nm jak1 or 0 2 nm jak2 100 mm hepes buffer  ph 7 2 0 015% brij 35 1 5  x3bc m peptide substrate atp  25  x3bc m 10 mm mgcl2 4 mm dtt at a final dmso concentration of 2% reactions were incubated at 22 xb0 c in 384 well polypropylene microtiter plates for 30 minutes and then stopped by addition of 25  x3bc l of an edta containing solution  100 mm hepes buffer  ph 7 2 0 015% brij 35 150 mm edta resulting in a final edta concentration of 50 mm after terminati
1845,CHEMBL2148,Tyrosine-protein kinase JAK3,CHEMBL3699557,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
597,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL106772,435999,Active,inhibition of lck
2269,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL1997617,748778,Active,inhibition of lck  64 to 509 amino acids  unknown origin by htrf assay
2268,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL1997617,223984,Active,inhibition of human p56 lck tyrosine kinase
2267,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL1997617,223955,Active,inhibition of human p56 lck tyrosine kinase  lck64 509 
2266,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL1997617,223955,Active,inhibition of human p56 lck tyrosine kinase  lck64 509 
505,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL2151321,692428,Active,inhibition of lck
1835,CHEMBL258,Tyrosine-protein kinase LCK,CHEMBL2311807,722272,Active,inhibition of human lck using poly[glu:tyr]  4:1 peptide substrate
980,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL504598,1032,Inactive,primary biochemical high throughput screening assay for agonists of the steroid receptor coactivator 2  src 2 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma 
979,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL504598,1032,Inactive,primary biochemical high throughput screening assay for agonists of the steroid receptor coactivator 2  src 2 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma 
976,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL504598,631,Inactive,primary biochemical high throughput screening assay for agonists of the steroid receptor coactivator 1  src 1 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma 
981,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL504598,1049,Inactive,measurement of tr fret detection format artefact in the screen for agonists of steroid receptor coactivator 2  src 2 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma 
982,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL504598,1049,Inactive,measurement of tr fret detection format artefact in the screen for agonists of steroid receptor coactivator 2  src 2 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma 
983,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL504598,588354,Inactive,luminescence based cell based primary high throughput screening assay to identify inhibitors of the steroid receptor coactivator 1  src1 ncoa1 
975,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL504598,631,Inactive,primary biochemical high throughput screening assay for agonists of the steroid receptor coactivator 1  src 1 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma 
931,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL495727,412619,Active,inhibition of src t341m mutant
2462,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL191389,242306,Active,inhibition of glutamate/tyrosine  4:1 copolymer phosphorylation by avian c src tyrosine kinase
978,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL504598,731,Inactive,primary biochemical high throughput screening assay for agonists of the steroid receptor coactivator 3  src 3 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma 
376,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL573578,588354,Inactive,luminescence based cell based primary high throughput screening assay to identify inhibitors of the steroid receptor coactivator 1  src1 ncoa1 
375,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL573578,512628,Active,inhibition of v src kinase i338g mutant
374,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL573578,512623,Active,inhibition of wild type v src
977,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL504598,731,Inactive,primary biochemical high throughput screening assay for agonists of the steroid receptor coactivator 3  src 3 recruitment by the peroxisome proliferator activated receptor gamma  ppargamma 
372,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL573578,435756,Active,percentage src activity remaining in the presence of 1um inhibitor
371,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL573578,435702,Active,inhibition of src in the presence of 50um atp
373,CHEMBL267,Tyrosine-protein kinase SRC,CHEMBL573578,435993,Active,percentage src activity remaining in the presence of 10um inhibitor
243,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3702974,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2239,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647735,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2240,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647735,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
353,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3915165,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
352,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3915165,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1745,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652283,1257788,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
1676,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3702894,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2428,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3955124,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2429,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3955124,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1620,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3703082,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1621,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3703082,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1637,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4112766,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
726,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3703003,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
725,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3703003,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1885,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3956550,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
244,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3702974,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2471,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3964413,1344217,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
1150,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3890701,1344216,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
7,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652382,1257789,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
6,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652382,1257788,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
1675,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3702894,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2476,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3944822,1344217,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
1638,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4112766,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
8,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652382,1257790,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
2322,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3925815,1344218,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
2279,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699526,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
810,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4113706,1344218,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
633,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3953856,1257790,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
632,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3953856,1257789,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
631,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3953856,1257788,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
1857,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3911472,1344216,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
819,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699500,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
809,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4113706,1344217,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
820,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699500,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2365,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4115665,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
2352,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3651005,1258733,Active,htrf assay: the ability of compounds to inhibit the activity of jakl jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jakl  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384  well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 of 1 1 ix enzyme and 1 1 ix substrate in ix assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at room temperature to allow compound binding to equilibrate after equilibration 2 \\xl of 10x atp in ix assay buffer was added to initiate the kinase reaction and the plates w
310,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647760,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
846,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3703069,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
847,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3703069,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
309,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647760,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2366,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4115665,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
2321,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3925815,1344217,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
808,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4113706,1344216,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
334,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4113680,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
2280,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699526,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1746,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652283,1257789,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
1747,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652283,1257790,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
2392,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3937835,1344218,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
1469,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652352,1257788,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
2391,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3937835,1344217,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
807,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4113706,1344216,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
2390,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3937835,1344216,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
1470,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652352,1257789,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
1471,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652352,1257790,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
2288,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652337,1257788,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
2289,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652337,1257789,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
2290,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652337,1257790,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
335,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4113680,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
1753,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3645541,1257634,Active,in vitro kinase enzyme assay: in vitro kinase enzyme assay using jak3 jak2 jak1 and tyk2 
2237,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652347,1257790,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
1151,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3890701,1344217,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
2235,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652347,1257788,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
2086,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3897417,1344216,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
2087,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3897417,1344217,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
2088,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3897417,1344218,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
1076,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3903941,1343592,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1075,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3903941,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1074,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3903941,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1073,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3903941,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1072,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3903941,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1055,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3702973,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1054,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3702973,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2236,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652347,1257789,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
452,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699485,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
451,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699485,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1025,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652339,1257790,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
1024,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652339,1257789,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
1023,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652339,1257788,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
153,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699489,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1981,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4108322,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
152,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699489,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1982,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4108322,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
500,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652311,1257790,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
1152,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3890701,1344218,Active,enzymatic assay: jak1/2/3 kinase assay are performed in vitro using kit tyr 6 peptide  invitrogen cat no pv4122 tyk2 kinase assay are performed in vitro using z' lyte x2122 kinase assay kit tyr 3 peptide  invitrogen cat no pv3192 recombinant human jak1/2/3 or tyk2 catalytic domains are from invitrogen  cat no pv4774/pv4210/pv3855/pv4790 all reactions  20  x3bc l are started by adding 2 5  x3bc l of the testing compound in 4% dmso solution 5  x3bc l of kinase/peptide substrate mixture  3 2 0 04 0 2 or 8  x3bc g/ml for recombinant human jak1/2/3 catalytic domains 4  x3bc m for z lyte x2122 tyr 6 peptide or z lyte x2122 tyr 3 peptide or phospho peptide solution  invitrogen cat no pv3192 diluted with 1 33 xd7 kinase buffer 2 5  x3bc l atp solution  300/100/40/100m jak1/jak2/jak3/tyk2 or 1 33 xd7 kinase buffer  invitrogen cat no pv3189 5 xd7 diluted with distilled water the 384 well assay plate  corning cat no 3575 is mixed and incubate
1159,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699544,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1160,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699544,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1161,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699544,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1162,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699544,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
2045,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3639511,1257788,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
2046,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3639511,1257789,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
2047,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3639511,1257790,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
492,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699513,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
493,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3699513,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1111,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3703038,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1110,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3703038,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
495,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652311,1257788,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
496,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652311,1257788,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
497,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652311,1257789,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
498,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652311,1257789,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
499,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3652311,1257790,Active,enzymatic assay: a peptide mobility shift assay was used to quantify the phosphorylation of the jaktide  jak2 and jak3 or the irs 1 peptide  jak1 and tyk2 reactions were carried out in a 384 well plate  matrical mp 101 in a 10 l total volume reaction mixtures contained 20 mm hepes ph 7 4 10 mm magnesium chloride 0 01% bovine serum albumin  bsa 0 0005% tween 20 atp  4 m for jak2 and jak3 40 m for jak1 and 7 m for tyk2 2% dmso and 1 m peptide substrate  jaktide for jak2 and jak3 and irs 1 peptide for jak1 and tyk2 compounds were diluted serially in 100% dimethyl sulfoxide and tested in an 11 point dose response in duplicate or quadruplicate  200 nl of compound/dmso was added per 10 l reaction the reactions were initiated by the addition of enzyme to the final concentration of 2 nm jak2 1 nm jak3 12 nm tyk2 or 20 nm jak1 the assay was run for 240 minutes for jak1 150 minutes for jak2 90 minutes for jak3 and 70 minutes for tyk2 
1220,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3601108,1239425,Active,antiproliferative activity against mouse ba/f3 cells expressing tyk2 e957d mutant after 72 hrs by cell titer glo assay
1378,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3943946,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
1884,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3956550,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2223,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647767,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
365,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3902770,1343590,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
2224,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647767,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
363,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647730,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1379,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647770,1258568,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
366,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3902770,1343591,Active,enzyme assay: jak1 jak2 jak3 and tyk2 were purchased from carna biosciences inc as the substrate lance ultra ulight jak1 peptide  manufactured by perkinelmer co ltd  pe was used dilute solutions of compounds and enzymes in assay buffer  50 mm hepes ph7 5 1 mm egta 1 mm mgcl2 2 mm dtt 0 01% tween20 were dispensed into wells of a 384 well black plate after 5 minutes of preincubation dilute solutions of the substrate and atp  adenosine triphosphate were added at a final concentration of 100  x3bc m and the plate was incubated at room temperature for 2 hours after addition of a termination reagent containing edta  ethylenediamine tetraacetic acid at a final concentration of 10 mm lance eu w1024 anti phosphotyrosine  pt66  manufactured by pe was added and after 1 hour of incubation the fluorescences were measured with arvo hts 
364,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647730,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
1380,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3647770,1258569,Active,htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 ml of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18 ul of 1 11x enzyme and 1 11x substrate in 1x assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2 ul of 10xatp in 1x assay buffer was added to initiate the kinase reaction 
968,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3927605,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
549,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4113767,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
967,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL3927605,1344530,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
550,CHEMBL3553,Tyrosine-protein kinase TYK2,CHEMBL4113767,1344531,Active,biochemical htrf assay: the ability of compounds to inhibit the activity of jak1 jak2 jak3 and tyk2 was measured using a recombinant purified gst tagged catalytic domain for each enzyme  invitrogen jak1  m4290 jak2  m4290 jak3  m4290 tyk2  m4290 in an htrf format biochemical assay the reactions employed a common peptide substrate lcb eqedepegdyfewlw nh2  in house the basic assay protocol is as follows: first 250 nl of diluted compounds in dmso were dispensed into the wells of a dry 384 well black plate  greiner  781076 using a labcyte echo 555 acoustic dispenser subsequent reagent additions employed an agilent bravo next 18  x3bc l of 1 11 xd7 enzyme and 1 11 xd7 substrate in 1 xd7 assay buffer  invitrogen kinase buffer  pv3189 2 mm dtt 0 05% bsa were added to the wells and shaken and then preincubated for 30 minutes at ambient temperature to allow compound binding to equilibrate after equilibration 2  x3bc l of 10 xd7 atp in 1 xd7 assay buffer was adde
83,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3976752,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
80,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3976752,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
81,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3976752,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
1980,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3962554,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
82,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3976752,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
2277,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3288854,1155232,Active,binding affinity to flt3  unknown origin 
1455,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3896142,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
1454,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3896142,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
68,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979172,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
67,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979172,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
66,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979172,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
65,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979172,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
64,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3979172,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
79,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3976752,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
1222,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969373,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
2397,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3984035,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
2399,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3984035,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
1763,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3933449,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
1762,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3933449,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
1761,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3933449,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
1226,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969373,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
1225,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969373,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
1224,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969373,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
2278,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3288854,1440304,Active,antiproliferative activity against human mv4 11 cells harboring flt3 itd mutant after 72 hrs by mts assay
591,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904777,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
1976,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3962554,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
1977,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3962554,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
1978,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3962554,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
590,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904777,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
1979,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3962554,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
589,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904777,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
2396,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3984035,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
565,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3897101,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
2398,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3984035,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
2400,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3984035,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
566,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3897101,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
1723,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3955563,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
588,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904777,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
2460,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3913051,1340083,Active,inhibition of recombinant human n terminal his6 tagged fgfr3 expressed in insect sf21 cells using btn flt3 as substrate after 3 hrs by time resolved fluorescence assay
12,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3898568,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
569,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3897101,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
567,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3897101,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
568,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3897101,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
481,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3694711,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate 
693,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3912630,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
2019,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690420,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w
2020,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690420,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w
2021,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690420,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w
692,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3912630,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
691,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3912630,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
690,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3912630,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
2022,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690420,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate 
2023,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690420,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate 
2024,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690420,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate 
689,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3912630,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
13,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3898568,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
1453,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3896142,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
14,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3898568,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
16,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3898568,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
1724,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3955563,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
1722,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3955563,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
758,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3937810,1344594,Active,biochemical assay: the assay was performed using flt3 cytoplasmic domain product and purified in house as gst fused protein the flt3 protein  1 microm was pre activated with 800 microm atp for 1 hour at 28 xb0 c in order to obtain a linear kinetic kinase buffer was composed of 50 mm hepes ph 7 9 containing 4 mm mgcl2 1 mm dtt 10 microm na3vo4 and 0 2 mg/ml bsa the flt3 kinase assay was run with a final pre activated enzyme concentration of 2 nm in the presence of 254 microm atp  residual atp from kit pre activation step is negligible 8 nm 33p  x3b3  atp and 55 microm of substrate biodb n*24  aminoacidic sequence: ggkkkvsrsglyrspsmpenlnrpr  seq id no: 1 
1721,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3955563,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
1720,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3955563,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
478,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3694711,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w
1452,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3896142,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
1451,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3896142,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
1096,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3968361,1340083,Active,inhibition of recombinant human n terminal his6 tagged fgfr3 expressed in insect sf21 cells using btn flt3 as substrate after 3 hrs by time resolved fluorescence assay
1097,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3968361,1340084,Active,inhibition of recombinant human n terminal his6 tagged vegfr2  790 end residues expressed in baculovirus infected insect sf21 cells using btn flt3 as substrate after 1 hr by time resolved fluorescence assay
479,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3694711,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w
480,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3694711,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate 
660,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3942328,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
661,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3942328,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
662,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3942328,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
663,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3942328,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
664,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3942328,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
15,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3898568,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
1764,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3933449,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
1223,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3969373,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
2120,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3930634,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
422,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3952539,1344594,Active,biochemical assay: the assay was performed using flt3 cytoplasmic domain product and purified in house as gst fused protein the flt3 protein  1 microm was pre activated with 800 microm atp for 1 hour at 28 xb0 c in order to obtain a linear kinetic kinase buffer was composed of 50 mm hepes ph 7 9 containing 4 mm mgcl2 1 mm dtt 10 microm na3vo4 and 0 2 mg/ml bsa the flt3 kinase assay was run with a final pre activated enzyme concentration of 2 nm in the presence of 254 microm atp  residual atp from kit pre activation step is negligible 8 nm 33p  x3b3  atp and 55 microm of substrate biodb n*24  aminoacidic sequence: ggkkkvsrsglyrspsmpenlnrpr  seq id no: 1 
878,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690469,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w
997,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3899721,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
998,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3893070,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
999,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3893070,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
1030,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL1908391,1345590,Active,human platelet derived growth factor receptor beta  type iii rtks: pdgfr csfr kit flt3 receptor family 
1029,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL1908391,1345563,Active,human platelet derived growth factor receptor alpha  type iii rtks: pdgfr csfr kit flt3 receptor family 
1028,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL1908391,1345555,Active,human kit proto oncogene receptor tyrosine kinase  type iii rtks: pdgfr csfr kit flt3 receptor family 
1027,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL1908391,1345555,Active,human kit proto oncogene receptor tyrosine kinase  type iii rtks: pdgfr csfr kit flt3 receptor family 
1534,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3927733,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
1533,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3927733,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
1513,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985222,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
1514,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985222,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
1000,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3893070,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
1515,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985222,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
1532,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3927733,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
1531,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3927733,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
879,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690469,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate 
880,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690469,1258132,Active,in vitro kinase inhibition assay: vegfr2  from upstate prepared at 2x final concentration was incubated with test compounds biotinylated flt3 substrate  biotin vassdneyfyvdf  cell signalling technology inc and atp in the appropriate assay buffer  table 1 the reaction was allowed to proceed for 1 hour at room temperature on a plate shaker at 700 rpm before being stopped with 35 mm edta ph 8  vegfr2 5x detection mix  50 mm hepes ph 7 5 0 1% bsa 11 34 nm eu anti py  py20 187 5 nm sa xl665 was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 700 rpm the plate was then read on a packard fusion plate reader or a bmg pherastar both in trf mode kinase assay buffers were: 50 mm hepes ph 7 5 6 mm mncl2 1 mm dtt 0 01% tritonx 100 0 1 mm sodium orthovanadate 
2316,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3968124,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
2317,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3968124,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
2318,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3968124,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
2319,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3968124,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
2176,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL272198,326794,Inactive,inhibition of flt3
2320,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3968124,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
150,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3944665,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
1530,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3927733,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
1516,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985222,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
1002,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3893070,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
1765,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3933449,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
1001,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3893070,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
1517,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985222,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
2137,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3545376,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
616,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985007,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
617,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985007,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
618,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3985007,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
2136,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3545376,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
2188,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3926406,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
2189,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3926406,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
1961,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3952706,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
2122,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3930634,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
149,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3944665,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
2121,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3930634,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
2119,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3930634,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
1962,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3952706,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
1963,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3952706,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
2190,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3926406,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
2191,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3926406,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
1964,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3952706,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
148,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3944665,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
592,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3904777,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
877,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3690469,1258131,Active,in vitro kinase inhibition assay: enzymes  from upstate were prepared at 2 xd7 final concentration in 1 xd7 kinase assay buffer  table 1 enzymes were then incubated with test compounds biotinylated flt3 substrate  biotin  x2212 dneyfyv  cell signalling technology inc and atp the reaction was allowed to proceed for 3 hours  fgfr3 or 2 5 hrs  pdgfr beta at room temperature on a plate shaker at 900 rpm before being stopped with 20  x3bc l of 35 mm edta ph 8  fgfr3 or 55 mm edta ph 8  pdgfr beta twenty pl of 5 xd7 detection mix  50 mm hepes ph 7 5 0 1% bsa 2 nm eu anti py  py20  perkinelmer 15 nm sa xl665  cisbio for fgfr3 and 50 mm hepes ph 7 5 0 5 m kf 0 1% bsa 11 34 nm eu anti py  pt66  perkinelmer 94 nm sa xl665  cisbio for pdgfr beta was then added to each well and the plate sealed and incubated at room temperature for one hour on a plate shaker at 900 rpm the plate was then read on a packard fusion plate reader in trf mode kinase assay buffers w
995,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3899721,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
2187,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3926406,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
996,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3899721,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
993,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3899721,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
151,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3944665,1340073,Active,inhibition of human fgfr4 using btn flt3 as substrate after 60 mins by tr fret assay
994,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3899721,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
2133,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3545376,1340070,Active,inhibition of human fgfr1 using btn flt3 as substrate after 60 mins by tr fret assay
2135,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3545376,1340072,Active,inhibition of human fgfr3 using btn flt3 as substrate after 60 mins by tr fret assay
2134,CHEMBL1974,Tyrosine-protein kinase receptor FLT3,CHEMBL3545376,1340071,Active,inhibition of human fgfr2 using btn flt3 as substrate after 60 mins by tr fret assay
510,CHEMBL1868,Vascular endothelial growth factor receptor 1,CHEMBL3699444,1258566,Active,kinase assay: the effect of test compounds on the activity of the protein kinases gsk 3 x3b2 vegfr 2 and flt 3 was evaluated based on half maximal inhibitory concentration  ic50 values determined by millipore uk ltd gemini crescent dundee technology park dundee dd2 1sw uk  ic50profiler detailed protocols can be found at: www millipore com/drugdiscovery/dd3/assayprotocols 
2338,CHEMBL1868,Vascular endothelial growth factor receptor 1,CHEMBL1668418,568310,Active,inhibition of human recombinant flt 3 kinase expressed in insect cells after 90 mins
1468,CHEMBL1868,Vascular endothelial growth factor receptor 1,CHEMBL569880,441969,Active,inhibition of flt1
509,CHEMBL1868,Vascular endothelial growth factor receptor 1,CHEMBL3699444,1258565,Active,kinase assay: the effect of test compounds on the activity of the protein kinases gsk 3 x3b2 vegfr 2 and flt 3 was evaluated based on half maximal inhibitory concentration  ic50 values determined by millipore uk ltd gemini crescent dundee technology park dundee dd2 1sw uk  ic50profiler detailed protocols can be found at: www millipore com/drugdiscovery/dd3/assayprotocols 
508,CHEMBL1868,Vascular endothelial growth factor receptor 1,CHEMBL3699444,1258564,Active,kinase assay: the effect of test compounds on the activity of the protein kinases gsk 3 x3b2 vegfr 2 and flt 3 was evaluated based on half maximal inhibitory concentration  ic50 values determined by millipore uk ltd gemini crescent dundee technology park dundee dd2 1sw uk  ic50profiler detailed protocols can be found at: www millipore com/drugdiscovery/dd3/assayprotocols 
1412,CHEMBL1868,Vascular endothelial growth factor receptor 1,CHEMBL3594105,1235503,Active,inhibition of flt 3  unknown origin using poly  glu tyr 4:1 as substrate after 30 mins by htrf assay
904,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL391184,306347,Active,inhibition of human vegfr2 by htrf method
2201,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL378299,268025,Active,inhibition of vegfr2
1650,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL119385,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um
719,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL315546,216622,Active,inhibitory activity against vascular endothelial growth factor receptor 2  flk1 
123,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653133,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
122,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL31965,1117353,Active,human kdr kinase inhibition screen
2043,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL375840,277448,Active,inhibition of kdr
124,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653133,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
1247,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL395665,298789,Active,inhibition of kdr
120,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL204727,263662,Active,inhibitory activity against vegfr2
2142,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL247252,306347,Active,inhibition of human vegfr2 by htrf method
421,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL14762,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um
1803,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3941174,1340079,Active,inhibition of vegfr2  unknown origin transfected in mouse ba/f3 cells assessed as decrease in cell proliferation in absence of mouse il3 after 24 hrs by alamar blue assay
1802,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3941174,1340074,Active,inhibition of human vegfr2 using btn flt3 as substrate after 120 mins by tr fret assay
1796,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL941,1444933,Active,inhibition of vegfr2  unknown origin using fam labeled peptide as substrate preincubated for 10 mins followed by substrate addition in presence of atp by mobility shift assay
1795,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL941,414724,Active,inhibition of vegfr2 by liquid scintillation counting
1794,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL941,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um
1313,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL211662,268025,Active,inhibition of vegfr2
1295,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL295528,89312,Active,inhibition of human vegf receptor 2  kdr kinase 
1077,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653123,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
1290,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653098,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
1289,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653098,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
804,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL205406,263662,Active,inhibitory activity against vegfr2
1385,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL245934,307202,Active,inhibition of kdr by htrf assay
628,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653121,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
627,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653121,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
1078,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653123,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
121,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL31965,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um
770,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653111,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
1219,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653120,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
1018,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653113,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
2002,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL377230,268025,Active,inhibition of vegfr2
1019,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653113,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
1020,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL2088107,683401,Active,inhibition of recombinant n terminal gst tagged human kdr  805 to 1356 expressed in baculovirus infected sf9 cells after 90 mins by caliper mobility shift assay
1021,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3940489,1342638,Active,inhibition of recombinant human n terminal gst fused kdr  d807 to v1356 residues expressed in baculovirus infected escherichia coli or insect sf9 cells using poly ey as substrate after 240 mins by luciferase coupled chemiluminescence assay
1985,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3917220,1342638,Active,inhibition of recombinant human n terminal gst fused kdr  d807 to v1356 residues expressed in baculovirus infected escherichia coli or insect sf9 cells using poly ey as substrate after 240 mins by luciferase coupled chemiluminescence assay
1322,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL10,256642,Inactive,average binding constant for vegfr2 nanot active at 10 um
2315,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL380702,263662,Active,inhibitory activity against vegfr2
114,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL396107,306347,Active,inhibition of human vegfr2 by htrf method
771,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653111,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
1189,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL380372,268025,Active,inhibition of vegfr2
200,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL375819,277448,Active,inhibition of kdr
1611,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL473825,414724,Active,inhibition of vegfr2 by liquid scintillation counting
1218,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL3653120,1258178,Active,lanthascreen tr fret assay: the assay has been run at room temperature on a liquid handling robot to the assay plates containing 50 ml compound or control solutions 4 5 ul of solution a  50 mm tris hcl ph7 4 2 0m mdtt 0 05% tween20 0 02 mm na3vo4 including a generic concentration of 2 0 um atp was added per well followed by 4 5 ul of solution b  0 5% bsa including a generic concentration of 50 nm poly eay to give 9 05 ul of a reaction volume with final concentrations of 2 0 um atp 50 nm poly eay 25 mm tris hcl ph7 4 1 0 mm dtt 0 025% tween20 0 01 mm na3vo4 0 025% bsa as well as specific concentration of the respective enzyme and individual concentrations of divalent cations:  fgfr 3 k650e 0 2 nm gst fgr 3 k650e 3 0 mm mgcl2  kit 36 6 nm gst kit 10 mm mncl2  ret 0 11 nm gst xa ret 1 0 mm mncl2 10 mm mgcl2  lck 3 3 nm his lck 10 mm mncl2  kdr 0 38 nm gst kdr 10 mm mgcl2 1 0 mm mncl2  pdgfav561d 4 4 nm gst pdgfrav561d 10 mm mncl2 
868,CHEMBL279,Vascular endothelial growth factor receptor 2,CHEMBL247790,306347,Active,inhibition of human vegfr2 by htrf method
2056,CHEMBL2276,c-Jun N-terminal kinase 1,CHEMBL3355157,1170952,Inactive,inhibition of jnk1  unknown origin up to 10 um after 1 hr by homogeneous time resolved fluorescence assay
700,CHEMBL2276,c-Jun N-terminal kinase 1,CHEMBL124660,256622,Inactive,average binding constant for jnk1 nanot active at 10 um
2163,CHEMBL2637,c-Jun N-terminal kinase 3,CHEMBL1421720,746,Inactive,primary biochemical high throughput screening assay for inhibitors of the c jun n terminal kinase 3  jnk3 
